Inhibitors Containing Bicyclic Derivatives, Methods for Their Preparation and Use - Patent application

Bicyclic derivative compounds are developed as selective RET inhibitors to address the limitations of current RET-targeted therapies, enhancing efficacy and overcoming drug resistance in cancers with RET-activating mutations.

JP7588095B2Active Publication Date: 2024-11-21SHANGHAI HANSOH BIOMEDICAL CO LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021568429
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-03-13
Filing Date
2020-05-14
Publication Date
2024-11-21
Estimated Expiration
2040-05-14

AI Technical Summary

Technical Problem

Current RET-targeted therapies face limitations such as low selectivity, significant side effects, and drug resistance, with no approved targeted drugs available, necessitating the development of more effective RET inhibitors.

Method used

Development of bicyclic derivative compounds represented by general formulas (I) and their stereoisomers or pharmaceutically acceptable salts, which act as selective RET inhibitors, addressing drug resistance and improving therapeutic efficacy.

Benefits of technology

The bicyclic derivatives demonstrate higher selectivity, better safety, and the ability to overcome drug resistance mutations, offering potential treatment options for various cancers with RET-activating mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588095000001
    Figure 0007588095000001
  • Figure 0007588095000002
    Figure 0007588095000002
  • Figure 0007588095000003
    Figure 0007588095000003
Patent Text Reader

Abstract

The present invention relates to inhibitors comprising bicyclic derivatives, their preparation methods and uses. In particular, the present invention relates to compounds represented by general formula (I), preparation methods and pharmaceutical compositions thereof, and their use as RET inhibitors in the treatment of cancer, inflammation, chronic liver disease, diabetes, cardiovascular disease and related diseases such as AIDS, wherein each substituent of general formula (I) is as defined in the specification. [Case 1] TIFF2022532758000618.tif59170
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to Chinese patent application CN201910400013.0, filed May 14, 2019, Chinese patent application CN20191061598.7, filed July 9, 2019, Chinese patent application CN201910816375.8, filed August 30, 2019, Chinese patent application CN201910895078.8, filed September 20, 2019, and Chinese patent application CN202010177893.2, filed March 13, 2020. This application cites the above Chinese patent applications in their entirety. [Technical Field]

[0002] The present invention relates to the field of drug synthesis, and specifically to inhibitors containing bicyclic derivatives, their preparation methods and uses. [Background technology]

[0003] The RET (rearranged during transfection) protein, encoded by the proto-oncogene RET located on chromosome 10, is a receptor tyrosine kinase consisting of an extracellular domain, a transmembrane domain, and an intracellular kinase domain. RET ligands are glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs), such as GDNF, neuroturin (NRTN), artemin (ARTN), and persephin (PSPN). Receptor activation requires the cooperation of the GFRα family of coreceptors. GFLs dimerize with GFRα and bind to RET, recruiting it to cholesterol-rich membrane domains. RET protein dimerizes and undergoes autophosphorylation, thereby activating downstream signaling pathways, including RAS-MAPK, PI3K-AKT, and PKC. RET plays an important role in the development of the kidney and enteric nervous system during embryogenesis; it is also important for the homeostasis of tissues such as neuroendocrine, hematopoietic, and male germ cells.

[0004] Impaired RET protein function can lead to the development of various diseases. During development, lack of RET protein function can lead to a series of congenital disorders, such as Hirschsprung's disease (HSCR) and congenital anomalies of the kidney and urinary tract (CAKUT). Activating RET mutations, including RET fusions caused by point mutations and chromosomal rearrangements, are also associated with the development of many diseases. RET fusions occur primarily in 1-2% of non-small cell lung cancer (NSCLC) patients and 5-10% of papillary thyroid carcinomas, while RET mutations occur primarily in 60% of medullary thyroid carcinomas. Activating RET mutations are also found in many other tumors, including breast cancer, gastric cancer, intestinal cancer, and chronic myelomonocytic leukemia.

[0005] Despite the great clinical need, currently, RET-targeted therapies still have significant limitations, and unlike the excellent clinical efficacy of ALK, EGFR, and other targeted drugs, there are no approved RET-targeted drugs. Currently, multikinase inhibitors (MKIs) such as vandetinib and cabozantinib are mainly used in clinical medicine, but these multikinase inhibitors have the disadvantages of low selectivity, significant side effects, and low efficacy, and they also cannot overcome the problem of drug resistance during treatment.

[0006] The demand for RET-targeted drugs has led many domestic and international pharmaceutical companies to develop RET-specific targeted drugs, among which the most prominent are Loxo Oncology's LOXO-292, which has entered Phase I / II clinical trials, and Blueprint's BLU-667, which has entered Phase I clinical trials. These two targeted drugs have shown excellent efficacy and safety in preclinical trials targeting patients with RET-activating mutations, and have also been shown to be effective in preclinical activity screening. This overcomes drug resistance mutations that can occur in cancers with RET activating mutations, and is expected to provide more treatment options for cancers with RET activating mutations in the future.

[0007] Currently, there are no specific targeted drugs for RET targeting, and there is a great clinical demand. RET inhibitors with higher selectivity, better activity, better safety, and the ability to overcome drug-resistant mutations have the potential to treat various cancers and have broad market prospects. Summary of the Invention

[0008] [DISCLOSURE OF THE INVENTION] An object of the present invention is to provide a compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the structure of the compound represented by general formula (I) is as follows:

[0009] [ka] where: X1 to X6 are independently C, N, CR5, CR aa R bb , or NR aa Selected from; L is a bond, -(CH2) n1 CR aa R bb -, -(CH2) n1 NR aa C(O)(CH2) n2 -, -(CH2) n1 C(O)(CH2) n2 (CR aa R bb ) m -, -(CH2) n1 C(O)(CR aa R bb ) m (CH2) n2 -, -(CH2) n1 C(O)NR cc (CR aa R bb ) n2 -, -(CH2) n1 (O)(CH2) n2 or (CH2) n1 NR aa (CH2) n2 -Selected from; Ring A is selected from a heterocyclic group, aryl, or heteroaryl; Ring B is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl; R1 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 R aa , -(CH2) n1 S(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 S(O) m R aa , -(CH2) n1 O(CH2) n2 S(O)(=NR aa )(CH2) m R bb , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb, -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa (CH2) n2 R bb , -(CH2) n1 NR aa C(O)R bb or h-(CH2) n1 NR aa S(O) m R bb wherein said alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, ... Nyl, alkynyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl further include hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxy, cyano, oxo, thiol, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH2) n1 R dd , -(CH2) n1 OR dd , -(CH2) n1 S(CH2) n2 R dd , -(CH2) n1 C(O)R dd , -(CH2) n1 C(O)OR dd , -(CH2) n1 S(O) m R dd , -(CH2) n1 S(O)(=NR dd )(CH2) n2 Ree , -(CH2) n1 NR dd R ee , -(CH2) n1 P(O)R dd R ee , -(CH2) n1 C(O)NR dd R ee , -(CH2) n1 NR dd C(O)R ee and -(CH2) n1 NR dd S(O) m R ee optionally substituted with one or more substituents selected from among R2 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, halogen, amino, oxo, thiol, nitro, cyano, hydroxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; R3 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, halogen, amino, oxo, thiol, nitro, cyano, hydroxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or any two adjacent or non-adjacent R3 are joined to form a cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; R4 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 R aa , -(CH2) n1 C(O)Raa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)N R aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl can further be selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amino, nitro, hydroxy, cyano, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH) n1 R cc , -(CH2) n1 OR cc , -(CH2) n1 S(CH2) n2 R cc , -(CH2) n1 C(O)R cc , -(CH2) n1 C(O)OR cc , -(CH2) n1 S(O)m R cc , -(CH2) n1 S(O)(=NR cc )(CH2) n2 R dd , -(CH2) n1 NR cc R dd , -(CH2) n1 P(O)R cc R dd , -(CH2) n1 C(O)NR cc R dd , -(CH2) n1 NR cc C(O)R dd or -(CH2) n1 NR cc S(O) m R dd optionally substituted with one or more substituents selected from among R5 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 R aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb, -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; R aa , R bb , R cc , R dd and R ee are each independently selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, cyano, nitro, hydroxy, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxy, amino, oxo, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; Or R aa , R bb , R cc , R dd and R eeany two of which may be linked to form a cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxy, amino, oxo, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; x is 0, 1, 2, 3, 4 or 5; y is 0, 1, 2, 3, 4 or 5; z is 0, 1, 2, 3, 4, 5 or 6; m is 0, 1 or 2; n1 is 0, 1, 2 or 3; and n2 is 0, 1, 2 or 3.

[0010] The present invention further provides a preferred embodiment of the compound represented by the general formula (I), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (I) is further represented by the general formula (II):

[0011] [ka] where: Ring C is selected from a cycloalkyl, heterocyclic, aryl, or heteroaryl group; R6 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 Raa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; R7 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 R aa , -(CH2) n1 S(CH2) n2 Raa ,-(CH2) n1 O(CH2) n2 S(O) m R aa ,-(CH2) n1 O(CH2) n2 S(O)(=NR) aa )(CH2) m R bb ,-(CH2) n1 C(O)R aa ,-(CH2) n1 C(O)OR aa ,-(CH2) n1 S(O) m R aa ,-(CH2) n1 S(O)(=NR) aa )(CH2) n2 R bb ,-(CH2) n1 NR aa R bb ,-(CH2) n1 P(O)R aa R bb ,-(CH2) n1 C(O)NR aa R bb ,-(CH2) n1 NR aa C(O)R bb ,-(CH2) n1 NR aa (CH2) n2 R bb or-(CH2) n1 NR aa S(O) m R bbwherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl can further be selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxy, cyano, oxo, thiol, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH) n1 R d d , -(CH2) n1 OR dd , -(CH2) n1 S(CH2) n2 R dd , -(CH2) n1 C(O)R dd , -(CH2) n1 C(O)OR dd , -(CH2) n1 S(O) m R dd , -(CH2) n1 S(O)(=NR dd )(CH2) n2 R ee , -(CH2) n1 NR dd R ee , -(CH2) n1 P(O)R dd R ee , -(CH2) n1 C(O)NR dd R ee , -(CH2) n1 NR dd C(O)R ee and -(CH2) n1 NR dd S(O) m R ee optionally substituted with one or more substituents selected from among p is 0, 1, 2 or 3; w is 0, 1, 2, 3, 4, 5 or 6; Ring A, Ring B, X1~X5, L, R2~R3, R aa ~R ee , y, z, n1, n2 and m are as represented by general formula (I).

[0012] The present invention further provides a preferred embodiment of the compound represented by the general formula (II), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (II) is further represented by the general formula (III):

[0013] [ka] where: X3 is selected from N or CR5; R5 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 R aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb, -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; Ring A, Ring B, Ring C, X3, L, R2, R3, R6~R7, R aa ~R bb , p, y, z, w, n1, n2 and m are as represented by general formula (II).

[0014] The present invention further provides a preferred embodiment of the compound represented by the general formula (II), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (II) is further represented by general formula (IV):

[0015] [ka] where: R8 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; q is 0, 1, 2, 3 or 4; Ring B, ring C, X1 to X5, L, R3, R6 to R7, x, z, and w are as represented by general formula (II).

[0016] The present invention further provides a preferred embodiment of the compound represented by the general formula (II), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (II) is further represented by general formula (V):

[0017] [ka] where: M1 and M2 are independently CR aa or N; R9 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 R aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; s is 0, 1, 2, 3, 4 or 5; Ring A, Ring B, X1~X5, L, R2, R3, R7, R aa , R bb , p, y, z, n1, n2 and m are as represented by general formula (II).

[0018] The present invention further provides a preferred embodiment of the compound represented by the general formula (II), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (II) is further represented by the general formula (VI):

[0019] [ka] where: G1 and G2 are independently CR aa or N; R 10 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; Or any two adjacent or non-adjacent R 10 are linked to form a cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; t is 0, 1, 2, 3 or 4; Ring A, Ring C, X1~X5, L, R1, R2, R6~R7, R aa , p, y and w are as represented by general formula (II).

[0020] The present invention further provides a preferred embodiment of the compound represented by the general formula (II), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (II) is further represented by the general formula (VII):

[0021] [ka] where: Ring B, ring C, X3, L, R6, R7, p and w are as represented by general formula (III); E, R3, R8, z and q are as represented by general formula (IV).

[0022] The present invention further provides a preferred embodiment of the compound represented by the general formula (II), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (II) is further represented by general formula (VIII):

[0023] [ka] where: L is a bond, -(CH2) n1 CR aa R bb -, -(CH2) n1 NR aa C(O)(CH2) n2 -, -(CH2) n1 C(O)(CH2) n2 (CR aa R bb ) m -, -(CH2) n1 C(O)(CR aa R bb ) m (CH2) n2 -, -(CH2) n1 C(O)NR cc (CR aa R bb ) n2 -, -(CH2) n1 (O)(CH2) n2 -or-(CH2) n1 NR aa (CH2) n2 -Selected from; G1 and G2 are independently CR aa or N; R4 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 Raa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 R aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl can further be selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amino, nitro, hydroxy, cyano, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH) n1 R cc , -(CH2) n1 OR cc , -(CH2) n1 S(CH2) n2 Rcc , -(CH2) n1 C(O)R cc , -(CH2) n1 C(O)OR cc , -(CH2) n1 S(O) m R cc , -(CH2) n1 S(O)(=NR cc )(CH2) n2 R dd , -(CH2) n1 NR cc R dd , -(CH2) n1 P(O)R cc R dd , -(CH2) n1 C(O)NR cc R dd , -(CH2) n1 NR cc C(O)R dd or -(CH2) n1 NR cc S(O) m R dd One or more selected from optionally substituted with substituents; R7 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 R aa , -(CH2)n1 S(CH2) n2 R aa ,-(CH2) n1 O(CH2) n2 S(O) m R aa ,-(CH2) n1 O(CH2) n2 S(O)(=NR) aa )(CH2) m R bb ,-(CH2) n1 C(O)R aa ,-(CH2) n1 C(O)OR aa ,-(CH2) n1 S(O) m R aa ,-(CH2) n1 S(O)(=NR) aa )(CH2) n2 R bb ,-(CH2) n1 NR aa R bb ,-(CH2) n1 P(O)R aa R bb ,-(CH2) n1 C(O)NR aa R bb ,-(CH2) n1 NR aa C(O)R bb ,-(CH2) n1 NR aa (CH2) n2 R bb or-(CH2) n1 NR aa S(O) m R bbwherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl can further be selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxy, cyano, oxo, thiol, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH) n1 R dd , -(CH2) n1 OR dd , -(CH2) n1 S(CH2) n2 R dd , -(CH2) n1 C(O)R dd , -(CH2) n1 C(O)OR dd , -(CH2) n1 S(O) m R dd , -(CH2) n1 S(O)(=NR dd )(CH2) n2 R ee , -(CH2) n1 NR dd R ee , -(CH2) n1 P(O)R dd R ee , -(CH2) n1 C(O)NR dd R ee , -(CH2) n1 NR dd C(O)R ee and -(CH2) n1 NR dd S(O) m R ee optionally substituted with one or more substituents selected from among R8 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; R9 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 R aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; R 10 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; Or any two adjacent or non-adjacent R 10 are linked to form a cycloalkyl, heterocyclic group, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic group, aryl, and heteroaryl can further be selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, and and substituted or unsubstituted heteroaryl; R 11 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 SR aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; t is 0, 1, 2 or 3; z is 0, 1, 2, 3, 4, 5 or 6; p is 0, 1, 2 or 3; q is 0, 1, 2, 3 or 4; and s can be 0, 1, 2, 3, 4 or 5.

[0024] The present invention further provides a preferred embodiment of the compound represented by the general formula (II), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (II) is further represented by general formula (IX):

[0025] [ka] where: X3, L, R7 and p are as represented by general formula (III); R8 and q are as described in general formula (IV); M1, M2, R9 and s are as described in general formula (V); G1, G2, R 10 and t is as described in general formula (VI).

[0026] The present invention further provides a preferred embodiment of the compound represented by the general formula (IX), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (IX) is further represented by the general formula (X):

[0027] [ka] where: G2 is CR aa or N; M2 is CR aa or N; L is a bond, -(CH2) n1 CR aa R bb -, -(CH2) n1 NR aa C(O)(CH2) n2 -, -(CH2)n1 C(O)(CH2) n2 (CR aa R bb ) m -, -(CH2) n1 C(O)(CR aa R bb ) m (CH2) n2 -, -(CH2) n1 C(O)NR cc (CR aa R bb ) n2 -, -(CH2) n1 (O)(CH2) n2 -or-(CH2) n1 NR aa (CH2) n2 -Selected from; R7 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 (CR aa R bb ) m R cc , -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 R aa , -(CH2) n1 S(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 S(O)m R aa ,-(CH2) n1 O(CH2) n2 S(O)(=NR) aa )(CH2) m R bb ,-(CH2) n1 C(O)R aa ,-(CH2) n1 C(O)OR aa ,-(CH2) n1 S(O) m R aa ,-(CH2) n1 S(O)(=NR) aa )(CH2) n2 R bb ,-(CH2) n1 NR aa R bb ,-(CH2) n1 P(O)R aa R bb ,-(CH2) n1 C(O)NR aa R bb ,-(CH2) n1 NR aa C(O)R bb ,-(CH2) n1 NR aa (CH2) n2 R bb or-(CH2) n1 NR aa S(O) m R bbwherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl can further be selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxy, cyano, oxo, thiol, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH) n1 R dd , -(CH2) n1 OR dd , -(CH2) n1 S(CH2) n2 R dd , -(CH2) n1 C(O)R dd , -(CH2) n1 C(O)OR dd , -(CH2) n1 S(O) m R dd , -(CH2) n1 S(O)(=NR dd )(CH2) n2 R ee , -(CH2) n1 NR dd R ee , -(CH2) n1 P(O)R dd R ee , -(CH2) n1 C(O)NR dd R ee , -(CH2) n1 NR dd C(O)R ee and -(CH2) n1 NR dd S(O) m R ee optionally substituted with one or more substituents selected from among R9 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, or alkynyl. , cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 R aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; R 10 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; Or any two adjacent or non-adjacent R 10are linked to form a cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; R 11 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 SR aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; R aa , R bb , R cc , Rdd and R ee are each independently selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, cyano, nitro, hydroxy, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxy, amino, oxo, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; Or R aa , R bb , R cc , R dd and R ee any two of which may be linked to form a cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxy, amino, oxo, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; s is 0, 1, 2, 3, 4 or 5; t is 0, 1, 2, 3, or 4; and p is 0, 1, 2 or 4.

[0028] The present invention further provides a preferred embodiment of the compound represented by the general formula (X), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (X) is further represented by general formula (XI-A):

[0029] [ka] where: R 12 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; R 13 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -(CH2) n1 (CR aa R bb ) m R cc , -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 OR aa , -(CH2) n1 O(CH2) n2 R aa , -(CH2) n1 S(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1O(CH2) n2 S(O) m R aa ,-(CH2) n1 O(CH2) n2 S(O)(=NR) aa )(CH2) m R bb ,-(CH2) n1 C(O)R aa ,-(CH2) n1 C(O)OR aa ,-(CH2) n1 S(O) m R aa ,-(CH2) n1 S(O)(=NR) aa )(CH2) n2 R bb ,-(CH2) n1 NR aa R bb ,-(CH2) n1 P(O)R aa R bb ,-(CH2) n1 C(O)NR aa R bb ,-(CH2) n1 NR aa C(O)R bb ,-(CH2) n1 NR aa (CH2) n2 R bb or-(CH2) n1 NR aa S(O) m R bbwherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl can further be selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxy, cyano, oxo, thiol, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH) n1 R dd , -(CH2) n1 OR dd , -(CH2) n1 S(CH2) n2 R dd , -(CH2) n1 C(O)R dd , -(CH2) n1 C(O)OR dd , -(CH2) n1 S(O) m R dd , -(CH2) n1 S(O)(=NR dd )(CH2) n2 R ee , -(CH2) n1 NR dd R ee , -(CH2) n1 P(O)R dd R ee , -(CH2) n1 C(O)NR dd R ee , -(CH2) n1 NR dd C(O)R ee and -(CH2) n1 NR dd S(O) m R ee optionally substituted with one or more substituents selected from among R 12is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; R 15 and R 16 are each independently hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, or -(CH2) n1 OR aa Selected from; L, R 11 , R aa ~R ee , n1, n2 and m are as represented by general formula (X).

[0030] The present invention further provides a preferred embodiment of the compound represented by the general formula (II), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (II) is further represented by the general formula (XII):

[0031] [ka] where: L is a bond, -(CH2) n1 CR aa R bb -, -(CH2) n1 NR aa C(O)(CH2) n2 -, -(CH2) n1 C(O)(CH2) n2 (CR aa R bb ) m -, -(CH2) n1 C(O)(CR aa R bb ) m (CH2) n2 -, -(CH2) n1 C(O)NR cc (CR aa R bb )n2 -, -(CH2) n1 (O)(CH2) n2 -or-(CH2) n1 NR aa (CH2) n2 -Selected from; M1 and M2 are independently CR aa or N; X1 and X2 are independently C and CR aa or N; R3 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; R9 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 S(CH2) n2 R aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bbor -(CH2) n1 NR aa S(O) m R bb Selected from; R 11 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -(CH2) n1 R aa , -(CH2) n1 OR aa , -(CH2) n1 SR aa , -(CH2) n1 C(O)R aa , -(CH2) n1 C(O)OR aa , -(CH2) n1 S(O) m R aa , -(CH2) n1 NR aa R bb , -(CH2) n1 P(O)R aa R bb , -(CH2) n1 C(O)NR aa R bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 NR aa S(O) m R bb Selected from; z is 0, 1, 2, 3, 4 or 5; s is 0, 1, 2, 3, 4 or 5; R 12 ~R 14 , R aa ~R ee , n1, n2 and m are as represented by general formula (XI).

[0032] The present invention further provides a preferred embodiment of the compound represented by the general formula (I), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (I) is further represented by general formula (IX-A):

[0033] [ka] where: L is a bond, -(CH2) n1 CR aa R bb -, -(CH2) n1 NR aa C(O)(CH2) n2 -, -(CH2) n1 C(O)(CH2) n2 (CR aa R bb ) m -, -(CH2) n1 C(O)(CR aa R bb ) m (CH2) n2 -, -(CH2) n1 C(O)NR cc (CR aa R bb ) n2 -, -(CH2) n1 (O)(CH2) n2 -or-(CH2) n1 NR aa (CH2) n2 -Selected from; Preferably, it is -CH2-, -CD2-, -O- or -NHC(O)-; G2 is N or CR aa is selected from, preferably N, CH or CCH; M1 is N or CR aa is selected from, preferably N, CH or CCH; M2 is N or CR aa is selected from, preferably N or CH; R9 is hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5-12 membered heteroaryl or -(CH2) n1 OR aa Selected from; Preferably, hydrogen, halogen, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy or -OR aa and; Most preferred are hydrogen, fluorine, chlorine, methyl, methoxy, deuterated methoxy or cyclopropoxy; R 17 is C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 2-6 Alkynyl, 3- to 12-membered heterocyclic group, 5- to 12-membered heteroaryl or -(CH2) n1 (CR aa R bb )R cc wherein C is selected from 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 2-6 Alkynyl, 3- to 12-membered heterocyclic group and 5- to 12-membered heteroaryl are further substituted with hydrogen, hydroxy, cyano, oxo, thiol, amino, imino, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Cyanoalkyl, C 3-8 optionally substituted with one or more substituents selected from cycloalkyl or 3- to 12-membered heterocyclic groups; R 24 and R 25 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 heavy water Alkyl chloride, C 1-6 Haloalkyl, C1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5-12 membered heteroaryl or -(CH2) n1 OR aa and is preferably hydrogen or methyl; Or R 24 and R 25 C together with the carbon atoms and G2 connected to them 3-8 forming a cycloalkyl or 3- to 12-membered heterocyclic group, preferably azetidinyl; R aa , R bb and R cc are each independently hydrogen, deuterium, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, Hydroxy, C 3-8 cycloalkyl, 3- to 12-membered heterocyclic group or C 6-14 aryl, wherein said C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, Hydroxy, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic groups and C 6-14 Aryl can also be hydrogen, halogen, cyano, hydroxy, alkoxy, imino, C 1-6 Alkyl and C 1-6 optionally substituted with one or more substituents selected from among hydroxyalkyl; Or R aa , R bb and R cc Any two of them can be concatenated to form a single C 3-8 can form a cycloalkyl or 3- to 12-membered heterocyclic group, wherein 3-8 The cycloalkyl and 3- to 12-membered heterocyclic groups may further include hydrogen, amino, halogen, cyano, hydroxy, oxo, imino, C1-6 Alkyl and C 1-6 optionally substituted with one or more substituents selected from among hydroxyalkyl; n1 is 0, 1 or 2; n2 is 0, 1 or 2; m is 0, 1 or 2; and s is 0, 1, 2 or 3.

[0034] The present invention further provides a preferred embodiment of the compound represented by the general formula (I), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (I) is further represented by general formula (IX-B):

[0035] [ka] where: M3 is selected from a bond, -O-, -S-, -NH-, or -NCH3-; R 18 and R 19 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 selected from aryl or 5- to 12-membered heteroaryl, preferably hydrogen or methyl; Or R 18 and R 19 C together with the carbon atoms connected to them 3-8 Forms a cycloalkyl or 3- to 12-membered heterocyclic group, preferably C 3-6 It is a cycloalkyl or a 3- to 7-membered heterocyclic group containing 1 to 2 oxygen atoms, nitrogen atoms or sulfur atoms, and more preferably a cycloalkyl. cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, bicyclo[1,1,1]pentane or 1-imino-1-oxothiopyran, wherein C 3-8 The cycloalkyl or 3- to 12-membered heterocyclic group may further include hydrogen, C 1-6 Alkyl, hydroxy, cyano and C 1-6 optionally substituted with one or more substituents selected from among hydroxyalkyl; R 20 are hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 aryl or 5- to 12-membered heteroaryl, preferably hydrogen, cyano or amino; R 24 and R 25 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5-12 membered heteroaryl or -(CH2) n1 OR aa and is preferably hydrogen or methyl; Or R 24 and R 25 is one C together with the carbon atom and G2 connected to it 3-8forming a cycloalkyl or 3- to 12-membered heterocyclic group, preferably azetidinyl; r is 0, 1 or 2; L, G2, M1, M2, R9 and s are as represented by general formula (IX-A).

[0036] The present invention further relates to a compound represented by the general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R 18 and R 19 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 A preferred embodiment is provided in which the aryl is selected from aryl or 5-12 membered heteroaryl, and is preferably hydrogen, methyl, ethynyl, amino, cyano or hydroxy; Or R 18 and R 19 C together with the carbon atoms connected to them 3-8 Forms a cycloalkyl or 3- to 12-membered heterocyclic group, preferably C 3-6 It is a cycloalkyl or a 3- to 7-membered heterocyclic group containing 1 to 2 oxygen atoms, nitrogen atoms or sulfur atoms, and more preferably cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, tetrahydropyran, bicyclo[1,1,1]pentane or 1-imino-1-oxothiopyran, wherein said C 3-8 The cycloalkyl or 3- to 12-membered heterocyclic group may further include hydrogen, C 1-6 Alkyl, halogen, hydroxy, cyano, C 1-6 Hydroxyalkyl and -(CH2) n1 C(O)NR aa R bboptionally substituted with one or more substituents selected from among R 20 are hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 It is selected from aryl or 5- to 12-membered heteroaryl, and is preferably hydrogen, methyl, ethynyl, amino, cyano or hydroxy.

[0037] The present invention further provides a preferred embodiment of the compound, its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (X) is further represented by general formula (XIII):

[0038] [ka] where: R 11 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 alkynyl; R 13 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, -O(CH2) n1 (CR aa R bb ) m R cc or

[0039] [ka] Selected from; R aa , R bb and R cc are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; R c and R d are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; Or R c and R d C together with the adjacent carbon atom 3-8 Forms a cycloalkyl, preferably deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl optionally substituted with one or more substituents selected from; M1 and M2 are each independently selected from -N- or -CH-; R 16 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; R a and R b are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 a Alkenyl or C 2-6 alkynyl; k is an integer of 0, 1, or 2; n1 is an integer of 1, 2, or 3; m is an integer of 1, 2 or 3.

[0040] The present invention further provides a preferred embodiment which is a compound represented by the general formula (XIII), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein: R 11 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano or C 1-3 alkyl; R 13 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-3 Alkyl, C 1-3Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, -OCH2CR aa R bb R cc or

[0041] [ka] Selected from; R aa , R bb and R cc are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; R c and R d are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy or C 1-3 haloalkoxy; Or R c and R d C together with the adjacent carbon atom 3-6 Forms cycloalkyl, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy or C1-3 optionally substituted with one or more substituents selected from haloalkoxy; M1 is -N- and M2 is -CH-, or M1 is -CH- and M2 is -N-; R 16 are hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy or C 1-3 haloalkoxy; R a and R b are each independently selected from hydrogen, deuterium, or halogen.

[0042] The present invention further provides a preferred embodiment of the compound represented by the general formula (I), its stereoisomer, or its pharmaceutically acceptable salt, wherein the general formula (I) is further represented by the general formula (X):

[0043] [ka] In a preferred embodiment of the present invention, R 18 and R 19 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3- to 6-membered heterocyclic group, C 6-10 selected from aryl or 5-6 membered heteroaryl, preferably hydroxy or methyl; R9 is hydrogen, deuterium, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 Alkenyl or C 2-4 alkynyl; s is 0, 1, 2 or 3.

[0044] The present invention further relates to a compound represented by the general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is represented by the general formula (IX-B):

[0045] [ka] teeth

[0046] [ka] A preferred embodiment selected from the following is provided.

[0047] The present invention further provides a preferred embodiment in which the compound represented by the general formula (I), its stereoisomer or pharmaceutically acceptable salt thereof is further represented by the general formula (IC):

[0048] [ka] where: R 21 and R 22 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5-12 membered heteroaryl, --(CH2) n1 C(O)R aa or -(CH2) n1 R aa Selected from; Or R 21 and R 22 together with the carbon atom to which they are attached form a 3- to 12-membered heterocyclic group, wherein the 3- to 12-membered heterocyclic group may further include hydrogen, amino, halogen, cyano, hydroxy, oxo, C 1-6 Alkyl and C 1-6 optionally substituted with one or more substituents selected from among hydroxyalkyl; Preferably, it is azetidinyl, pyrrolidinyl, 2-azaspiro[3.3]heptane or piperidinyl, wherein the azetidinyl, pyrrolidinyl, 2-azaspiro[3.3]heptane or piperidinyl may further include hydrogen, C 1-6 optionally substituted with one or more substituents selected from alkyl, hydroxy, or hydroxyalkyl; R 24 and R 25 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5-12 membered heteroaryl or -(CH2) n1 OR aa and is preferably hydrogen or methyl; Or R 24 and R 25 is one C together with the carbon atom and G2 connected to it 3-8 forming a cycloalkyl or 3- to 12-membered heterocyclic group, preferably azetidinyl; L, G2, M1, M2, R9, R aa , s and n1 are as represented by general formula (IX-A).

[0049] The present invention further provides a preferred embodiment, wherein in the compound represented by the general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R 21 and R 22 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5-12 membered heteroaryl, -(CH2) n1 C(O)R aa or -(CH2) n1 R aa Selected from; Or R 21 and R 22 together with the carbon atom to which they are attached form a 3- to 12-membered heterocyclic group, wherein the 3- to 12-membered heterocyclic group may further include hydrogen, amino, halogen, cyano, hydroxy, oxo, C 1-6 Alkyl and C 1-6 optionally substituted with one or more substituents selected from among hydroxyalkyl; Preferably, it is azetidinyl, pyrrolidinyl, 2-azaspiro[3.3]heptane or piperidinyl, wherein the azetidinyl, pyrrolidinyl, 2-azaspiro[3.3]heptane or piperidinyl may further include hydrogen, C 1-3 It is optionally substituted with one or more substituents selected from alkyl, hydroxy, or hydroxyalkyl.

[0050] The present invention further relates to a compound represented by the general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which is represented by the general formula (IX-C):

[0051] [ka] teeth,

[0052] [ka] Provided are preferred embodiments selected from: where R 26 and R 27 are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 aryl or 5-12 membered heteroaryl; Preferably, hydrogen, hydroxy, cyano, C 1-3 Alkyl or C 1-3 is hydroxyalkyl; More preferably, it is hydrogen, hydroxy, cyano, methyl or hydroxyisopropyl.

[0053] In a preferred embodiment of the present invention, L is selected from -CH2-, -CD2-, -O-, -S-, -C(O)NH- or -NHC(O)-; G2 is selected from -N-, -CH-, or -CCH3-; M1 is selected from -N-, -CH-, or -CCH3-; M2 is selected from -N or -CH-.

[0054] The present invention further provides a preferred embodiment in which the compound represented by the general formula (I), its stereoisomer or pharmaceutically acceptable salt thereof is further represented by the general formula (ID):

[0055] [ka] where: R 22 are hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5-12 membered heteroaryl, -(CH2) n1 C(O)R aa or -(CH2) n1 R aa Selected from; Preferably, hydroxy, cyano or C 1-6 is hydroxyalkyl; L, G2, M1, M2, M3, R9, R aa , s and n1 are as represented by general formula (IX-A).

[0056] The present invention further relates to a compound represented by the general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R 23 are hydroxy, cyano, C 1-6 Hydroxyalkyl or -(CH2) n1 C(O)NR aa R bb A preferred embodiment is provided in which:

[0057] The present invention further relates to a compound represented by each of the above general formulae, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: Ring A is the following group:

[0058] [ka] Selected from; Ring B is the following group:

[0059] [ka] Selected from; Ring C is the following group:

[0060] [ka] A preferred embodiment selected from the following is provided.

[0061] The present invention further relates to a compound represented by each of the above general formulae, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: L is a bond, -(CH2) n1 CR aa R bb -, -(CH2) n1 NR aa C(O)(CH2) n2 -, -(CH2) n1 C(O)(CR aa R bb ) m (CH2) n2 -, -(CH2) n1 C(O)(CH2) m (CR aa R bb ) n2 -, -(CH2) n1 C(O)NR cc (CR aa R bb ) n2 -, -(CH2) n1 (O)(CH2) n2 -or-(CH2) n1 NR aa (CH2) n2-Selected from; Preferably, it is -(CH2)2-, -(CD2)2-, -O-, -C(O)NH-, -C(O)N(CH3)-, -NHC(O)- or -O(CH2)2-; R1 is hydrogen, halogen, or C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, oxo, C 2-6 Alkynyl, 3- to 12-membered heterocyclic group, 5- to 12-membered heteroaryl, -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m C(O)NHR cc , -(CH2) n1 S(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 S(O) m R aa , -(CH2) n1 O(CH2) n2 S(O)(=NR aa )(CH2) m R bb , -(CH2) n1 O(CH2) n2 R aa , -(CH2) n1 NR aa (CH2) n2 CR bb , -(CH2) n1 NR aaC(O)R bb or -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb wherein C is selected from 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkynyl, 3- to 12-membered heterocyclic group and 5- to 12-membered heteroaryl can further include hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Cyanoalkyl, C 1-6 Alkoxy, halogen, hydroxy, amino, cyano, oxo, thiol, imino, C 3-8 optionally substituted with one or more substituents selected from cycloalkyl and 3- to 12-membered heterocyclic groups; R2 is selected from hydrogen or halogen; R3 is hydrogen, C 1-6 alkyl or amino; or any two adjacent or non-adjacent R3 are linked to form one C 3-8 forming a cycloalkyl or 3- to 12-membered heterocyclic group; R4 is C 1-6 Alkyl, C 6-10 aryl or 5- to 12-membered heteroaryl, wherein said C 1-6 Alkyl, C 6-10 Aryl and 5- to 12-membered heteroaryl may further include hydrogen, amino, C 1-6 Alkyl, C 1-6 Alkoxy, halogen, -(CH2) n1 OR aa , -(CH2) n1 C(O)NR aa R bb or -(CH2) n1 NR aa C(O)R bb optionally substituted with one or more substituents selected from among R5 is cyano, -C(O)NR aa R bb or -(CH2) n1 P(O)R aa Rbb Selected from; R6 is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino, -(CH2) n1 OR aa , -(CH2) n1 C(O)NR aa R bb or -(CH2) n1 NR aa C(O)R bb Selected from; R7 is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, oxo, C 2-6 Alkynyl, 3- to 12-membered heterocyclic group, 5- to 12-membered heteroaryl, -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m C(O)NHR cc , -(CH2) n1 S(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 S(O) m R aa , -(CH2) n1 O(CH2) n2 S(O)(=NR aa )(CH2) m R bbb , -(CH2) n1 O(CH2) n2 Raa , -(CH2) n1 NR aa (CH2) n2 CR bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb wherein C is selected from 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkynyl, 3- to 12-membered heterocyclic group and 5- to 12-membered heteroaryl can further include hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Cyanoalkyl, C 1-6 Alkoxy, halogen, hydroxy, amino, cyano, oxo, thiol, imino, C 3-8 optionally substituted with one or more substituents selected from cycloalkyl or 3- to 12-membered heterocyclic groups; R8 is selected from hydrogen or halogen; R9 is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogen or -OR aa Selected from; R 10 is hydrogen, C 1-6 selected from alkyl or amino; Or any two adjacent or non-adjacent R 10 are concatenated into one C 3-8 forming a cycloalkyl or 3- to 12-membered heterocyclic group; R 11 is cyano, -(CH2) n1 P(O)R aa R bb or -(CH2) n1 C(O)NR aa R bb Selected from; R 12 is hydrogen, C 1-6 selected from alkyl or halogen; R 13 is C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkynyl, 3-12 membered heterocyclic group, 5-12 membered heteroaryl, (C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 (CR aa R bb ) m C(O)NHR cc , -(CH2) n1 S(CH2) n2 (CR aa R bb ) m R cc , -(CH2) n1 O(CH2) n2 S(O) m R aa , -(CH2) n1 O(CH2) n2 S(O)(=NR aa )(CH2) m R bb , -(CH2) n1 O(CH2) n2 R aa , -(CH2) n1 NR aa (CH2) n2 CR bb , -(CH2) n1 NR aa C(O)R bb or -(CH2) n1 S(O)(=NR aa )(CH2) n2 R bb wherein C is selected from 1-6Alkyl, C 1-6 Alkoxy, C 2-6 Alkynyl, 3- to 12-membered heterocyclic group, and 5- to 12-membered heteroaryl can further include hydrogen, C 1-6 Alkyl, hydroxy, thiol, imino, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Cyanoalkyl, C 3-8 optionally substituted with one or more substituents selected from cycloalkyl or 3- to 12-membered heterocyclic groups; R 14 is selected from hydrogen or halogen; R 15 is selected from hydrogen or halogen; R 16 is hydrogen, alkoxy or -OR aa Selected from; R aa , R bb and R cc are each independently hydrogen, deuterium, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, Hydroxy, C 3-8 cycloalkyl, 3- to 12-membered heterocyclic group or C 6-14 aryl, wherein said C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, Hydroxy, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic groups and C 6-14 Aryl can also be hydrogen, halogen, cyano, hydroxy, alkoxy, imino, C 1-6 Alkyl and C 1-6 optionally substituted with one or more substituents selected from among hydroxyalkyl; Or R aa , R bb and R cc Any two of them can be concatenated to form a single C 3-8 can form a cycloalkyl or 3- to 12-membered heterocyclic group, wherein 3-8The cycloalkyl and 3- to 12-membered heterocyclic groups may further include hydrogen, halogen, cyano, hydroxy, oxo, imino, C 1-6 Alkyl and C 1-6 Optionally substituted with one or more substituents selected from among hydroxyalkyl.

[0062] The present invention also relates to a method for preparing a compound represented by general formula (IX-A) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, comprising the steps of:

[0063] [ka] A compound represented by general formula (IX-A1) and general formula (IX-A2) is subjected to a coupling reaction to obtain a compound represented by general formula (IX-A) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; where: X1 is selected from halogen; preferably fluorine, chlorine, bromine or iodine; more preferably More preferably, it is bromine.

[0064] The present invention also relates to a method for preparing a compound represented by general formula (IX-B) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, comprising the steps of:

[0065] [ka] Reacting general formula (IX-B1) with general formula (IX-B2) to obtain a compound represented by general formula (IX-B) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; where: R 28 is selected from halogen, -B(OH)2, or a boronate ester; preferably, fluorine, chlorine, bromine, iodine, -B(OH)2, or

[0066] [ka] and; R 29is selected from halogen, boronic acid or boronic ester; preferably fluorine, chlorine, bromine, iodine, -B(OH)2 or

[0067] [ka] and; R 28 is a halogen, R 29 is selected from a boronic acid or a boronic ester; R 28 When R is selected from boronic acids or boronic esters, 29 is a halogen.

[0068] The present invention also relates to a method for preparing a compound represented by general formula (IX-B) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, comprising the steps of:

[0069] [ka] Reacting general formula (IX-B3) with general formula (IX-B4) to obtain a compound represented by general formula (IX-B) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; where: M3 is selected from a bond, -O-, -S-, -NH-, or -NCH3-; R 30 is selected from halogen, hydroxy; preferably fluorine, chlorine, bromine or iodine; more preferably bromine or hydroxy; Pg is selected from hydrogen, halogen or a hydroxy protecting group, said halogen being preferably fluorine, chlorine, bromine or iodine; When Pg is a hydroxy protecting group, it is selected from methyl, tert-butyl, triphenyl, methylthiomethyl ether, 2-methoxyethoxymethyl ether, methoxymethyl ether, p-methoxybenzyl ether, pivaloyl, benzyl ether, methoxymethyl, trimethylsilyl, tetrahydrofuranyl, tert-butyldimethylsilyl, acetyl, benzoyl, or p-toluenesulfonyl; preferably p-toluenesulfonyl; When M3 is -O-, Pg is selected from hydrogen or a hydroxy protecting group.

[0070] The present invention also relates to a method for producing a compound represented by general formula (IX-C) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, comprising the steps of:

[0071] [ka] Reacting general formula (IX-C1) with general formula (IX-C2) to obtain a compound represented by general formula (IX-C) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; where: X2 is selected from halogen; preferably fluorine, chlorine, bromine or iodine; more preferably bromine.

[0072] The present invention also relates to a method for producing a compound represented by general formula (X) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, the method comprising the steps of:

[0073] [ka] where: R 18 and R 19 are independently hydrogen, deuterium, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 aryl or 5-12 membered heteroaryl; Or R 18 and R 19 C together with the carbon atoms connected to them 3-8 Forms a cycloalkyl or 3- to 12-membered heterocyclic group, preferably C 3-6 It is a cycloalkyl or a 3- to 7-membered heterocyclic group containing 1 to 2 oxygen atoms, nitrogen atoms or sulfur atoms, and more preferably cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, bicyclo[1,1,1]pentane or 1-imino-1-oxothiopyran, wherein 3-8 The cycloalkyl or 3- to 12-membered heterocyclic group may further include hydrogen, C 1-6 Alkyl, hydroxy, cyano and C 1-6 optionally substituted with one or more substituents selected from among hydroxyalkyl; Preferably, R 18 and R 19 are each independently selected from hydrogen, methyl, or hydroxy.

[0074] The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound represented by each of the above general formulas and its stereoisomers or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients. The present invention further provides preferred embodiments relating to the use of the compounds represented by the above general formulas, their stereoisomers or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions in the manufacture of RET inhibitor-related medicines.

[0075] The present invention further provides a preferred embodiment, which relates to use of the compound represented by general formula (I), its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the manufacture of a medicament for treating and / or preventing related diseases such as non-small cell lung cancer, fibrosarcoma, pancreatic tumor, medullary thyroid carcinoma, papillary thyroid tumor, soft tissue sarcoma, high-grade solid tumor, breast tumor, and colon tumor.

[0076] The present invention further relates to use of the compound represented by the general formula (I), its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the manufacture of a medicament for treating and / or preventing related diseases such as non-small cell lung cancer, fibrosarcoma, pancreatic tumor, medullary thyroid carcinoma, papillary thyroid tumor, soft tissue sarcoma, high-grade solid tumor, breast tumor, and colon tumor.

[0077] The present invention further provides a method for treating non-small cell lung cancer, fibrosarcoma, pancreatic tumor, medullary thyroid cancer, papillary thyroid tumor, soft tissue sarcoma, high-grade malignant tumor, or fibrosarcoma, which comprises administering to said mammal a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate, or derivative thereof. The present invention provides methods for treating and / or preventing diseases associated with advanced solid tumors, breast tumors, colon tumors, and the like.

[0078] In some embodiments, the methods further relate to the treatment and / or prevention of related disorders, such as non-small cell lung cancer, fibrosarcoma, pancreatic tumors, medullary thyroid cancer, papillary thyroid tumors, soft tissue sarcoma, high-grade solid tumors, breast tumors, and colon tumors.

[0079] The methods of treatment provided herein comprise administering to a test subject a therapeutically effective amount of a compound of the present invention. In one embodiment, the present invention provides a method of treating a menopausal heat-related disorder in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate, or derivative thereof. [Detailed Description of the Invention] Unless stated to the contrary, terms used in the description and claims of this invention have the following meanings.

[0080] The term "alkyl" refers to a straight or branched chain saturated hydrocarbon group containing 1 to 20 carbon atoms, preferably an alkyl containing 1 to 8 carbon atoms, more preferably an alkyl containing 1 to 6 carbon atoms, and most preferably an alkyl containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, Examples include 3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof.More preferably, it is a lower alkyl containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, and said substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carbamate groups, and preferably in the present invention methyl, ethyl, isopropyl, tert-butyl, haloal. alkyl, deuterated alkyl, alkoxy-substituted alkyl and hydroxy-substituted alkyl.

[0081] The term "alkylene" refers to an alkyl in which a hydrogen atom is further substituted, for example: "methylene" refers to -CH-, "ethylene" refers to -(CH)-, "propylene" refers to -(CH)-, and "butylene" refers to -(CH)-. The term "alkenyl" refers to an alkyl as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, etc. An alkenyl can be substituted or unsubstituted, and if substituted, the substituents are preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0082] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, and more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, and cyclooctyl; polycyclic cycloalkyls include spiro, fused, and bridged cycloalkyls, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, and cycloheptyl, and more preferably cyclopropyl, cyclobutyl, and cyclopentyl.

[0083] The term "spirocycloalkyl" refers to a polycyclic group that shares one carbon atom (called a spiro atom) between 5- to 20-membered monocyclic rings, which contain one or more double bonds but no ring has a completely conjugated π-electron system. Preferably, it has 6 to 14 members, more preferably 7 to 10 members. Based on the number of shared spiro atoms between the rings, spirocycloalkyls can be classified as monospirocycloalkyls, bisspirocycloalkyls, or polyspirocycloalkyls, with monospirocycloalkyls and bisspirocycloalkyls being preferred. More preferred are 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospirocycloalkyls. Non-limiting examples of spirocycloalkyls include:

[0084] [ka] Includes; Also included are spirocycloalkyls in which monospirocycloalkyls and heterocycloalkyls share a spiro atom, non-limiting examples of which include:

[0085] [ka] Includes:

[0086] The term "fused cycloalkyl" refers to an all-carbon polycyclic group having 5 to 20 members, in which each ring in the system shares an adjacent pair of carbon atoms with another ring in the system, where one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron system. Preferably, it has 6 to 14 members, more preferably 7 to 10 members. Depending on the number of rings, fused cycloalkyls can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic, preferably bicyclic or tricyclic, and more preferably 5-membered / 5-membered or 5-membered / 6-membered bicycloalkyls. Non-limiting examples of fused cycloalkyls include:

[0087] [ka] Includes:

[0088] The term "bridged cycloalkyl" refers to an all-carbon polycyclic group having 5 to 20 members, in which any two rings share two carbon atoms that are not directly connected, and which may contain one or more double bonds, but no ring has a completely conjugated π-electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, bridged cycloalkyls can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyls include:

[0089] [ka] Includes:

[0090] The cycloalkyl ring can be fused to an aryl, heteroaryl, or heterocycloalkyl ring, where the ring connected to the core structure is a cycloalkyl, non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl, etc. The cycloalkyl can be optionally substituted or unsubstituted, and if substituted, the substituents are preferably independently selected from one or more of the following groups: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carbamate.

[0091] The term "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which may be nitrogen, oxygen, C( O), S(O)(=NH) or S(O) m S(O) m(where m is an integer of 0 to 2), but does not contain a ring moiety of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 10 ring atoms; and most preferably, it contains 3 to 8 ring atoms. Non-limiting examples of monocyclic heterocyclic groups include trimethylene oxide, triethylene sulfide, azetidinyl, tetrahydropyranyl, azepanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, and the like, and preferably include trimethylene oxide, triethylene sulfide, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1-imino-1-oxothiopyranyl, azepanyl, piperidinyl, and piperazinyl. Polycyclic heterocyclic groups include spirocyclic, fused-ring, and bridged-ring heterocyclic groups; wherein related spirocyclic, fused-ring, and bridged-ring multicyclic groups are optionally linked to other groups through single bonds, or further linked to other cycloalkyl, heterocyclic, aryl, and heteroaryl groups through any two or more atoms on the ring. Heterocyclic groups can be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups, independently selected from hydrogen, alkyl, hydroxyalkyl, amino, imino, cyano, oxo, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

[0092] The term "spiropolycyclic group" refers to a 5- to 20-membered polycyclic polycyclic group sharing one atom (called a spiroatom) between the monocyclic rings, where one or more of the ring atoms is nitrogen, oxygen, S(O)(=NH) or S(O) m(where m is an integer from 0 to 2), with the remaining ring atoms being carbon. It may contain one or more double bonds, but no ring has a completely conjugated π-electron system. Preferably, it has 6 to 14 members, more preferably 7 to 10 members. Based on the number of spiro atoms shared between the rings, spiropolycyclic groups can be classified as monospiropolycyclic groups, bisspiropolycyclic groups, or polyspiropolycyclic groups, with monospiropolycyclic groups and bisspiropolycyclic groups being preferred. More preferred are 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospiropolycyclic groups. Non-limiting examples of spirocycloalkyls include:

[0093] [ka] Includes:

[0094] The term "fused multi-ring group" refers to a 5- to 20-membered polycyclic multi-ring group in which each ring in the system shares an adjacent pair of atoms with another ring in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated pi-electron system, and in which one or more ring atoms is nitrogen, oxygen, or S(O) m (where m is an integer of 0 to 2), and the remaining ring atoms are carbon. Preferably, it has 6 to 14 ring members, more preferably 7 to 10 ring members. Depending on the number of rings, it may be a bicyclic, tricyclic, tetracyclic or polycyclic fused ring. They can be classified as chloroalkyls, and are preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclo-fused multi-ring groups. Non-limiting examples of fused multi-ring groups are:

[0095] [ka] Includes:

[0096] The term "bridged cycloalkyl" refers to a 5- to 14-membered polycyclic multi-ring group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, but no ring has a completely conjugated pi-electron system, and in which one or more ring atoms is nitrogen, oxygen, or S(O). m (where m is an integer of 0 to 2), and the remaining ring atoms are carbon. Preferably, it has 6 to 14 ring members, more preferably 7 to 10 ring members. Depending on the number of rings, bridged cycloalkyls can be classified as bicyclic, tricyclic, tetracyclic or polycyclic, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyls are:

[0097] [ka] Includes:

[0098] The multi-ring group ring can be fused to an aryl, heteroaryl, or cycloalkyl ring, and the ring connected to the core structure is a multi-ring group, non-limiting examples of which are:

[0099] [ka] Includes:

[0100] Multi-ring groups can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carbamate.

[0101] The term "aryl" refers to 6- to 14-membered all-carbon monocyclic and fused polycyclic rings (i.e., rings that share adjacent pairs of carbon atoms) having a conjugated π-electron system, preferably 6- to 10-membered, such as phenyl and naphthyl. Phenyle is more preferred. The aryl ring can be fused to a heteroaryl, multicyclic group, or cycloalkyl ring, in which the ring connected to the core structure is aryl, non-limiting examples of which include:

[0102] [ka] Includes:

[0103] Aryl can be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carbamate.

[0104] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, where the heteroatoms are selected from oxygen, sulfur, and nitrogen. Heteroaryl is preferably 5 to 10-membered, more preferably 5- or 6-membered, such as imidazole, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazolyl, pyridazinyl, pyrazinyl, oxadiazolyl, etc., preferably triazolyl, thienyl, imidazolyl, pyrazole, pyridazinyl, and pyrimidinyl; more preferably triazolyl. The heteroaryl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, where the ring connected to the core structure is a heteroaryl ring, non-limiting examples of which include:

[0105] [ka] Includes:

[0106] The heteroaryl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carbamate.

[0107] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), where alkyl is as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy. Alkoxy can be optionally substituted or unsubstituted, and if substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carbamate. "Haloalkyl" refers to alkyl substituted with one or more halogens, where alkyl is as defined above. "Haloalkoxy" refers to an alkoxy substituted with one or more halogens, where alkoxy is as defined above.

[0108] "Hydroxyalkyl" refers to an alkyl substituted with a hydroxy, where said alkyl is as defined above. "Alkenyl" refers to an alkenyl group, also called alkenyl, where the alkenyl may be further substituted with other related groups, such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carbamate.

[0109] "Alkynyl" refers to (CH≡C- or -C≡C-), where the alkynyl may be further substituted with other related groups, such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyclohexyl ... The alkyl group is selected from the group consisting of aryl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, and carbamate.

[0110] "Hydroxy" refers to the group --OH. "Halogen" refers to fluorine, chlorine, bromine or iodine. "Amino" refers to -NH2. "Cyano" refers to -CN. "Nitro" refers to -NO2. "Carboxyl" refers to --C(O)OH.

[0111] "THF" refers to tetrahydrofuran. "EtOAc" refers to ethyl acetate. "MeOH" refers to methanol. "DMF" refers to N,N-dimethylformamide. "DIPEA" refers to diisopropylethylamine. "TFA" refers to trifluoroacetic acid.

[0112] "MeCN" refers to acetonitrile. "DMA" refers to N,N-dimethylacetamide. "Et2O" refers to diethyl ether. "DCE" refers to 1,2-dichloroethylene. "DIPEA" refers to diisopropylethylamine. "NBS" refers to N-bromosuccinimide.

[0113] "NIS" refers to N-N-iodobromosuccinimide. "Cbz-Cl" refers to benzyl chloroformate. "Pd2(dba)3" refers to tris(dibenzylideneacetone)dipalladium. "Dppf" refers to 1,1'-bis(diphenylphosphino)ferrocene. "HATU" refers to 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

[0114] "KHMDS" refers to potassium hexamethyldisilazide. "LIHMDS" refers to lithium bis(trimethylsilyl)amide. "MeLI" refers to methyllithium. "n-BuLI" refers to n-butyllithium. "NaBH(OAc)3" refers to sodium triacetoxyborohydride. Different terms such as "X is selected from A, B, or C," "X is selected from A, B, and C," "X is A, B, or C," and "X is A, B, and C" represent the same meaning, i.e., X can be any one or more of A, B, and C.

[0115] Any hydrogen atom described in the present invention can be replaced with its isotope, deuterium, and any hydrogen atom in the example compounds of the present invention can also be replaced with a deuterium atom. "Optional" or "optionally" means that the described item or circumstance may, but need not, occur, and the description includes instances where the described item or circumstance occurs and instances where the item or circumstance does not occur. For example, "a multi-ring group optionally substituted with alkyl" means that alkyl may, but need not, be present, and the description includes situations where the multi-ring group is substituted with alkyl and situations where the multi-ring group is not substituted with alkyl.

[0116] "Substituted" refers to one or more hydrogen atoms of a group, preferably up to five, more preferably Preferably, 1 to 3 hydrogen atoms are independently substituted with a corresponding number of substituents. Needless to say, the substituents are only in their possible chemical positions, and those skilled in the art can easily determine possible or impossible substitutions (through experiment and theory) without much effort. For example, when an amino or hydroxyl containing free hydrogen is bonded to a carbon atom having an unsaturated (e.g., olefinic) bond, it may be unstable.

[0117] A "pharmaceutical composition" refers to a mixture of one or more compounds described herein or physiologically / pharmacologically acceptable salts or prodrugs thereof with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a "pharmaceutical composition" is to facilitate administration to an organism and promote absorption of the active ingredients, thereby exerting their biological activity.

[0118] "Pharmaceutically acceptable salt" refers to salts of compounds of the present invention, which are safe and effective when used in mammals and possess the desired biological activity. DETAILED DESCRIPTION OF THE INVENTION

[0119] The present invention will be further described below based on examples, but the present invention is not limited to the scope of these examples.

[0120] Example The structure of the compounds of the present invention can be identified by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are reported in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 nuclear magnetic resonance spectrometer, with deuterated dimethyl sulfoxide (DMSO-d), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3) as solvents, and tetramethylsilane (TMS) as the internal standard.

[0121] For liquid chromatography mass spectrometry (LC-MS), an Agilent 1200 infinity series mass spectrometer was used. For HPLC, an Agilent A 1200DAD high performance liquid chromatograph (column: Sunfire C18 150 x 4.6 mm) and a Waters 2695-2996 high performance liquid chromatograph (column: Gimini C18 150 x 4.6 mm) are used.

[0122] Thin layer chromatography silica gel plates are Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plates, with a 0.15mm to 0.20mm diameter for TLC and a 0.4mm to 0.5mm diameter for thin layer chromatography (thin layer chromatography) for product separation and purification. Column chromatography typically uses Yantai Yellow Sea silica gel 200-300 mesh silica gel as the carrier.

[0123] The starting materials in the examples of the present invention are known and commercially available or can be synthesized according to methods known in the art. Unless otherwise specified, all reactions of the present invention are carried out under a continuous magnetic stirrer under an atmosphere of dry nitrogen or argon gas, the solvents are dry solvents, and the reaction temperatures are in °C.

[0124] Example 1 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfinyl<sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carboxamide Bonitrile

[0125] [ka] Step 1: 2-(methylthio)ethan-1-ol

[0126] [ka] Ethyl 2-(methylthio)acetate (500 mg, 3.7 mmol) was dissolved in 20 mL of MeOH, and NaBH (562 mg, 14.8 mmol) was added at 0 °C. The mixture was stirred at room temperature for 0.5 h. 10 mL of NH Cl solution was added, followed by extraction with ethyl acetate (20 mL × 3). The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. Filtration and spin-drying afforded 2-(methylthio)ethan-1-ol (240 mg, colorless liquid, 70% yield).

[0127] Step 2: 4-Bromo-6-(2-(methylthio)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0128] [ka] 4-Bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (100 mg, 0.42 mmol) was dissolved in 10 mL of THF, and 2-(methylthio)ethan-1-ol (16 mg, 0.5 mmol), triphenylphosphine (165 mg, 0.63 mmol), and dihydrobenzofuran (127 mg, 0.63 mmol) were added. The mixture was stirred at room temperature overnight. 10 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (dichloromethane / methanol = 10 / 1) to give 4-bromo-6-(2-(methylthio)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (69 mg, white solid, yield: 53%).

[0129] MS m / z(ESI):311.9[M+H] + . Step 3: 4-Bromo-6-(2-(methylsulfinyl<sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0130] [ka] 4-Bromo-6-(2-(methylthio)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (200 mg, 0.64 mmol) was dissolved in 20 mL of DCM, m-chloroperoxybenzoic acid (110 mg, 0.64 mmol) was added, and the mixture was stirred at room temperature for 4 hours. 10 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (washing with dichloromethane / methanol = 10 / 1) to give 4-bromo-6-(2-(methylsulfinyl<sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (189 mg, white solid, yield: 90%).

[0131] MS m / z(ESI):327.9[M+H]+ . Step 4: tert-Butyl 3-(5-bromopyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0132] [ka] 5-Bromo-2-fluoropyridine (500 mg, 2.5 mmol) was dissolved in 20 mL of DMSO, and tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (489 mg, 2.8 mmol) and potassium carbonate (1.7 g, 12.5 mmol) were added. The mixture was stirred at 90 °C overnight. 10 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (washing with petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl 3-(5-bromopyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (650 mg, white solid, yield: 73%). MS m / z(ESI):354.0[M+H] + .

[0133] Step 5: 3-(5-bromopyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane [ka] tert-Butyl 3-(5-bromopyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (100 mg, 0.28 mmol) was dissolved in 3 mL of DCM, 1 mL of TFA was added, and the mixture was stirred at room temperature for 2 hours. The mixture was spin-dried, and the pH was adjusted to basic by adding aqueous sodium bicarbonate solution, followed by extraction with ethyl acetate (20 mL x 3). The organic layer was washed with water and saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, spin-dried, and 3-(5-bromopyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (100 mg, 0.28 mmol) was obtained. Bicyclo[3.1.1]heptane (70 mg, white solid, yield: 99%) was obtained.

[0134] MS m / z (ESI): 254.0 [M + H] + . Step 6: 3-(5-bromopyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane

[0135] [ka] 3-(5-Bromopyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane (70 mg, 0.28 mmol) and 6-methoxynicotinaldehyde (113 mg, 0.83 mmol) were dissolved in 10 mL of DCE, and NaBH(OAc)3 (176 mg, 0.83 mmol) was added. The mixture was stirred overnight at room temperature. 10 mL of water was added, and the mixture was extracted with ethyl acetate (20 × 3). The organic layer was washed with water and saturated brine, and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (washing with dichloromethane / methanol = 10 / 1) to give 3-(5-bromopyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane (60 mg, white solid, yield: 57%).

[0136] MS m / z(ESI):375.0[M+H] + . Step 7: 6-(2-(methylsulfinyl<sulfinyl>)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0137] [ka] 4-Bromo-6-(2-(methylsulfinyl<sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (200 mg, 0.6 mmol), bis(pinacolato)diboron (232 mg, 0.91 mmol), Pd(dppf)Cl (44 mg, 0.06 mmol), and KOAc (176 mg, 1.8 mmol) were dissolved in dioxane / HO (20 mL, v / v = 10:1) and stirred overnight at 90 °C under nitrogen gas protection. 10 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. After filtration and spin-drying, the crude product was separated by column chromatography (washing with dichloromethane / methanol = 10 / 1) to give 6-(2-(methylsulfinyl<sulfinyl>)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (117 mg, white solid, yield: 52%).

[0138] MS m / z(ESI):376.1[M+H] + . Step 8: 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfinyl<sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0139] [ka] 6-(2-(methylsulfinyl<sulfinyl>ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (60 mg, 0.16 mmol), 3-(5-bromopyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane (72 mg, 0.19 mmol), Pd(dppf)Cl (15 mg, 0.02 mmol), and KOAc (44 mg, 0.5 mmol) were dissolved in dioxane / HO (20 mL, v / v = 10:1) and stirred overnight at 90 °C under nitrogen gas protection. 10 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and spun dry. The crude product was purified by prep-HPLC to give the product, 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfinyl<sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (41 mg, white solid, 48% yield).

[0140] MS m / z(ESI):544.2[M+H] + . 1 H NMR(400MHz,DMSO)δ8.82(d,J=1.9Hz,1H),8.62(s,1H),8.41(d,J=2.3Hz,1H),8.07(d,J=1.9Hz,1H) ),7.85(dd,J=8.8,2.4Hz,1H),7.68(dd,J=8.5,2.2Hz,1H),7.32(d,J=2.0Hz,1H),6.78(t,J=9.4Hz, 2H),4.62-4.44(m,2H),3.82(s,3H),3.73(d,J=11.6Hz,2H),3.67(d,J=5.7Hz,2H),3.58-3.52(m,2H ),3.50(s,2H),3.13(dt,J=13.6,4.4Hz,1H),2.67(s,3H),2.59-2.52(m,2H),1.59(d,J=8.5Hz,1H).

[0141] Example 2 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfonyl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0142] [ka]

[0143] [ka] Using 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfinyl<sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material, and following Step 3 of Example 1, 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfonyl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (45 mg, white solid, 70% yield) was obtained. MS m / z(ESI):560.2[M+H] + .

[0144] Example 3 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(S-methylsulfonimidoyl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0145] [ka]

[0146] [ka] 4-(6-(6-((6-Methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfonyl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (60 mg, 0.11 mmol) was dissolved in 5 mL of methanol, and ammonium carbamate (17 mg, 0.22 mmol) and iodobenzene diacetate (70 mg, 0.22 mmol) were added. The mixture was allowed to react at room temperature for 2 hours. 10 mL of water was added, and the mixture was extracted with ethyl acetate (10 × 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was purified by prep-HPLC to give the product 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(S-methylsulfonimidoyl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (25 mg, white solid, 45% yield). MS m / z (ESI): 559.2 [M + H] + .

[0147] Example 4 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-(methylsulfinyl<sulfinyl>)propoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0148] [ka] Starting from ethyl 3-(methylthio)propionate and following Example 1, the title compound (35 mg, white solid, 40%) was obtained. MS m / z(ESI):558.2[M+H] + .

[0149] Example 5 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-(methylsulfonyl)propoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0150] [ka]

[0151] [ka] Using 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-(methylsulfinyl<sulfinyl>)propoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material and following Example 2, 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-(methylsulfonyl)propoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (32 mg, white solid, yield 56%) was obtained. MS m / z (ESI): 574.2 [M + H] + .

[0152] Example 6 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-(S-methylsulfonimidoyl)propoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0153] [ka]

[0154] [ka] 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-(methyl Using 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-(S-methylsulfonimidoyl)propoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material and following the procedure of Example 3, 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-(S-methylsulfonimidoyl)propoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (28 mg, white solid, yield 44%) was obtained. MS m / z (ESI): 573.2 [M + H] + .

[0155] Example 7 6-((2-hydroxy-2-methylpropyl)thio)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0156] [ka] Step 1: 4-Bromo-3-cyanopyrazolo[1,5-a]pyridin-6-yl trifluoromethanesulfonate

[0157] [ka] A 25 mL single-neck flask was charged with 4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (200 mg, 0.84 mmol), dichloromethane (5 mL), and pyridine (1 mL). The reaction mixture was stirred for 2 minutes, followed by the slow dropwise addition of trifluoromethanesulfonic anhydride (355 mg, 1.26 mmol). The reaction mixture was stirred at room temperature for 12 hours, concentrated, dissolved in ethyl acetate (10 mL), and washed with saturated brine (5 mL x 3). The organic layer was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate: 1 / 1) to give 4-bromo-3-cyanopyrazolo[1,5-a]pyridin-6-yl trifluoromethanesulfonate (280 mg, pale yellow solid, 90.0% yield). MS m / z (ESI): 370.0 [M + H] + ,372.0[M+H+2] + .

[0158] Step 2: 4-Bromo-6-((2-hydroxy-2-methylpropyl)thio)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0159] [ka] A 25 mL three-neck flask was charged with 4-bromo-3-cyanopyrazolo[1,5-a]pyridin-6-yl trifluoromethanesulfonate (280 mg, 0.75 mmol), 1-mercapto-2-methylpropan-2-ol (80 mg, 0.75 mmol), tris(dibenzylideneacetone)dipalladium (68 g, 0.075 mmol), 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (71 mg, 0.15 mmol), diisopropylethylamine (193 mg, 1.5 mmol), and dioxane (10 mL), and the reaction solution was purged with nitrogen gas five times. The reaction solution was heated to 85°C under nitrogen gas protection and stirred for 5 hours. After cooling to room temperature, the reaction solution was concentrated and dissolved in ethyl acetate (10 mL). After washing with saturated brine (5 mL x 3), the organic layer was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated and purified by column chromatography (dichloromethane / methanol: 30 / 1) to obtain the product 4-bromo-6-((2-hydroxy-2-methylpropyl)thio)pyrazolo[1,5-a]pyridine-3-carbonitrile (140 mg, white solid, yield: 56.6%). MS m / z(ESI):326.0[M+H] + ,328.0[M+H+2] + .

[0160] Step 3: 6-((2-hydroxy-2-methylpropyl)thio)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0161] [ka] A 25 mL three-neck flask was charged sequentially with 4-bromo-6-((2-hydroxy-2-methylpropyl)thio)pyrazolo[1,5-a]pyridine-3-carbonitrile (50 mg, 0.15 mmol), 6-((6-methoxypyridin-3-yl)methyl)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane (64 mg, 0.15 mmol), tetrakis(triphenylphosphine)palladium (17 mg, 0.015 mmol), sodium carbonate (48 mg, 0.45 mmol), dioxane (5 mL), and water (1 mL), and the reaction solution was purged with nitrogen gas five times. The reaction mixture was heated to 85°C under nitrogen gas protection and stirred for 5 hours. After cooling to room temperature, the reaction mixture was concentrated, dissolved in ethyl acetate (10 mL), washed with saturated brine (5 mL x 3), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by prep-HPLC to give 6-((2-hydroxy-2-methylpropyl)thio)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (25 mg, white solid, 30.1% yield). MS m / z (ESI): 542.2 [M + H] + .

[0162] Example 8 6-((2-hydroxy-2-methylpropyl)thio)-4-(6-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0163] [ka] Step 1: 4-(6-fluoropyridin-3-yl)-6-((2-hydroxy-2-methylpropyl)thio)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0164] [ka] A 25 mL three-neck flask was charged sequentially with 4-bromo-6-((2-hydroxy-2-methylpropyl)thio)pyrazolo[1,5-a]pyridine-3-carbonitrile (100 mg, 0.30 mmol), 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (68 mg, 0.30 mmol), tetrakis(triphenylphosphine)palladium (27 mg, 0.03 mmol), sodium carbonate (97 mg, 0.09 mmol), dioxane (5 mL), and water (1 mL). The reaction solution was purged with nitrogen gas five times. The reaction solution was heated to 85 °C under nitrogen gas protection and stirred for 5 hours. After cooling to room temperature, the reaction solution was concentrated, dissolved in ethyl acetate (10 mL), and washed with saturated brine (5 mL × 3). The organic layer was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated by column chromatography (dichloromethane / methanol: 30 / 1) and purified to give 4-(6-fluoropyridin-3-yl)-6-((2-hydroxy-2-methylpropyl)thio)pyrazolo[1,5-a]pyridine-3-carbonitrile (85 mg, pale yellow solid, yield: 80.9%). MS m / z(ESI):343.1[M+H] + .

[0165] Step 2: 6-((2-hydroxy-2-methylpropyl)thio)-4-(6-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0166] [ka] A 25 mL three-neck flask was charged sequentially with 4-(6-fluoropyridin-3-yl)-6-((2-hydroxy-2-methylpropyl)thio)pyrazolo[1,5-a]pyridine-3-carbonitrile (85 mg, 0.25 mmol), 2-methoxy-5-(piperidin-4-oxy)pyridine (52 mg, 0.25 mmol), diisopropylethylamine (65 mg, 0.50 mmol), and dimethyl sulfoxide (2 mL). The reaction solution was heated to 90 °C under nitrogen gas protection and stirred for 48 hours. After cooling to room temperature, the reaction solution was concentrated, dissolved in ethyl acetate (10 mL), and washed with saturated brine (5 mL × 3). The organic layer was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by prep-HPLC to give 6-((2-hydroxy-2-methylpropyl)thio)-4-(6-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (60 mg, white solid, yield: 45.5%). MS m / z (ESI): 531.2 [M + H] + .

[0167] Example 9 6-(2-hydroxy-2-methylpropylsulfonimidoyl)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0168] [ka] Step 1: 4-Bromo-6-((2-hydroxy-2-methylpropyl)sulfinyl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0169] [ka] 4-Bromo-6-((2-hydroxy-2-methylpropyl)thio)pyrazolo[1,5-a]pyridine-3-carbonitrile (100 mg, 0.30 mmol) was dissolved in dichloromethane (5 mL) and cooled to -20 °C in a dry ice / ethyl acetate bath. m-Chloroperoxybenzoic acid (51 mg, 0.3 mmol) was added in batches. After the addition was complete, the ice bath was removed and the mixture was allowed to warm to room temperature and stirred for 30 minutes. Saturated sodium carbonate (5 mL) was added to the reaction solution, which was then extracted with ethyl acetate (5 mL × 2). The organic layers were combined, washed with saturated sodium chloride solution (5 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 4-bromo-6-((2-hydroxy-2-methylpropyl)sulfinyl ) Pyrazolo[1,5-a]pyridine-3-carbonitrile (95 mg, 90.5%) was obtained. MS m / z(ESI):342.0[M+H]+, 344.0[M+H+2]+.

[0170] Step 2: 4-Bromo-6-(2-hydroxy-2-methylpropylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0171] [ka] 4-Bromo-6-((2-hydroxy-2-methylpropyl)thionyl)pyrazolo[1,5-a]pyridine-3-carbonitrile (95 mg, 0.28 mmol) was dissolved in methanol (5 mL), and ammonium carbamate (108 mg, 1.39 mmol) and iodobenzene diacetate (268 mg, 0.83 mmol) were added sequentially. The mixture was stirred at room temperature for 1 hour. The reaction was stopped and quenched by the addition of water (5 mL). The mixture was extracted with ethyl acetate (5 mL × 2), and the organic layers were combined. The organic layer was washed with saturated sodium chloride (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 4-bromo-6-(2-hydroxy-2-methylpropylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile (90 mg, 90.7%). MS m / z(ESI):357.0[M+H] + , 359.0[M+H+2] + .

[0172] Step 3: 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0173] [ka] Using 4-bromo-6-(2-hydroxy-2-methylpropylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile as the raw material, 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile (95 mg, white solid, yield 95.6%) was obtained by referring to Step 1 of Example 8. MS m / z(ESI):374.1[M+H] + .

[0174] Step 4: 6-(2-hydroxy-2-methylpropylsulfonimidoyl)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0175] [ka] Using 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile as the raw material, 6-(2-hydroxy-2-methylpropylsulfonimidoyl)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (30 mg, white solid, yield 22.0%) was obtained by referring to Step 2 of Example 8. MS m / z(ESI):532.2[M+H]+ .

[0176] Example 10 6-(Ethylsulfonimidoyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0177] [ka] Step 1: 4-Bromo-6-(ethylthio)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0178] [ka] A 25 mL three-neck flask was charged with 4-bromo-3-cyanopyrazolo[1,5-a]pyridin-6-yl trifluoromethanesulfonate (200 mg, 0.54 mmol), sodium ethanethiolate (90 mg, 1.08 mmol), and dioxane (5 mL). The reaction mixture was heated to 85 °C under nitrogen gas protection and stirred for 5 h. After cooling to room temperature, the reaction mixture was concentrated, dissolved in ethyl acetate (10 mL), and washed with saturated brine (5 mL x 3). The organic layer was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated and purified by column chromatography (dichloromethane / methanol: 30 / 1) to give the product, 4-bromo-6-(ethylthio)pyrazolo[1,5-a]pyridine-3-carbonitrile (120 mg, white solid, yield: 78.7%). MS m / z (ESI): 282.0 [M + H] + , 284.0[M+H+2] + .

[0179] Step 2: 4-Bromo-6-(ethylsulfinyl)pyrazolo[1 ,5-a]pyridine-3-carbonitrile

[0180] [ka] Using 4-bromo-6-(ethylthio)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material, 4-bromo-6-(ethylsulfinyl<sulfinyl>)pyrazolo[1,5-a]pyridine-3-carbonitrile (120 mg, white solid, 96.6% yield) was obtained by following Step 1 of Example 9. MS m / z (ESI): 298.0 [M + H] + , 300.0[M+H+2] + .

[0181] Step 3: 4-Bromo-6-(ethylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0182] [ka] Using 4-bromo-6-(ethylsulfinyl<sulfinyl>)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material, 4-bromo-6-(ethylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile (120 mg, white solid, 95.9% yield) was obtained by following Step 2 of Example 9. MS m / z (ESI): 313.0 [M + H] + , 315.0[M+H+2] + .

[0183] Step 4: 6-(ethylsulfonimidoyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0184] [ka] Using 4-bromo-6-(ethylsulfonimidoyl)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material, 6-(ethylsulfonimidoyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (45 mg, white solid, 22.2% yield) was obtained by referring to Step 3 of Example 7. MS m / z(ESI):529.2[M+H] + .

[0185] Example 11 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile

[0186] [ka] Step 1: 5-Bromo-3-methoxy-2-methylpyridine

[0187] [ka] 5-Bromo-2-methylpyridin-3-ol (10 g, 53.2 mmol) was dissolved in acetonitrile (50 mL), potassium carbonate (14.7 g, 106.4 mmol) was added, and iodomethane (22.66 g, 160 mmol) was added dropwise. The mixture was then stirred at 80°C for 16 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and dried. The layers were separated and purified (petroleum ether / ethyl acetate = 15:1) to obtain a pale yellow solid, 5-bromo-3-methoxy-2-methylpyridine (5 g, yield: 46.7%). 1 H NMR(400MHz,CDCl3)δ8.14(d,J=1.6Hz,1H),7.22(d,J=1.4Hz,1H),3.84(s,3H),2.42(s,3H). MS m / z (ESI): 202.0 [M + H] + .

[0188] Step 2: 1-amino-5-bromo-3-methoxy-2-methylpyridin-1-ium 2,4,6-trimethylbenzenesulfonate

[0189] [ka] To a solution of 2-[(aminooxy)sulfonyl]-1,3,5-trimethylbenzene (5.32 g, 24.75 mmol) in dichloromethane (50 mL) at 0°C, 5-bromo-3-methoxy-2-methylpyridine (5 g, 24.75 mmol) was added in batches, followed by stirring at 0°C for 1.5 hours. Methyl tert-butyl ether (30 mL) was added to the reaction solution, which was then slurried for 15 minutes. The mixture was then filtered, and the cake was dried to obtain a white solid, 2,4,6-trimethylbenzenesulfonic acid 1-amino-5-bromo-3-methoxy-2-methylpyridine. -methylpyridin-1-ium (9 g, yield: 87.3%) was obtained.

[0190] Step 3: 4-Bromo-6-methoxy-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile [ka] To a solution of 1-amino-5-bromo-3-methoxy-2-methylpyridin-1-ium 2,4,6-trimethylbenzenesulfonate (9 g, 21.6 mmol) and 2-chloroacrylonitrile (2.8 g, 32.37 mmol) in dichloromethane (100 mL) at 0°C, 1,8-diazabicyclo[5.4.0]undec-7-ene (6.6 g, 43.2 mmol) was added in batches, and the mixture was warmed to room temperature and stirred for 24 hours. Methyl tert-butyl ether (50 mL) was added to the reaction solution, and the mixture was slurried at room temperature for 15 minutes. The mixture was then filtered, and the cake was dried to obtain a pale yellow solid, 4-bromo-6-methoxy-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (2 g, yield: 35%).

[0191] MS m / z (ESI): 266.0 [M + H] + . Step 4: 4-Bromo-6-hydroxy-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile

[0192] [ka] To a solution of 4-bromo-6-methoxy-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (2 g, 7.55 mmol) in 1,2-dichloroethane (20 mL) was added aluminum trichloride (2 g, 15.1 mmol) in a batchwise manner, followed by stirring at 80° C. for 2 hours, cooling to room temperature, quenching by adding sodium sulfate decahydrate, filtering, washing the cake with dichloromethane, and adding saturated brine to the filtrate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a black solid, 4-bromo-6-hydroxy-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (1.5 g, yield: 79%). MS m / z(ESI):249.7[MH] + .

[0193] Step 5: 4-Bromo-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile

[0194] [ka] To a solution of 4-bromo-6-hydroxy-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (1.5 g, 5.95 mmol), potassium carbonate (1.6 g, 11.9 mmol), and acetonitrile (10 mL), 2,2-dimethyloxirane (857 mg, 11.9 mmol) was added, and the mixture was stirred at 80°C for 16 hours. The reaction solution was concentrated under reduced pressure, dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, 4-bromo-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (1.4 g, yield: 74%). MS m / z(ESI):324.0[M+H] + .

[0195] Step 6: 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile

[0196] [ka] A mixture of 4-bromo-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (1.4 g, 4.32 mmol), 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.15 g, 5.18 mmol), potassium acetate (847 mg, 8.64 mmol), and dioxane (15 mL) was treated with 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane. After adding tungsten complex (178 mg, 0.22 mmol), the mixture was purged with nitrogen gas three times and then stirred at 100°C under nitrogen gas protection for 16 hours. After the reaction was completed, the mixture was cooled and filtered. The filtrate was concentrated under reduced pressure and dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (1.2 g, yield: 82%). MS m / z(ESI):341.1[M+H] + .

[0197] Step 7: tert-Butyl 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0198] [ka] A mixture of 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (1.2 g, 3.52 mmol), tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (1.4 g, 7.04 mmol), N,N-diisopropylethylamine (1.36 g, 10.56 mmol) and dimethyl sulfoxide (10 mL) was stirred at 100°C for 24 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic layers were combined and washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The mixture was separated by column chromatography (dichloromethane / methanol = 10:1) to give a colorless oily substance, tert-butyl 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (800 mg, yield: 44%). MS m / z (ESI): 519.2 [M + H] + .

[0199] Step 8: 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile

[0200] [ka] tert-Butyl 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carbamate (800 mg, 1.54 mmol) was dissolved in dichloromethane (9 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure and dried. The resulting mixture was used directly in the next step without further purification to obtain a pale yellow oily substance, 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (1 g, crude product). MS m / z(ESI):419.2[M+H] + .

[0201] Step 9: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile

[0202] [ka] To a solution of 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (100 mg, 0.24 mmol), 6-methoxynicotinaldehyde (66 mg, 0.48 mmol), and 1,2-dichloroethane (3 mL), sodium cyanoborohydride (45 mg, 0.72 mmol) was added, followed by stirring at room temperature for 24 hours. After completion of the reaction, water was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (20 mL × 3), and the combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The resulting mixture was separated by preparative chromatography to give a white solid: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (10 mg, yield: 8%). MS m / z(ESI):540.2[M+H] + .

[0203] Example 12 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-N-phenyl-3-diazabicyclo[3.1.1]heptane-6-formamide

[0204] [ka]

[0205] [ka] To a solution of 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (100 mg, 0.24 mmol), triethylamine (48 mg, 0.48 mmol) and dichloromethane (3 mL), carbonyldiimidazole (58 mg, 0.36 mmol) was added, and the mixture was stirred at room temperature for 1 hour. Then, aniline (33 mg, 0.36 mmol) was added, and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The mixture was separated by preparative chromatography to obtain a white solid, 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-N-phenyl-3-diazabicyclo[3.1.1]heptane-6-formamide (15 mg, yield: 12%). MS m / z(ESI):538.2[M+H] + .

[0206] Example 13 6-(2-hydroxy-2-methylpropoxy)-7-methyl-4-(6-(4-(pyridin-3-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0207] [ka]

[0208] [ka] A mixture of 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile (100 mg, 0.24 mmol), 3-(piperidin-4-yloxy)pyridine (85 mg, 0.48 mmol), potassium carbonate (99 mg, 0.72 mmol), and acetonitrile (3 mL) was stirred at 100°C for 16 hours. After the reaction was completed, water was added to quench the reaction, and the resulting mixture was concentrated with acetic acid. The organic layer was extracted with ethyl acetate (20 mL × 3), washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness and separated by preparative chromatography to give a white solid: 6-(2-hydroxy-2-methylpropoxy)-7-methyl-4-(6-(4-(pyridin-3-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (15 mg, yield: 13%). MS m / z (ESI): 499.2 [M + H] + .

[0209] Example 14 4-(6-(6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0210] [ka] Step 1: 5-Bromo-2-fluoro-3-methoxypyridine

[0211] [ka] 5-Bromo-2-fluoropyridin-3-ol (5 g, 26.18 mmol) was dissolved in acetonitrile (50 mL), potassium carbonate (7.2 g, 52.36 mmol) was added, and iodomethane (11.2 g, 78.54 mmol) was added dropwise. The mixture was then stirred at 80°C for 16 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, dried, and separated and purified by column chromatography (petroleum ether / ethyl acetate = 1:1) to obtain a pale yellow solid, 5-bromo-2-fluoro-3-methoxypyridine (4.5 g, yield: 83%). 1 H NMR (400MHz, CDCl3) δ7.80(d,J=1.8Hz,1H),7.38(dd,J=8.8,1.9Hz,1H),3.91(s,3H). MS m / z (ESI): 206.0 [M + H] + .

[0212] Step 2: 1-amino-5-bromo-2-fluoro-3-methoxypyridin-1-ium 2,4,6-trimethylbenzenesulfonate

[0213] [ka] To a solution of 2-[(aminooxy)sulfonyl]-1,3,5-trimethylbenzene (4.7 g, 21.84 mmol) in dichloromethane (50 mL) at 0°C, 5-bromo-2-fluoro-3-methoxypyridine (5 g, 21.84 mmol) was added in batches, followed by stirring at 0°C for 1.5 hours. Methyl tert-butyl ether (100 mL) was added to the reaction solution, and the mixture was slurried for 15 minutes. After filtration, the cake was dried to obtain a pale yellow solid, 2,4,6-trimethylbenzenesulfonic acid 1-amino-5-bromo-2-fluoro-3-methoxypyridin-1-ium (8 g, yield: 87%).

[0214] Step 3: 4-Bromo-7-fluoro-6-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile [ka] 2,4,6-trimethylbenzenesulfonic acid 1-amino-5-bromo-2-fluoro-3-methoxypyridin-1-ium (8 g, 19 mmol) and 2-chloroacrylonitrile (2.5 g, 28.5 mmol) in dichloromethane (100 mL) solution at 0 ° C. 1,8-diazabicyclo[5.4.0]undec-7-ene (5.8 g, 38 mmol) was added in batches, and the mixture was warmed to room temperature and stirred for 24 hours. Methyl tert-butyl ether (100 mL) was added to the reaction solution, and the mixture was slurried at room temperature for 15 minutes. After that, it was filtered, and the cake was dried to obtain a pale yellow solid, 4-bromo-7-fluoro-6-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile (3 g, yield: 58%).

[0215] MS m / z (ESI): 270.0 [M + H] + . Step 4: 4-Bromo-7-fluoro-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile

[0216] [ka] To a solution (30 mL) of 4-bromo-7-fluoro-6-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile (3 g, 11.11 mmol) in 1,2-dichloroethane, aluminum trichloride (3 g, 22.22 mmol) was added in batches, followed by stirring at 80° C. for 2 hours, cooling to room temperature, quenching by adding sodium sulfate decahydrate, filtering, washing the cake with dichloromethane, and adding saturated brine to the filtrate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness to give a white solid, 4-bromo-7-fluoro-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (2.2 g, yield: 77%). MS m / z(ESI):255.0[MH] + .

[0217] Step 5: 4-Bromo-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0218] [ka] 4-Bromo-7-fluoro-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (2.2 g, 8.6 mmol), potassium carbonate (2.37 g, 17.2 mmol), 2,2-Dimethyloxirane (1.24 g, 17.2 mmol) was added to a solution of 4-bromo-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (2 g, yield: 71%) as a colorless oil. The mixture was stirred at 80°C for 16 hours. The reaction solution was concentrated under reduced pressure, dried, and separated by column chromatography (dichloromethane / methanol = 10:1). MS m / z(ESI):328.0[M+H] + .

[0219] Step 6: 7-Fluoro-4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0220] [ka] A mixture of 4-bromo-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (2 g, 6.1 mmol), 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.63 g, 7.32 mmol), potassium acetate (1.2 g, 12.2 mmol), and dioxane (30 mL) was added to 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride in dichloromethane. The complex (50 mg, 0.061 mmol) was added, and the mixture was purged with nitrogen gas three times. The mixture was then stirred at 100°C for 16 hours under nitrogen gas protection. After the reaction was completed, the mixture was cooled and filtered. The filtrate was concentrated under reduced pressure and dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, 7-fluoro-4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (1.4 g, yield: 67%). MS m / z(ESI):345.1[M+H] + .

[0221] Step 7: tert-Butyl 3-(5-(3-cyano-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0222] [ka] 7-Fluoro-4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (1.4 g, 4.06 mmol), tert-butyl 3,6-diazabicyclo[3.1.1]hepta A mixture of N,N-diisopropylethylamine (1.57 g, 12.18 mmol) and dimethyl sulfoxide (10 mL) was stirred at 100 ° C. for 24 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The mixture was separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, tert-butyl 3-(5-(3-cyano-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (1.05 g, yield: 50%). MS m / z (ESI): 523.2 [M + H] + .

[0223] Step 8: 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0224] [ka] tert-Butyl 3- (5- (3-cyano-7-fluoro-6- (2-hydroxy-2-methylpropoxy) pyrazolo [1,5-a] pyridin-4-yl) pyridin-2-yl) -3,6-diazabicyclo [3.1.1] heptane-6-carboxylate (1.05 g, 2.01 mmol) was dissolved in dichloromethane (9 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure and dried. It was used directly in the next step without purification to obtain a pale yellow oily substance, 4- (6- (3,6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -7-fluoro-6- (2-hydroxy-2-methylpropoxy) pyrazolo [1,5-a] pyridine-3-carbonitrile (1.2 g, crude product). MS m / z(ESI):423.2[M+H] + .

[0225] Step 9: 4-(6-(6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0226] [ka] 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[ To a solution of 1,5-a]pyridine-3-carbonitrile (120 mg, 0.28 mmol), 6-ethoxy-5-fluoronicotinaldehyde (73 g, 0.43 mmol), and 1,2-dichloroethane (5 mL), sodium cyanoborohydride (54 mg, 0.85 mmol) was added, and the mixture was stirred at room temperature for 24 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic layer was washed with saturated brine and then dissolved in anhydrous sulfuric acid. The mixture was dried over sodium hydroxide, filtered, and the filtrate was concentrated under reduced pressure to dryness and separated by preparative chromatography to give a white solid: 4-(6-(6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (15 mg, yield: 9%). MS m / z (ESI): 576.2 [M + H] + .

[0227] Example 15 7-Fluoro-6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0228] [ka] The title compound was obtained using 7-fluoro-4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as a starting material and following the synthesis method of Example 13. MS m / z(ESI):503.2[M+H] + .

[0229] Example 16 7-Fluoro-6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-((6-methylpyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0230] [ka] Step 1: tert-Butyl 4-((6-methylpyridazin-3-yl)oxo)piperidine-1-carboxylate

[0231] [ka] tert-Butyl 4-hydroxypiperidine-1-carboxylate (2 g, 9.95 mmol) was added to anhydrous N,N-dimethylformamide (20 mL) at 0 ° C., followed by addition of sodium hydride (796 mg, 19.9 mmol) at 0 ° C. and stirring at room temperature for 30 minutes. Then, 3-chloro-6-methylpyridazine (1.9 g, 14.93 mmol) was added. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 ml × 3). The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness to give tert-butyl 4-((6-methylpyridazin-3-yl)oxo)piperidine-1-carboxylate (1.2 g, yield: 41%). MS m / z (ESI): 294.1 [M + H] + .

[0232] Step 2: 3-Methyl-6-(piperidin-4-oxy)pyridazine [ka] Trifluoroacetic acid (3 mL) was added dropwise to a solution of tert-butyl 4-((6-methylpyridazin-3-yl)oxo)piperidine-1-carboxylate (1.2 g, 4.1 mmol) in dichloromethane (9 mL), and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was directly concentrated under reduced pressure and dried to give a pale yellow solid, 3-methyl-6-(piperidin-4-oxy)pyridazine (1.5 g, crude product). MS m / z (ESI): 194.1 [M + H] + .

[0233] Step 3: 7-Fluoro-6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-((6-methylpyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0234] [ka] The title compound was obtained using 4-(6-methylpyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-7-methylpyrazolo[1,5-a]pyridine-3-carbonitrile and 3-methyl-6-(piperidin-4-oxy)pyridazine as starting materials, following the method of Example 13. MS m / z(ESI):518.2[M+H] + .

[0235] Example 17 3-(5-(3-cyano-7-fluoro-6-(2-hydroxy-2-methylpropoxy) (c) Pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide

[0236] [ka] The title compound was obtained using 7-fluoro-4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as a starting material and with reference to Example 13. MS m / z(ESI):533.2[M+H] + .

[0237] Example 18 3-(5-(3-cyano-7-fluoro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide

[0238] [ka] The title compound was obtained using 7-fluoro-4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as a starting material and with reference to Example 12. MS m / z (ESI): 542.2 [M + H]+ .

[0239] Example 19 7-chloro-6-((R)-2-hydroxypropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0240] [ka] See Example 14, Step 1: 5-bromo-2-fluoropyridin-3-ol Substitution with 5-bromo-2-chloropyridin-3-ol and replacement of 2,2-dimethyloxirane in step 5 with (R)-2-methyloxirane gave the title compound. MS m / z (ESI): 546.2 [M + H] + .

[0241] Example 20 5-chloro-6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0242] [ka] Step 1: 1-amino-3-bromo-4-chloro-5-methoxypyridin-1-ium 2,4,6-trimethylbenzenesulfonate

[0243] [ka] To a solution of 2-[(aminooxy)sulfonyl]-1,3,5-trimethylbenzene (4.8 g, 22.52 mmol) in dichloromethane (100 mL) at 0°C, 3-bromo-4-chloro-5-methoxypyridine (5 g, 22.52 mmol) was added in batches, followed by stirring at 0°C for 1.5 hours. Methyl tert-butyl ether (30 mL) was added to the reaction solution, and the mixture was slurried for 15 minutes. The mixture was then filtered, and the cake was dried to obtain a pale yellow solid, 2,4,6-trimethylbenzenesulfonic acid 1-amino-3-bromo-4-chloro-5-methoxypyridin-1-ium (9 g, crude product).

[0244] Step 2: 4-Bromo-5-chloro-6-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile [ka] To a solution of 1-amino-3-bromo-4-chloro-5-methoxypyridin-1-ium 2,4,6-trimethylbenzenesulfonate (9 g, 20.6 mmol) and 2-chloroacrylonitrile (2.7 g, 30.9 mmol) in dichloromethane (100 mL) at 0°C, 1,8-diazabicyclo[5.4.0]undec-7-ene (6.3 g, 41.2 mmol) was added in batches, and the mixture was warmed to room temperature and stirred for 24 hours to give a reaction solution containing methyl tert- Butyl ether (50 mL) was added and the mixture was slurried at room temperature for 15 minutes, then filtered and the cake was dried to give a pale yellow solid, 4-bromo-5-chloro-6-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile (3 g, yield: 51%). MS m / z (ESI): 286.0 [M + H] + .

[0245] Step 3: 4-Bromo-5-chloro-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile [ka] To a solution of 4-bromo-5-chloro-6-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile (3 g, 10.53 mmol) in 1,2-dichloroethane (30 mL), aluminum trichloride (7 g, 52.63 mmol) was added in batches, followed by stirring at 80° C. for 2 hours, cooling to room temperature, quenching by adding sodium sulfate decahydrate, filtering, washing the cake with dichloromethane, and adding saturated brine to the filtrate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness to give 4-bromo-5-chloro-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (2.1 g, yield: 74%) as a white solid. MS m / z(ESI):269.9[MH] + .

[0246] Step 4: 4-Bromo-5-chloro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0247] [ka] To a solution of 4-bromo-5-chloro-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (2.1 g, 7.75 mmol), potassium carbonate (2.14 g, 15.5 mmol), and acetonitrile (25 mL), 2,2-dimethyloxirane (1.1 g, 15.5 mmol) was added, and the mixture was stirred at 80°C for 16 hours. The reaction solution was concentrated under reduced pressure, dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, 4-bromo-5-chloro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (1.4 g, yield: 53%). MS m / z(ESI):344.0[M+H] + .

[0248] Step 5: 5-chloro-4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0249] [ka] A mixture of 4-bromo-5-chloro-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (1.4 g, 4.08 mmol), 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.1 g, 4.9 mmol), potassium acetate (800 mg, 8.16 mmol), and dioxane (20 mL) was treated with 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane. After adding tungsten complex (330 mg, 0.4 mmol), the mixture was purged with nitrogen gas three times and then stirred at 100°C under nitrogen gas protection for 16 hours. After the reaction was completed, the mixture was cooled and filtered. The filtrate was concentrated under reduced pressure and dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, 5-chloro-4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (1 g, yield: 68%). MS m / z(ESI):361.1[M+H] + .

[0250] Step 6: 5-chloro-6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-(pyridin-2-yloxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0251] [ka] The synthesis of Example 22 was carried out in accordance with Example 13. MS m / z (ESI): 519.2 [M + H] + .

[0252] Example 21 5-Fluoro-6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0253] [ka] The title compound was obtained by replacing 3-bromo-4-chloro-5-methoxypyridine with 3-bromo-4-fluoro-5-methoxypyridine and following the reactions of steps 1-5 of Example 20, followed by steps 7-9 of Example 14. MS m / z(ESI):544.2[M+H] + .

[0254] Example 22 5-Fluoro-6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-(pyridin-2-yloxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0255] [ka] Substituting 3-bromo-4-chloro-5-methoxypyridine for 3-bromo-4-fluoro-5-methoxypyridine, the title compound was obtained with reference to Example 20. MS m / z(ESI):503.2[M+H] + .

[0256] Example 23 6-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0257] [ka] Step 1: 6-Bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate

[0258] [ka] Starting from 6-bromo-4-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile, the product 6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate was obtained by following Step 1 of Example 7. MS m / z (ESI): 370.0 [M + H] + , 372.0[M+H+2] + .

[0259] Step 2: 6-Bromo-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0260] [ka] Starting from 6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate, the product 6-bromo-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 3 of Example 7. MS m / z(ESI):516.1[M+H] + , 518.1[M+H+2] + .

[0261] Step 3: 6-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0262] [ka] 6-Bromo-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (80 mg, 0.15 mmol), 2-(azetidin-3-yl)propan-2-ol (36 mg, 0.30 mmol), tris(dibenzylideneacetone)dipalladium (7 mg, 0.0075 mmol), 2-diphenyldiazolidin-3-ylpyridine (3.1.1)heptan ... A mixture of cyclohexylphosphino-2',4',6'-triisopropylbiphenyl (4 mg, 0.0075 mmol), cesium carbonate (146 mg, 0.45 mmol), and toluene (4 mL) was purged with nitrogen gas and stirred at 130 °C for 2 hours under microwave conditions. After the reaction was completed, the mixture was cooled to room temperature, concentrated, dissolved in ethyl acetate (20 mL), and washed with saturated brine (15 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and spin-dried. The product was then separated and purified by preparative chromatography (18 mg, white solid, yield: 21%).

[0263] MS m / z (ESI): 551.2 [M + H] + . 1H NMR(400MHz,MeOD)δ8.32(d,J=2.1Hz,1H),8.24(s,1H),8.08(s,1H),7.85-7.79(m,2H), 7.71(dd,J=8.5,2.3Hz,1H),6.92(d,J=1.7Hz,1H),6.86(d,J=8.8Hz,1H),6.78(d,J=8.5 Hz,1H),3.97(t,J=7.8Hz,2H),3.92-3.84(m,7H),3.78(d,J=5.6Hz,2H),3.65(s,1H),3. 62(s,3H),2.95-2.81(m,1H),2.70(d,J=7.0Hz,1H),1.70(d,J=8.8Hz,1H),1.21(s,6H).

[0264] Example 24 6-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)-4-(6-(4-((6-methoxypyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0265] [ka] Step 1: 6-Bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0266] [ka] Starting from 6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate, the product 6-bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by following Step 3 of Example 7. MS m / z(ESI):317.0[M+H] + , 319.0[M+H+2] + .

[0267] Step 2: 6-Bromo-4-(6-(4-((6-methoxypyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine -3-carbonitrile

[0268] [ka] Starting from 6-bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, the product 6-bromo-4-(6-(4-((6-methoxypyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 2 of Example 8. MS m / z(ESI):506.1[M+H] + , 508.1[M+H+2] + .

[0269] Step 3: 6-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)-4-(6-(4-((6-methoxypyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0270] [ka] Starting from 6-bromo-4-(6-(4-((6-methoxypyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, the product 6-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)-4-(6-(4-((6-methoxypyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 2 of Example 7. MS m / z (ESI): 541.2 [M + H] + .

[0271] Example 25 (6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide

[0272] [ka] Step 1: 4-Bromo-3-iodopyrazolo[1,5-a]pyridin-6-ol

[0273] [ka] 4-Bromopyrazolo[1,5-a]pyridin-6-ol (500 mg, 2.3 mmol) was dissolved in 20 mL of THF, and N-iodosuccinimide (792 mg, 3.5 mmol) was added. The mixture was allowed to react at room temperature for 6 hours. 10 mL of aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (dichloromethane / methanol = 10 / 1) to give 4-bromo-3-iodopyrazolo[1,5-a]pyridin-6-ol (404 mg, white solid, 52% yield). MS m / z(ESI):338.8[M+H] + .

[0274] Step 2: 1-((4-bromo-3-iodopyrazolo[1,5-a]pyridin-6-yl)oxo)-2-methylpropan-2-ol

[0275] [ka] 4-Bromo-3-iodopyrazolo[1,5-a]pyridin-6-ol (300 mg, 0.89 mmol) was dissolved in 20 mL of DMF, and 2,2-dimethyloxirane (641 mg, 8.9 mmol) and K2CO3 (368 mg, 2.7 mmol) were added. The mixture was incubated at 85 °C overnight. 10 mL of aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (dichloromethane / methanol = 10 / 1) to give 1-((4-bromo-3-iodopyrazolo[1,5-a]pyridin-6-yl)oxo)-2-methylpropan-2-ol (262 mg, white solid, 72% yield). MS m / z(ESI):410.9[M+H] + .

[0276] Step 3: (4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide

[0277] [ka] 1-((4-Bromo-3-iodopyrazolo[1,5-a]pyridin-6-yl)oxo)-2-methylpropan-2-ol (300 mg, 0.89 mmol) was dissolved in 20 mL of dioxane, and dimethylphosphine oxide (104 mg, 1.3 mmol), Pd(dba) (82 mg, 0.09 mmol), Pd(dba) (103 mg, 0.18 mmol), and triethanolamine (270 mg, 2.7 mmol) were added. The mixture was incubated at 85 °C overnight. 10 mL of aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin-drying, the crude product was separated by column chromatography (washing with dichloromethane / methanol = 10 / 1) to give (4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide (180 mg, white solid, yield: 56%). MS m / z(ESI):361.0[M+H] + .

[0278] Step 4: (6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide

[0279] [ka] Using (4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide as a starting material, and following Step 7 of Example 1, (6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide (120 mg, white solid, 65% yield) was obtained. MS m / z(ESI):409.2[M+H] + .

[0280] Step 5: (6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide

[0281] [ka] Using (6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide and 3-(5-bromopyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane as raw materials, and referring to Step 8 of Example 1, (6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide (35 mg, white solid, 53% yield) was obtained. MS m / z (ESI): 577.2 [M + H] + .

[0282] Example 26 4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide

[0283] [ka]

[0284] [ka] Using (6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide and 3-(5-bromopyridin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane as raw materials, 4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide was prepared by the following procedure in accordance with Step 8 of Example 1. The compound (28 mg, white solid, 49% yield) was obtained. MS m / z (ESI): 595.2 [M + H] + .

[0285] Example 27 3-(5-(3-(dimethylphosphoryl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide

[0286] [ka]

[0287] [ka] Using (6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridin-3-yl)dimethylphosphine oxide and 3-(5-bromopyridin-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide as raw materials, 3-(5-(3-(dimethylphosphoryl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide (38 mg, white solid, 56% yield) was obtained by referring to Step 8 of Example 1. MS m / z (ESI): 575.2 [M + H] + .

[0288] Example 28 4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide

[0289] [ka] Step 1: 1-amino-5-bromo-3-methoxy-2-methylpyridin-1-ium 2,4,6-trimethylbenzenesulfonate

[0290] [ka] To a solution of 2-[(aminooxy)sulfonyl]-1,3,5-trimethylbenzene (12.4 g, 57.8 mmol) in dichloromethane (50 mL) at 0°C, 3-bromo-5-methoxypyridine (10 g, 57.8 mmol) was added in batches, followed by stirring at 0°C for 1.5 hours. Methyl tert-butyl ether (150 mL) was added to the reaction solution, and the mixture was slurried for 15 minutes. The mixture was then filtered, and the cake was dried to obtain a crude product, a white solid, 2,4,6-trimethylbenzenesulfonate 1-amino-5-bromo-3-methoxy-2-methylpyridin-1-ium (15 g, yield: 62%).

[0291] Step 2: Ethyl 4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carboxylate [ka] Ethyl propionate (7.05 g, 71.94 mmol) was added to a solution of 1-amino-5-bromo-3-methoxy-2-methylpyridin-1-ium 2,4,6-trimethylbenzenesulfonate (15 g, 35.97 mmol), triethylamine (10.9 g, 107.91 mmol), and anhydrous N,N-dimethylformamide (100 mL) at 0°C, and the mixture was stirred at room temperature for 16 hours. The reaction solution was added to ice water and slurried for 15 minutes, then filtered, and the cake was dried and separated by column chromatography to obtain a pale yellow solid, ethyl 4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carboxylate (1 g, yield: 9%). MS m / z (ESI): 299.0 [M + H] + .

[0292] Step 3: 4-Bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carboxylic acid [ka] To a solution of ethyl 4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carboxylate (1 g, 3.34 mmol) in methanol (10 mL) and water (10 mL) was added lithium hydroxide monohydrate (281 mg, 6.68 mmol), followed by stirring at room temperature for 16 hours. After the reaction was completed, dilute hydrochloric acid was added to adjust the pH to 2, and a white solid precipitated. The solid was filtered, the cake washed with water, and the cake was dried to obtain a white solid, 4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carboxylic acid (800 mg, crude product). MS m / z (ESI): 271.0 [M + H] + .

[0293] Step 4: 4-Bromo-6-methoxy-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide [ka] A mixture of 4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carboxylic acid (800 mg, 2.96 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.35 g, 3.55 mmol), triethylamine (897 mg, 8.88 mmol), N,N-dimethylamine hydrochloride (485 mg, 5.92 mmol), and dichloromethane (15 mL) was heated at room temperature. The mixture was stirred at rt for 16 hours, and after completion of the reaction, water was added to quench the reaction, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The mixture was separated by column chromatography (dichloromethane / methanol=10:1) to obtain a colorless oily substance, 4-bromo-6-methoxy-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide (700 mg, yield: 80%). MS m / z (ESI): 298.0 [M + H] + .

[0294] Step 5: 4-Bromo-6-hydroxy-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide [ka] Aluminum trichloride (1.57 g, 11.8 mmol) was added batchwise to a solution of 4-bromo-6-methoxy-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide (700 mg, 2.36 mmol) in 1,2-dichloroethane (10 mL), followed by stirring at 80°C for 2 hours, cooling to room temperature, and quenching by the addition of sodium sulfate decahydrate. The cake was washed with dichloromethane, the filtrate was washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a brown solid, 4-bromo-6-hydroxy-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide (620 mg, crude product %). MS m / z(ESI):282.0[MH] + .

[0295] Step 6: 4-Bromo-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide

[0296] [ka] To a solution of 4-bromo-6-methoxy-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide (620 mg, 2.2 mmol), potassium carbonate (605 mg, 4.4 mmol), and acetonitrile (10 mL) was added 2,2-dimethyloxirane (317 mg, 4.4 mmol), followed by stirring at 80°C for 16 hours. The reaction solution was concentrated under reduced pressure, dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, 4-bromo-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide (520 mg, yield: 67%). MS m / z(ESI):356.2[M+H] + .

[0297] Step 7: 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide

[0298] [ka] A mixture of 4-bromo-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide (520 mg, 1.46 mmol), 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (391 mg, 1.75 mmol), potassium acetate (286 mg, 2.92 mmol), and dioxane (10 mL) was added to 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride. Chloride dichloromethane complex (60 mg, 0.07 mmol) was added, and the atmosphere was replaced with nitrogen gas three times. The mixture was then stirred at 100°C under nitrogen gas protection for 16 hours. After the reaction was completed, the mixture was cooled and filtered. The filtrate was concentrated under reduced pressure and dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide ( 405 mg was obtained, yield: 75%. MS m / z (ESI): 373.2 [M + H] + .

[0299] Step 8: tert-Butyl 3-(5-(3-(dimethylcarbamoyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0300] [ka] A mixture of 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide (405 mg, 1.09 mmol), tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (432 mg, 2.18 mmol), N,N-diisopropylethylamine (422 mg, 3.27 mmol) and dimethyl sulfoxide (8 mL) was stirred at 100°C for 24 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic layers were combined and washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The mixture was separated by column chromatography (dichloromethane / methanol = 10:1) to give a colorless oily substance, tert-butyl 3-(5-(3-(dimethylcarbamoyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (280 mg, yield: 47%). MS m / z (ESI): 551.2 [M + H] + .

[0301] Step 9: 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide

[0302] [ka] tert-Butyl 3-(5-(3-(dimethylcarbamoyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (280 mg, 0.51 mmol) was dissolved in dichloromethane (9 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure and dried. This product was used directly in the next step without further purification. The pale yellow oily product, 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethyl Pyrazolo[1,5-a]pyridine-3-formamide (300 mg, crude product) was obtained. MS m / z(ESI):451.2[M+H] + .

[0303] Step 10: 4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide

[0304] [ka] The title compound was obtained by referring to Step 9 of Example 14, using 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide as the reaction raw material. MS m / z(ESI):590.3[M+H] + .

[0305] Example 29 6-(2-Methoxyethoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide

[0306] [ka] Step 1: 8-Bromo-6-(2-methoxyethoxy)-N,N-dimethylindolizine-1-formamide

[0307] [ka] A mixture of 4-bromo-6-hydroxy-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide (1.2 g, 4.24 mmol), 2-methoxyethan-1-ol (322 mg, 5.09 mmol), triphenylphosphine (1.67 g, 6.36 mmol), and tetrahydrofuran (15 mL) was added with diisopropyl azodicarboxylate at 0°C. After adding diethyl ether (1.28 g, 6.36 mmol) dropwise, the mixture was stirred at room temperature under nitrogen gas protection for 16 hours. After the reaction was completed, the mixture was concentrated under reduced pressure, dried, and separated by column chromatography to obtain a colorless oily substance, 8-bromo-6-(2-methoxyethoxy)-N,N-dimethylindolizine-1-formamide (1.3 g, yield: 90%). MS m / z (ESI): 341.0 [M + H] +

[0308] The reactions of steps 2 to 5 were carried out in accordance with the synthesis of steps 7 to 10 of Example 28 to obtain 6-(2-methoxyethoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-N,N-dimethylpyrazolo[1,5-a]pyridine-3-formamide. MS m / z(ESI):558.3[M+H] + .

[0309] Example 30 N-Cyclopropyl-6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-formamide

[0310] [ka] Referring to the synthesis of Example 28, substituting N,N-dimethylamine hydrochloride for cyclopropylamine hydrochloride in Step 4, the title compound was obtained. MS m / z(ESI):584.3[M+H] + .

[0311] Example 31 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0312] [ka] Step 1: 6-Bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0313] [ka] Starting from 6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate, 6-bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (620 mg, white solid, 56% yield) was obtained by following Step 7 of Example 1. MS m / z(ESI):348.0[M+H] + .

[0314] Step 2: 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0315] [ka] 6-Bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (300 mg, 0.86 mmol) was dissolved in 20 mL of triethylamine, and 2-methylbut-3-yn-2-ol (108 mg, 1.3 mmol), Pd(PPh)Cl (120 mg, 0.17 mmol), and CuI (17 mg, 0.09 mmol) were added. The mixture was incubated overnight at 65 °C under nitrogen gas protection. 10 mL of aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (washing with dichloromethane / methanol = 10 / 1) to give 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (197 mg, white solid, yield: 65%). MS m / z(ESI):352.1[M+H] + .

[0316] Step 3: 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0317] [ka] 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and 3-(5-bromopyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane were used as raw materials, and 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (25 mg, white solid, 43% yield) was obtained by referring to step 8 of Example 1. MS m / z(ESI):520.2[M+H] + .

[0318] 1 H NMR(400MHz,MeOD)δ8.83(s,1H),8.47(s,1H),8.35(d,J=2.1Hz,1H),8.09(s,1H) ,7.84(dd,J=8.8,2.3Hz,1H),7.72(dd,J=8.4,2.1Hz,1H),7.41(s,1H),6.88(d,J= 8.9Hz,1H),6.78(d,J=8.5Hz,1H),3.91(s,1H),3.88(s,4H),3.79(d,J=5.7Hz,2H) ,3.66(s,1H),3.63(s,3H),2.74-2.62(m,1H),1.70(d,J=8.9Hz,1H),1.59(s,6H).

[0319] Example 32 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(6-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0320] [ka]

[0321] [ka] Using 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and 5-bromo-2-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridine as raw materials, and referring to Step 8 of Example 1, 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(6-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (33 mg, white solid, 49% yield) was obtained. MS m / z(ESI):509.2[M+H] + .

[0322] 1 H NMR(400MHz,MeOD)δ8.82(s,1H),8.45(s,1H),8.29(d,J=2.2Hz,1H),7.84(d,J=2. 9Hz,1H),7.76(dd,J=8.8,2.4Hz,1H),7.43(dd,J=8.9,3.0Hz,1H),7.39(s,1H),6. 99(d,J=9.0Hz,1H),6.76(d,J=8.9Hz,1H),4.67-4.47(m,2H),4.10-3.98(m,2H),3 .86(s,3H),3.60-3.49(m,2H),2.11-2.04(m,2H),1.84-1.76(m,2H),1.58(s,6H).

[0323] Example 33 N-(1-(5-(3-cyano-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)-5-fluoro-2-methylbenzamide

[0324] [ka]

[0325] [ka] Using 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and N-(1-(5-bromopyridin-2-yl)-4-methylpiperidin-4-yl)-5-fluoro-2-methylbenzamide as raw materials, N-(1-(5-(3-cyano-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)-5-fluoro-2-methylbenzamide (30 mg, white solid, 45% yield) was obtained by referring to step 8 of Example 1. MS m / z (ESI): 551.2 [M + H] + .

[0326] 1 H NMR(400MHz,Methanol-d4)δ8.82(d,J=1.3Hz,1H),8.46(s,1H),8.29(d,J=2. 5Hz,1H),7.76(dd,J=9.0,2.5Hz,1H),7.41-7.36(m,1H),7.28-7.21(m,1H),7 .09-7.02(m,2H),6.98(d,J=8.9Hz,1H),4.10-4.00(m,2H),3.44-3.39(m,2H) ,2.44-2.38(m,2H),2.38(s,3H),1.77-1.69(m,2H),1.58(s,6H),1.54(s,3H).

[0327] Example 34 6-(2-cyano-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0328] [ka] Step 1: 4-Bromo-6-(2-cyano-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0329] [ka] 4-Bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (200 mg, 0.84 mmol) and 3-hydroxy-2,2-dimethylpropionitrile (83 mg, 0.84 mmol) were dissolved in 5 mL of anhydrous tetrahydrofuran, followed by the addition of triphenylphosphine (330 mg, 1.26 mmol) and diisopropyl azodicarboxylate (202 mg, 1 mmol). The reaction solution was stirred at 0 °C for 12 h under nitrogen gas protection. The reaction solution was concentrated, dissolved in ethyl acetate (10 mL), and washed three times with water (5 mL × 3). The organic layer was concentrated, separated by column chromatography (dichloromethane / methanol: 30 / 1), and purified to give the product 4-bromo-6-(2-cyano-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (180 mg). g of a yellow solid, yield: 67.1%). MS m / z(ESI):319.0[M+H], 321.0[M+H+2] + .

[0330] Step 2: 6-(2-cyano-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0331] [ka] Starting from 4-bromo-6-(2-cyano-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile, the product 6-(2-cyano-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 3 of Example 7. MS m / z(ESI):535.2[M+H] + .

[0332] 1 H NMR(400MHz,Chloroform-d)δ8.43(d,J=2.5Hz,1H),8.23(s,1H),8.16(d,J=2.1Hz,1H),8.13(d,J=2.4Hz,1H),7.81-7.75(m,2H),7.19(d,J=2.1Hz,1H ),6.75(d,J=8.5Hz,1H),6.70(d,J=8.8Hz,1H),3.97(s,3H),3.96-3.86(m, 6H), 3.78-3.64(m, 4H), 2.94-2.80(m, 1H), 1.78-1.72(m, 1H), 1.55(s, 6H).

[0333] Example 35 6-(2-cyano-2-methylpropoxy)-4-(6-(4-((6-methylpyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0334] [ka] Step 1: 6-(2-cyano-2-methylpropoxy)-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0335] [ka] Starting from 4-bromo-6-(2-cyano-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile, the product 6-(2-cyano-2-methylpropoxy)-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by following Step 3 of Example 7. MS m / z(ESI):336.1[M+H] + .

[0336] Step 2: 6-(2-cyano-2-methylpropoxy)-4-(6-(4-((6-methylpyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0337] [ka] Starting from 6-(2-cyano-2-methylpropoxy)-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, the product 6-(2-cyano-2-methylpropoxy)-4-(6-(4-((6-methylpyridazin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 2 of Example 8. MS m / z(ESI):509.2[M+H] + .

[0338] Example 36 6-((1-cyanocyclopropyl)methoxy)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0339] [ka] Step 1: 4-Bromo-6-((1-cyanocyclopropyl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0340] [ka] Starting from 4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile, the product 4-bromo-6-((1-cyanocyclopropyl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by following Step 1 of Example 34. MS m / z (ESI): 317.0 [M+H] + , 319.0[M+H+2] + .

[0341] Step 2: 6-((1-cyanocyclopropyl)methoxy)-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0342] [ka] Starting from 4-bromo-6-((1-cyanocyclopropyl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile, the product 6-((1-cyanocyclopropyl)methoxy)-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by following Step 3 of Example 7. MS m / z(ESI):334.1[M+H] + .

[0343] Step 3: 6-((1-cyanocyclopropyl)methoxy)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0344] [ka] Starting from 6-((1-cyanocyclopropyl)methoxy)-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, the product 6-((1-cyanocyclopropyl)methoxy)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 2 of Example 8. MS m / z (ESI): 492.2 [M + H] + .

[0345] Example 37 6-((6-methoxypyridin-3-yl)methyl)-3-(5-(6-((1-methylazetidin-3-yl)methoxy)-[1,2,4]triazolo[1,5-a]pyridin (benzo-8-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane

[0346] [ka] Step 1: Preparation of N-(3,5-dibromopyridin-2-yl)-N'-hydroxyformimidamide

[0347] [ka] 3,5-Dibromopyridin-2-amine (10 g, 39.7 mmol) was dissolved in isopropanol (100 mL) and DMFDMA (6.15 g, 51.6 mmol) was added. The reaction solution was stirred at 100°C for 2 hours. The reaction solution was cooled to 50°C, and hydroxyamine hydrochloride (3.59 g, 51.6 mmol) was added, followed by stirring overnight. The reaction solution was directly spun dry. The crude product was purified by column chromatography to obtain the target molecule, N-(3,5-dibromopyridin-2-yl)-N'-hydroxyformimidamide (11 g, yield: 94%). MS m / z (ESI): 293.8 [M + H] + .

[0348] Step 2: Preparation of 6,8-dibromo-[1,2,4]triazolo[1,5-a]pyridine [ka] N-(3,5-Dibromopyridin-2-yl)-N'-hydroxyformamidine (11 g, 37.3 mmol) was dissolved in anhydrous tetrahydrofuran (100 mL) and TFAA (8.62 g, 41.0 mmol) was added dropwise at 0 °C. After the addition was complete, the reaction solution was slowly warmed to room temperature and stirred for 3 h. Aqueous NaHCO3 was slowly added to the reaction solution to quench the reaction, and further methyl tert-butyl ether was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give 6,8-dibromo-[1,2,4]triazolo[1,5-a]pyridine (8.2 g, 79% yield). MS m / z(ESI):275.8[M+H] + .

[0349] Step 3: Preparation of 3-(5-(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-8-yl)pyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane

[0350] [ka] 6,8-Dibromo-[1,2,4]triazolo[1,5-a]pyridine (4 g, 14.4 mmol) was dissolved in DMF (50 mL), and 6-((6-methoxypyridin-3-yl)methyl)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane (7.3 g, 17.3 mmol) and saturated aqueous sodium carbonate (15 mL) were added. Under nitrogen gas protection, [1,1'-bis(diphenylphosphino)ferrocene]palladium chloride (1.05 g, 1.44 mmol) was added to the reaction solution. The reaction solution was stirred at 90°C for 3 hours. Water (50 mL) was added, and the mixture was extracted with ethyl acetate (100 mL). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to obtain the target molecule, 3-(5-(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-8-yl)pyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane (3.5 g, yield: 49%). MS m / z(ESI):492.1[M+H] + .

[0351] Step 4: Preparation of 8-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-ol

[0352] [ka] 3-(5-(6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-8-yl)pyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane (3.5 g, 7.1 mmol) was dissolved in dioxane (40 mL), and potassium hydroxide (0.6 g, 10.7 mmol) and water (20 mL) were added. Under nitrogen gas protection, tris(dibenzylideneacetone)dipalladium (0.65 g, 0.71 mmol) and tBu-Xphos (0.6 g, 1.42 mmol) were added. The reaction solution was stirred overnight at 90 °C. Water (50 mL) was added to the reaction solution, followed by extraction with ethyl acetate (100 mL). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give 8-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-ol (2 g, yield: 65%). MS m / z(ESI):430.2[M+H] + .

[0353] Step 5: Preparation of 6-((6-methoxypyridin-3-yl)methyl)-3-(5-(6-((1-methylazetidin-3-yl)methoxy)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane

[0354] [ka] 8-(6-(6-((6-Methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-ol (300 mg, 0.699 mmol) was dissolved in DMAc (10 mL), and 3-(bromomethyl)-1-methylazetidine (172 mg, 1.05 mmol) and cesium carbonate (569 mg, 1.75 mmol) were added. The reaction solution was stirred overnight at 100°C. Water (20 mL) was added to the reaction solution, followed by extraction with ethyl acetate (50 mL). The organic phase was dried and then spin-dried. The crude product was purified by prep-HPLC to give 6-((6-methoxypyridin-3-yl)methyl)-3-(5-(6-((1-methylazetidin-3-yl)methoxy)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane (50 mg, yield: 14%). MS m / z(ESI):513.2[M+H] + .

[0355] Example 38 3-(((8-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)oxo)methyl)cyclobutan-1-ol

[0356] [ka]

[0357] [ka] 8- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3,6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) - [1,2,4] triazolo [1,5-a] pyridin-6-ol and 3- (bromomethyl) cyclobutan-1-ol were used as raw materials, and 3- (((8- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3,6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) - [1,2,4] triazolo [1,5-a] pyridin-6-yl) oxo) methyl) cyclobutan-1-ol (40 mg, yield: 11%) was obtained by referring to step 5 of Example 37. MS m / z(ESI):514.2[M+H] + .

[0358] Example 39 (R)-1-((8-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)oxo)propan-2-ol

[0359] [ka] Step 1: Preparation of 6-bromo-8-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine

[0360] [ka] Starting from 6,8-dibromo-[1,2,4]triazolo[1,5-a]pyridine and 1-((6-methoxypyridin-3-yl)methyl)-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine, 6-bromo-8-(6-(4-((6-methoxypyridin-3-yl)methyl)-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine was prepared by referring to Step 3 of Example 37. Lysin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (1 g, yield: 70%) was obtained. MS m / z(ESI):480.2[M+H] + .

[0361] Step 2: Preparation of 8-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-ol

[0362] [ka] Using 6-bromo-8-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine as a starting material, 8-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-ol (400 mg, yield: 57%) was obtained by referring to step 4 of Example 37. MS m / z(ESI):418.2[M+H] + .

[0363] Step 3: Preparation of (R)-1-((8-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)oxo)propan-2-ol

[0364] [ka] 8-(6-(4-((6-Methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-ol (300 mg, 0.719 mmol) was dissolved in DMF (5 mL), and (R)-2-methyloxirane (835 mg, 14.4 mmol) and potassium carbonate (497 mg, 3.59 mmol) were added. The reaction solution was stirred at 50°C for 3 days. Water (10 mL) was added to the reaction solution, followed by extraction with ethyl acetate (20 mL). The organic phase was dried and then spin-dried. The crude product was purified by prep-HPLC to give ((R)-1-((8-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)oxo)propan-2-ol (100 mg, yield: 29%). MS m / z (ESI): 476.2 [M + H] + .

[0365] Example 40 7-(2-hydroxy-2-methylpropoxy)-5-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile

[0366] [ka] Step 1: Preparation of 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carboxylate

[0367] [ka] 6-Bromo-4-methoxypyridin-2-amine (10 g, 49.2 mmol) was dissolved in ethanol (100 mL) and ethyl 2-chloro-3-carbonylpropionate (7.42 g, 49.2 mmol) was added. The reaction was refluxed overnight. The reaction solution was spun dry and directly purified by column chromatography to give the target molecule, 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carboxylate (3.0 g, yield: 20%). MS m / z (ESI): 299.2 [M + H] + .

[0368] Step 2: Preparation of 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid [ka] Ethyl 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carboxylate (3.0 g, 10.0 mmol) was dissolved in THF (20 mL) and 2N LiOH (10 mL) was added. The reaction solution was stirred overnight at room temperature. Ethyl acetate (20 mL) was added and extracted. The aqueous layer was collected, and 1N HCl was added to adjust the pH to 3-4. Ethyl acetate (50 mL) was added and extracted. The organic layer was collected, dried, and spun to give 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid (2.5 g, 92% yield). MS m / z(ESI):270.8[M+H] + .

[0369] Step 3: Preparation of 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-formamide [ka] 5-Bromo-7-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid (2.5 g, 9.2 mmol) was dissolved in DMF (30 mL) and NHCl (0.99 g, 18.5 mmol), HATU (5.3 g, 13.8 mmol), and DIEA (3.6 g, 27.7 mmol) were added. The reaction was stirred overnight at room temperature. Water (50 mL) was added to the reaction solution, followed by extraction with ethyl acetate (100 mL). The organic phase was washed with saturated sodium chloride, dried, and spun dry. The crude product was purified by column chromatography to give 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-formamide (2 g, 80% yield). MS m / z (ESI): 269.8 [M + H] + .

[0370] Step 4: Preparation of 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carbonitrile [ka] 5-Bromo-7-methoxyimidazo[1,2-a]pyridine-3-formamide (2 g, 7.4 mmol) was dissolved in anhydrous tetrahydrofuran (30 mL) and pyridine (1.46 g, 18.5 mmol) was added. TFAA (3.9 g, 18.5 mmol) was added dropwise slowly. After the addition was complete, the reaction was stirred at room temperature for 3 hours. Water (50 mL) was added and the mixture was extracted with ethyl acetate (100 mL). The organic phase was dried and then spun down. The crude product was purified by column chromatography to give 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carbonitrile (1.5 g, 80% yield). MS m / z (ESI): 251.8 [M + H] + .

[0371] Step 4: Preparation of 5-bromo-7-hydroxyimidazo[1,2-a]pyridine-3-carbonitrile [ka] 5-Bromo-7-methoxyimidazo[1,2-a]pyridine-3-carbonitrile (1.5 g, 6.0 mmol) was dissolved in DCE (20 mL). AlCl (2.4 g, 17.9 mmol) was slowly added to the reaction solution. After the addition was complete, the reaction was refluxed overnight under nitrogen gas protection. Tetrahydrofuran (100 mL) was added to the reaction solution, followed by excess sodium sulfate decahydrate (20 g) and stirring at room temperature overnight. The mixture was filtered, and the filtrate was spun dry. The crude product was purified by column chromatography to give 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carbonitrile (1.5 g, 6.0 mmol). AlCl (2.4 g, 17.9 mmol) was slowly added to the reaction solution. After the addition was complete, the reaction was refluxed overnight under nitrogen gas protection. Tetrahydrofuran (100 mL) was added to the reaction solution, followed by excess sodium sulfate decahydrate (20 g). The mixture was stirred at room temperature overnight. The mixture was filtered, and the filtrate was spun dry. The crude product was purified by column chromatography to give 5-bromo-7-methoxyimidazo[1,2-a]pyridine-3-carbonitrile (1.5 g, 6.0 mmol). Mo-7-hydroxyimidazo[1,2-a]pyridine-3-carbonitrile (1.2 g, yield: 85%) was obtained. MS m / z(ESI):237.8[M+H] + .

[0372] Step 6: Preparation of 5-bromo-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridine-3-carbonitrile

[0373] [ka] 5-Bromo-7-hydroxyimidazo[1,2-a]pyridine-3-carbonitrile (1.2 g, 5.0 mmol) was dissolved in DMF (20 mL), and 2,2-dimethyloxirane (3.6 g, 50.4 mmol) and potassium carbonate (2.1 g, 15.1 mmol) were added. The reaction mixture was stirred at 85 °C overnight. Water (30 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (50 mL). The organic phase was washed with saturated aqueous sodium chloride, dried, and spun dry. The crude product was purified by column chromatography to give 5-bromo-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridine-3-carbonitrile (1.3 g, 83% yield). MS m / z(ESI):310.2[M+H] + .

[0374] Step 7: Preparation of 7-(2-hydroxy-2-methylpropoxy)-5-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile

[0375] [ka] 5-Bromo-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridine-3-carbonitrile and 6-((6-methoxypyridin-3-yl)methyl)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane were used as raw materials, and 7-(2-hydroxy-2-methylpropoxy)-5-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane was used as raw materials, and 7-(2-hydroxy-2-methylpropoxy)-5-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (100 g, yield: 55%) was obtained by referring to step 3 of Example 37. MS m / z(ESI):526.2[M+H] + .

[0376] Example 41 7-(2-hydroxy-2-methylpropoxy)-5-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile

[0377] [ka]

[0378] [ka] Using 5-bromo-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridine-3-carbonitrile and 2-(4-(pyridine-3-oxy)piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine as raw materials, 7-(2-hydroxy-2-methylpropoxy)-5-(6-(4-(pyridine-2-oxy)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (85 mg, yield: 65%) was obtained by referring to step 3 of Example 37. MS m / z(ESI):485.2[M+H] + .

[0379] Example 42 N-(1-(5-(3-cyano-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)-2,6-difluorobenzamide

[0380] [ka] Step 1: Preparation of benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-methylpiperidine-1-carboxylate

[0381] [ka] Benzyl 4-((tert-butylsulfinyl<sulfinyl>)imino)piperidine-1-carboxylate (5 g, 14.9 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL) and cooled to 0°C. Methylmagnesium bromide (17.9 mL, 17.9 mmol) was slowly added dropwise to the reaction solution. After the addition was complete, the reaction solution was slowly warmed to room temperature and then stirred for 3 hours. Aqueous ammonium chloride solution (10 mL) was slowly added dropwise to quench the reaction, and further ethyl acetate (100 mL) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-methylpiperidine-1-carboxylate (4.2 g, yield: 80%). MS m / z (ESI): 353.2 [M + H] + .

[0382] Step 2: Preparation of benzyl 4-amino-4-methylpiperidine-1-carboxylate [ka] Benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-methylpiperidine-1-carboxylate (4.2 g, 11.9 mmol) was dissolved in 25% trifluoroacetic acid / dichloromethane solution (50 mL). The reaction solution was stirred at room temperature for 2 hours. After spin drying, additional dichloromethane (100 mL) was added. Aqueous NaHCO3 solution was slowly added to adjust the pH to 7-8. The organic layer was dried and then spin dried to obtain benzyl 4-amino-4-methylpiperidine-1-carboxylate (2.8 g, yield: 95%). MS m / z (ESI): 249.2 [M + H] + .

[0383] Step 3: Preparation of benzyl 4-(2,6-difluorobenzamido)-4-methylpiperidine-1-carboxylate

[0384] [ka] Starting from benzyl 4-amino-4-methylpiperidine-1-carboxylate and 2,6-difluorobenzoic acid, benzyl 4-(2,6-difluorobenzamido)-4-methylpiperidine-1-carboxylate (1.5 g, yield: 84%) was obtained by following Step 3 of Example 40. MS m / z(ESI):389.2[M+H] + .

[0385] Step 4: Preparation of 2,6-difluoro-N-(4-methylpiperidin-4-yl)benzamide [ka] Methyl 4-(2,6-difluorobenzamido)-4-methylpiperidine-1-carboxylate (1.5 g, 3.9 mmol) was dissolved in methanol (50 mL) and palladium on carbon (200 mg) was added. The reaction was stirred under hydrogen gas for 6 hours. The reaction solution was filtered. The filtrate was spun to dryness to give 2,6-difluoro-N-(4-methylpiperidin-4-yl)benzamide (900 mg, 92% yield). MS m / z(ESI):255.2[M+H] + .

[0386] Step 5: Preparation of 5-(6-fluoropyridin-3-yl)-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridine-3-carbonitrile

[0387] [ka] Using 5-bromo-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridine-3-carbonitrile and 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine as raw materials, 5-(6-fluoropyridin-3-yl)-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridine-3-carbonitrile (200 mg, yield: 72%) was obtained by referring to step 3 of Example 37. MS m / z(ESI):327.2[M+H] + .

[0388] Step 6: Preparation of N-(1-(5-(3-cyano-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)-2,6-difluorobenzamide

[0389] [ka] 5-(6-fluoropyridin-3-yl)-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridine-3-carbonitrile (100 mg, 0.306 mmol) was dissolved in DMSO (10 ml) and 2,6-difluoro-N-(4-methyl N-(1-(5-(3-cyano-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)-2,6-difluorobenzamide (70 mg, 41% yield) was added. The reaction was stirred at 90°C for 2 days. Water (20 mL) was added to the reaction solution, followed by extraction with ethyl acetate (30 mL). The organic phase was washed with saturated aqueous sodium chloride, dried, and then spun dry. The crude product was purified by prep-HPLC to give N-(1-(5-(3-cyano-7-(2-hydroxy-2-methylpropoxy)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)-2,6-difluorobenzamide (70 mg, 41% yield). MS m / z (ESI): 561.2 [M + H] + .

[0390] Example 43 (R)-5-(6-(4-(3-hydroxy-3-phenylpropionyl)piperazin-1-yl)pyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carbonitrile

[0391] [ka] Step 1: Preparation of tert-butyl 4-(5-(3-cyano-7-hydroxyimidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate

[0392] [ka] Using 5-bromo-7-hydroxyimidazo[1,2-a]pyridine-3-carbonitrile and tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-carboxylate as starting materials, and following Step 3 of Example 37, tert-butyl 4-(5-(3-cyano-7-hydroxyimidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate (1 g, yield: 72%) was obtained. MS m / z(ESI):421.2[M+H] + .

[0393] Step 2: Preparation of tert-butyl 4-(5-(3-cyano-7-(((trifluoromethyl)sulfonyl)oxo)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate

[0394] [ka] tert-Butyl 4-(5-(3-cyano-7-hydroxyimidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate (1 g, 2.4 mmol) was dissolved in anhydrous dichloromethane (20 mL) and cooled to 0°C. DIEA (0.46 g, 3.6 mmol) was added to the reaction solution. Trifluoromethanesulfonic anhydride (0.74 g, 2.6 mmol) was added slowly. After the addition was complete, the reaction solution was allowed to warm to room temperature and then stirred for 3 hours. Water (20 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20 mL). The organic layer was dried and then spin-dried to give tert-butyl 4-(5-(3-cyano-7-(((trifluoromethyl)sulfonyl)oxo)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate (1.2 g, yield: 91%). MS m / z (ESI): 553.2 [M + H] + .

[0395] Step 3: Preparation of tert-butyl 4-(5-(3-cyano-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate

[0396] [ka] Using tert-butyl 4-(5-(3-cyano-7-(((trifluoromethyl)sulfonyl)oxo)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole as raw materials, and referring to Step 3 of Example 37, tert-butyl 4-(5-(3-cyano-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate (0.8 g, yield: 76%) was obtained. MS m / z(ESI):485.2[M+H] + .

[0397] Step 4: Preparation of 7-(1-methyl-1H-pyrazol-4-yl)-5-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile

[0398] [ka] Tert-butyl 4-(5-(3-cyano-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)piperazine-1-carboxylate (0.8 g, 1.7 mmol) was dissolved in 25% trifluoroacetic acid / dichloromethane solution (20 mL). The reaction solution was stirred at room temperature for 2 hours. After spin drying, additional dichloromethane (30 mL) was added. Aqueous NaHCO3 was slowly added to adjust the pH to 7-8. The organic layer was dried and then spin-dried to give 7-(1-methyl-1H-pyrazol-4-yl)-5-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (0.6 g, yield: 95%). MS m / z(ESI):385.2[M+H] + .

[0399] Step 5: Preparation of (R)-5-(6-(4-(3-hydroxy-3-phenylpropanoyl)piperazin-1-yl)pyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carbonitrile

[0400] [ka] Using 7-(1-methyl-1H-pyrazol-4-yl)-5-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile and (R)-3-hydroxy-3-phenylpropionic acid as raw materials, and referring to step 3 of Example 40, (R)-5-(6-(4-(3-hydroxy-3-phenylpropanoyl)piperazin-1-yl)pyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carbonitrile (70 mg, yield: 62%) was obtained. MS m / z(ESI):533.2[M+H] + .

[0401] Example 44 (R)-5-(6-(4-(2-hydroxy-3-phenylpropanoyl)piperazin-1-yl)pyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carbonitrile

[0402] [ka]

[0403] [ka] Using 7-(1-methyl-1H-pyrazol-4-yl)-5-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile and (R)-2-hydroxy-3-phenylpropionic acid as raw materials, and referring to step 3 of Example 40, (R)-5-(6-(4-(2-hydroxy-3-phenylpropanoyl)piperazin-1-yl)pyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carbonitrile (65 mg, yield: 66%) was obtained. MS m / z(ESI):533.2[M+H] + .

[0404] Example 45 4-(5-(3-cyano-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)-N-isobutylpiperazine-1-formamide

[0405] [ka]

[0406] [ka] 7-(1-Methyl-1H-pyrazol-4-yl)-5-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (0.1 g, 0.26 mmol) was dissolved in dichloromethane (5 mL), and DIEA (168 mg, 1.3 mmol) and CDI (84 mg, 0.52 mmol) were added. The reaction solution was stirred at room temperature for 2 hours, and 2-methylpropan-1-amine (38 mg, 0.52 mmol) was added. The reaction solution was stirred for 2 days. Water (10 mL) was added to the reaction solution, followed by extraction with dichloromethane (20 mL). The organic phase was dried and then spin-dried. The crude product was purified by prep-HPLC to give 4-(5-(3-cyano-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl)pyridin-2-yl)-N-isobutylpiperazine-1-formamide (30 mg, yield: 24%). MS m / z(ESI):484.2[M+H] + .

[0407] Example 46 6-((R)-2-Hydroxypropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-1-methyl-1H-indazole-3-carbonitrile

[0408] [ka] Step 1: 2-Bromo-6-fluoro-4-methoxybenzaldehyde

[0409] [ka] Lithium diisopropylamide (73.17mmol, 36.6mL, 2M tetrahydrofuran) was added dropwise to a solution of 1-bromo-3-fluoro-5-methoxybenzene (10g, 48.78mmol) in tetrahydrofuran (100mL) at -78°C, and the mixture was stirred at -78°C for 1 hour. Anhydrous N,N-dimethylformamide (7.12g, 97.56mmol) was added dropwise, and the mixture was stirred at -78°C for 2 hours. A saturated ammonium chloride solution was added to quench the mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The crude product, 2-bromo-6-fluoro-4-methoxybenz(methyl)aldehyde (6.2g, yield: 55%), was obtained. MS m / z(ESI):232.9[M+H] + .

[0410] Step 2: 4-Bromo-6-methoxy-1H-indazole [ka] A mixed solution of 2-bromo-6-fluoro-4-methoxybenzaldehyde (6.2 g, 26.84 mmol), hydrazine hydrate (2.7 g, 53.68 mmol, 98%) and dimethyl sulfoxide (50 mL) was stirred at 130°C for 2 hours, cooled to room temperature, and water was added to form a slurry. A solid precipitated, filtered, and the cake was washed with water and dried to obtain a pale yellow solid, 4-bromo-6-methoxy-1H-indazole (5.3 g, yield: 87%). MS m / z (ESI): 227.0 [M + H] + .

[0411] Step 3: 4-Bromo-6-methoxy-1-methyl-1H-indazole [ka] To a solution of 4-bromo-6-methoxy-1H-indazole (5.3 g, 23.45 mmol) in tetrahydrofuran (50 mL) at 0°C, sodium hydride (1.8 g, 46.9 mmol) was added, followed by stirring for 30 minutes. Methyl iodide (5 g, 35.17 mmol) was added dropwise, and the mixture was then stirred at room temperature for 2 hours. Water was added to quench the reaction, followed by extraction with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The mixture was separated by column chromatography (dichloromethane / methanol = 10:1) to obtain 4-bromo-6-methoxy-1H-indazole (2.8 g, yield: 50%) as a colorless oil. MS m / z (ESI): 241.0 [M + H] + .

[0412] Step 4: 4-Bromo-3-iodo-6-methoxy-1-methyl-1H-indazole [ka] To a mixed solution of 4-bromo-6-methoxy-1-methyl-1H-indazole (2.8 g, 11.67 mmol), potassium hydroxide (1.3 g, 23.34 mmol), and N,N-dimethylformamide (30 mL), iodine (4.4 g, 17.5 mmol) was added, followed by stirring at room temperature for 3 hours. After the reaction was completed, saturated sodium hydrogen sulfite solution was added, and a solid precipitated. The solid was filtered, the cake was washed with water, and the cake was dried to obtain a pale yellow solid, 4-bromo-3-iodo-6-methoxy-1-methyl-1H-indazole (3.1 g, yield: 73%). MS m / z(ESI):366.8[M+H] + .

[0413] Step 5: 4-Bromo-6-methoxy-1-methyl-1H-indazole-3-carbonitrile [ka] To a mixture of 4-bromo-3-iodo-6-methoxy-1-methyl-1H-indazole (3.1 g, 8.47 mmol), zinc cyanide (2 g, 16.94 mmol), and anhydrous N,N-dimethylformamide (50 mL) was added tris(dibenzylideneacetone)dipalladium (388 mg, 0.42 mmol), followed by nitrogen gas replacement three times and stirring at 100 °C under nitrogen gas protection for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and filtered. Water and dichloromethane were added to the filtrate, followed by extraction with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness to give the crude product, which was used directly in the next step to give a black solid, 4-bromo-6-methoxy-1-methyl-1H-indazole-3-carbonitrile (3.5 g, crude product). MS m / z (ESI): 266.0 [M + H] + .

[0414] Step 6: 4-Bromo-6-hydroxy-1-methyl-1H-indazole-3-carbonitrile [ka] To a solution of 4-bromo-6-methoxy-1-methyl-1H-indazole-3-carbonitrile (3.5 g, 13.21 mmol) in 1,2-dichloroethane (40 mL) was added aluminum trichloride (8.8 g, 66.05 mmol) in a batchwise manner, followed by stirring at 80° C. for 2 hours, cooling to room temperature, quenching by adding sodium sulfate decahydrate, filtering, washing the cake with dichloromethane, adding saturated brine to the filtrate and washing it, drying the organic layer over anhydrous sodium sulfate, filtering, and concentrating the filtrate to dryness under reduced pressure to give a brown solid, 4-bromo-6-hydroxy-1-methyl-1H-indazole-3-carbonitrile (3.2 g, crude product). MS m / z(ESI):250.9[MH] + .

[0415] Step 7: 4-Bromo-6-(2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile [ka] 4-Bromo-6-hydroxy-1-methyl-1H-indazole-3-carbonitrile To a solution of 4-bromo-6-(2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile (900 mg, yield: 41%) was added 2-methyloxirane (835 mg, 14.16 mmol), and the mixture was stirred at 80°C for 16 hours. The reaction solution was concentrated under reduced pressure, dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, 4-bromo-6-(2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile (900 mg, yield: 41%). MS m / z(ESI):310.0[M+H] + .

[0416] Step 8: (R)-4-(6-fluoropyridin-3-yl)-6-(2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile

[0417] [ka] A mixture of 4-bromo-6-(2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile (900 mg, 2.91 mmol), 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (778 mg, 3.49 mmol), potassium acetate (570 mg, 5.82 mmol), and dioxane (10 mL) was added to 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride in dichloromethane. The complex (120 mg, 0.15 mmol) was added, and the air was replaced with nitrogen gas three times. The mixture was then stirred at 100°C under nitrogen gas protection for 16 hours. After the reaction was completed, the mixture was cooled and filtered. The filtrate was concentrated under reduced pressure and dried, and separated by column chromatography (dichloromethane / methanol = 10:1) to obtain a colorless oily substance, (R)-4-(6-fluoropyridin-3-yl)-6-(2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile (650 mg, yield: 69%). MS m / z(ESI):327.1[M+H] + .

[0418] Step 9: Ethyl 3-(5-(3-cyano-6-((R)-2-hydroxypropoxy)-1-methyl-1H-indazol-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3]3.1.1]heptane-6-carboxylate

[0419] [ka] A mixture of (R)-4-(6-fluoropyridin-3-yl)-6-(2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile (650 mg, 1.99 mmol), tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (788 mg, 3.98 mmol), N,N-diisopropylethylamine (770 mg, 5.97 mmol) and dimethyl sulfoxide (8 mL) was stirred at 100°C for 24 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. (50 mL × 3), the organic layers were combined and washed with saturated brine, the organic layers were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness, and separated by column chromatography (dichloromethane / methanol = 10:1) to give a colorless oily substance, ethyl 3-(5-(3-cyano-6-((R)-2-hydroxypropoxy)-1-methyl-1H-indazol-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (410 mg, yield: 41%). MS m / z(ESI):505.2[M+H] + .

[0420] Step 10: 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-((R)-2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile

[0421] [ka] Ethyl 3-(5-(3-cyano-6-((R)-2-hydroxypropoxy)-1-methyl-1H-indazol-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (410 mg, 0.81 mmol) was dissolved in dichloromethane (6 mL), and then trifluoroacetic acid (2 mL) was added and stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure and dried. It was not purified and was used directly in the next step to obtain a pale yellow oily substance, 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-((R)-2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile (520 mg, crude product). MS m / z(ESI):405.2[M+H] + .

[0422] Step 11: 6-((R)-2-hydroxypropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-1-methyl-1H-indazole-3-carbonitrile

[0423] [ka] A solution of 4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-((R)-2-hydroxypropoxy)-1-methyl-1H-indazole-3-carbonitrile (100 mg, 0.25 mmol), 6-methoxynicotinaldehyde (51 mg, 0.37 mmol) and 1,2-dichloroethane (3 mL) was added. After adding sodium borohydride (47 mg, 0.75 mmol), the mixture was stirred at room temperature for 24 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The resulting mixture was separated by preparative chromatography to obtain a white solid: 6-((R)-2-hydroxypropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-1-methyl-1H-indazole-3-carbonitrile (12 mg, yield: 9%). MS m / z(ESI):526.2[M+H] + .

[0424] Example 47 4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxyethoxy)-1-methyl-1H-indazole-3-carbonitrile

[0425] [ka] Refer to Steps 1-8 of Example 46, where 2-methyloxirane in Step 7 was replaced with ethylene oxide to give the title compound. MS m / z(ESI):530.2[M+H] + .

[0426] Example 48 6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)pyridin-3-yl)-1-methyl-1H-indazole-3-carbonitrile

[0427] [ka] See Example 46, in which 2-methyloxirane in Step 7 was replaced with 2,2-dimethyloxirane, followed by reference to Example 13 to obtain the title compound. MS m / z(ESI):529.2[M+H] + .

[0428] Example 49 6-(2-hydroxy-2-methylpropoxy)-4-(2-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazol-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0429] [ka] Step 1: tert-Butyl 3-(5-bromothiazol-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0430] [ka] tert-Butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (300 mg, 1.5 mmol) was dissolved in 20 mL of DMF, and 2,5-dibromothiazole (547 mg, 2.2 mmol), K2CO3 (621 mg, 4.5 mmol), and KI (25 mg, 0.15 mmol) were added. The mixture was incubated overnight at 90 °C under nitrogen gas protection. 10 mL of aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (dichloroethane / methanol = 10 / 1) to give tert-butyl 3-(5-bromothiazol-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (230 mg, white solid, yield: 42%). MS m / z(ESI):360.0[M+H] + . Step 2: 2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-bromothiazole

[0431] [ka] Starting from tert-butyl 3-(5-bromothiazol-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate, 2-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-5-bromothiazole (210 mg, white solid, 99%) was obtained by following Step 5 of Example 1. MS m / z(ESI):259.9[M+H] + .

[0432] Step 3: 5-Bromo-2-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazole

[0433] [ka] Starting from 2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-bromothiazole, 5-bromo-2-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazole (100 mg, white solid, 52%) was obtained by following Step 6 of Example 1. MS m / z (ESI): 381.0 [M + H] + .

[0434] Step 4: (6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0435] [ka] Starting from 4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile, and following Step 7 of Example 1, (6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained (130 mg, white solid, 61%). MS m / z(ESI):358.1[M+H] + .

[0436] Step 5: 6-(2-hydroxy-2-methylpropoxy)-4-(2-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazol-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0437] [ka] Starting from 6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and 5-bromo-2-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazole, 6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was synthesized by the procedure of Step 8 of Example 1. -(2-(6-((6-Methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazol-5-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (33 mg, white solid, 47%) was obtained. MS m / z(ESI):532.2[M+H] + .

[0438] Example 50 4-(2-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazol-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0439] [ka] Step 1: 5-Bromo-2-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazole

[0440] [ka] Starting from 2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-bromothiazole and 5-fluoro-6-methoxynicotinaldehyde, 5-bromo-2-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazole (220 mg, white solid, 62%) was obtained by referring to Step 6 of Example 1. MS m / z (ESI): 399.0 [M + H] + .

[0441] Step 2: 4-(2-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazol-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0442] [ka] 6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and 5-bromo-2-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazole were used as raw materials, and 4-(2-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)thiazol-5-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (35 mg, white solid, 48%) was obtained by referring to step 8 of Example 1. MS m / z(ESI):550.2[M+H] + .

[0443] Example 51 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)thiazol-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide

[0444] [ka] Step 1: 3-(5-bromothiazol-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide

[0445] [ka] 2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-bromothiazole (300 mg, 1.2 mmol) was dissolved in 20 mL of DCM, and CDI (280 mg, 1.7 mmol) and TEA (245 mg, 2.4 mmol) were added. The mixture was allowed to react at room temperature for 2 hours. Aniline (223 mg, 2.4 mmol) was added, and the mixture was allowed to react at room temperature overnight. 10 mL of aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (washing with dichloroethane / methanol = 10 / 1) to give 3-(5-bromothiazol-2-yl)-N-phenyl-3,6- Diazabicyclo[3.1.1]heptane-6-formamide (223 mg, white solid, yield: 49%) was obtained. MS m / z (ESI): 379.0 [M + H] + .

[0446] Step 2: 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)thiazol-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide

[0447] [ka] Using 6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and 3-(5-bromothiazol-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide as raw materials, and referring to Step 8 of Example 1, 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)thiazol-2-yl)-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-6-formamide (29 mg, white solid, 39%) was obtained. MS m / z(ESI):530.1[M+H] + .

[0448] Example 52 6-(2-hydroxyethoxy)-4-(5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazol-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0449] [ka] Step 1: tert-butyl 3-(5-bromo-1,3,4-thiadiazol-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0450] [ka] 2,5-Dibromo-1,3,4-thiadiazole was used as a starting material, and Step 1 of Example 49 tert-Butyl 3-(5-bromo-1,3,4-thiadiazol-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (530 mg, white solid, 67%) was obtained with reference to the procedure described above. MS m / z(ESI):361.0[M+H]+ .

[0451] Step 2: 2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-bromo-1,3,4-thiadiazole

[0452] [ka] Starting from tert-butyl 3-(5-bromo-1,3,4-thiadiazol-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate, 2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-bromo-1,3,4-thiadiazole (350 mg, white solid, 99%) was obtained by following Step 5 of Example 1. MS m / z(ESI):260.9[M+H] + .

[0453] Step 3: 2-Bromo-5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazole

[0454] [ka] Starting from 2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-bromo-1,3,4-thiadiazole, 2-bromo-5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazole (120 mg, white solid, 56%) was obtained by following Step 6 of Example 1. MS m / z (ESI): 382.0 [M + H] + .

[0455] Step 4: 6-(2-hydroxyethoxy)-4-(5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazol-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0456] [ka] Using 6-(2-hydroxyethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and 2-bromo-5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazole as raw materials, and referring to step 8 of Example 1, 6-(2-hydroxyethoxy)-4-(5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazol-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (25 mg, white solid, 38%) was obtained. MS m / z(ESI):505.1[M+H] + .

[0457] Example 53 4-(5-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazol-2-yl)-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0458] [ka] Step 1: 2-Bromo-5-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazole

[0459] [ka] Starting from 2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-bromo-1,3,4-thiadiazole, 2-bromo-5-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazole (150 mg, white solid, 59%) was obtained by following Step 6 of Example 1. MS m / z (ESI): 400.0 [M + H] + .

[0460] Step 2: 4-(5-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazol-2-yl)-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0461] [ka] 6-(2-hydroxyethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and 2-bromo-5-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazole were used as raw materials, and 4-(5-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,3,4-thiadiazol-2-yl)-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (32 mg, white solid, 41%) was obtained by referring to step 8 of Example 1. MS m / z(ESI):523.1[M+H] + .

[0462] Example 54 6-(2-hydroxy-2-methylpropoxy)-4-(3-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0463] [ka] Step 1: Preparation of tert-butyl 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0464] [ka] 3-Bromo-1-(4-methoxybenzyl)-1H-pyrazole (5g, 18.7mm (ol) was dissolved in DMF (30 mL) and tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carbamate (4.45 g, 22.5 mmol) and sodium tert-butoxide (2.7 g, 28.1 mmol) were added. Pd2(dba)3 (1.7 g, 1.87 mmol) and RuPhos (1.75 g, 3.74 mmol) were added separately under nitrogen gas protection. The reaction was stirred at 90 °C overnight. Water (50 mL) was added to the reaction solution, followed by extraction with ethyl acetate (100 mL). The organic phase was dried and then spun down. The crude product was purified by column chromatography to give tert-butyl 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (5 g, yield: 69%). MS m / z(ESI):385.2[M+H] + .

[0465] Step 2: Preparation of 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane

[0466] [ka] Using tert-butyl 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate as the starting material, 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane was obtained by following Step 4 of Example 43. MS m / z(ESI):285.2[M+H] + .

[0467] Step 3: 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane

[0468] [ka] 3-(1-(4-Methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane (2 g, 7.0 mmol) was dissolved in DCE (30 mL), and 6-methoxynicotinaldehyde (1.9 g, 14.1 mmol) and sodium triacetoxyborohydride (4.5 g, 21.0 mmol) were added. The reaction solution was stirred overnight at room temperature. Water (60 mL) was added to the reaction solution, followed by extraction with dichloromethane (50 mL). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane (2.1 g, 75% yield). MS m / z(ESI):406.2[M+H] + .

[0469] Step 4: 6-((6-methoxypyridin-3-yl)methyl)-3-(1H-pyra (3-yl)-3,6-diazabicyclo[3.1.1]heptane

[0470] [ka] Using 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane as a raw material, 6-((6-methoxypyridin-3-yl)methyl)-3-(1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane (yield: 80%) was obtained by referring to Step 4 of Example 42. MS m / z(ESI):286.2[M+H] + .

[0471] Step 5: Preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(3-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0472] [ka] Using 6-((6-methoxypyridin-3-yl)methyl)-3-(1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane and 4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as raw materials, 6-(2-hydroxy-2-methylpropoxy)-4-(3-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to step 4 of Example 42. MS m / z(ESI):515.2[M+H] + .

[0473] Example 55 4-(3-(6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-pyrazol-1-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0474] [ka] Step 1: Preparation of tert-butyl 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0475] [ka] 3-Bromo-1-(4-methoxybenzyl)-1H-pyrazole (5 g, 18.7 mmol) was dissolved in DMF (30 mL) and tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (4.45 g, 22.5 mmol) and sodium tert-butoxide (2.7 g, 28.1 mmol) were added. Pd2(dba)3 (1.7 g, 1.87 mmol) and RuPhos (1.75 g, 3.74 mmol) were added separately under nitrogen gas protection. The reaction was stirred at 90 °C overnight. Water (50 mL) was added to the reaction solution, followed by extraction with ethyl acetate (100 mL). The organic phase was dried and then spun down. The crude product was purified by column chromatography to give tert-butyl 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (5 g, yield: 69%). MS m / z(ESI):385.2[MH] + .

[0476] Step 2: Preparation of 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane

[0477] [ka] Using tert-butyl 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate as the starting material, 3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane (3.5 g, yield: 95%) was obtained by following Step 4 of Example 43. MS m / z(ESI):285.2[MH] + .

[0478] Step 3: Preparation of 6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane

[0479] [ka] 3-(1-(4-Methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane (2 g, 7.0 mmol) was dissolved in DCE (30 mL), and 6-ethoxy-5-fluoronicotinaldehyde (2.4 g, 14.1 mmol) and sodium triacetoxyborohydride (4.5 g, 21.0 mmol) were added. The reaction solution was stirred overnight at room temperature. Water (60 mL) was added to the reaction solution, followed by extraction with dichloromethane (50 mL). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give 6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane (2.5 g, yield: 81%). MS m / z(ESI):438.2[M+H] + .

[0480] Step 4: Preparation of 6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3-(1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane

[0481] [ka] Using 6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3-(1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane as a raw material, 6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3-(1H-pyrazol-3-yl)-3,6-diazabicyclo[3.1.1]heptane (500 mg, yield: 86%) was obtained by referring to step 4 of Example 42. MS m / z(ESI):318.2[M+H] + .

[0482] Step 5: Preparation of 4-(3-(6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-pyrazol-1-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0483] [ka] 6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3-(1H-pyridin-3-yl)methyl Using 4-(3-(6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane and 4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as raw materials, and referring to step 4 of Example 42, 4-(3-(6-((6-ethoxy-5-fluoropyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1H-pyrazol-1-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (80 mg, yield: 32%) was obtained. MS m / z (ESI): 547.2 [M + H] + .

[0484] Example 56 6-(2-hydroxy-2-methylpropoxy)-4-(3-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0485] [ka] Step 1: Preparation of 2-methoxy-5-(piperidin-4-oxy)pyridine

[0486] [ka] Starting from tert-butyl 4-((6-methoxypyridin-3-yl)oxo)piperidine-1-carboxylate, 2-methoxy-5-(piperidin-4-oxy)pyridine (2 g, yield: 90%) was obtained by following Step 4 of Example 43. MS m / z (ESI): 209.2 [M + H] + .

[0487] Step 2: Preparation of tert-butyl 3-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)-1H-pyrazole-1-carboxylate

[0488] [ka] Starting from 2-methoxy-5-(piperidin-4-oxy)pyridine and tert-butyl 3-bromo-1H-pyrazole-1-carboxylate, the reaction was carried out in accordance with Step 1 of Example 55. Elution with tert-butyl 3-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)-1H-pyrazole-1-carboxylate gave 68% yield. MS m / z(ESI):375.2[M+H] + .

[0489] Step 3: Preparation of 5-((1-(1H-pyridol-3-yl)piperidin-4-yl)oxo)-2-methoxypyridine

[0490] [ka] Using tert-butyl 3-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)-1H-pyrazole-1-carboxylate as a starting material, 5-((1-(1H-pyridin-3-yl)piperidin-4-yl)oxo)-2-methoxypyridine (yield: 88%) was obtained by following Step 4 of Example 43. MS m / z(ESI):275.2[M+H] + .

[0491] Step 4: Preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(3-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0492] [ka] Using 5-((1-(1H-pyrazol-3-yl)piperidin-4-yl)oxo)-2-methoxypyridine and 4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as raw materials, and referring to step 4 of Example 42, 6-(2-hydroxy-2-methylpropoxy)-4-(3-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (75 mg, yield: 30%) was obtained. MS m / z(ESI):504.2[M+H] + .

[0493] Example 57 4-(4-chloro-6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0494] [ka] Step 1: tert-Butyl 3-(5-bromo-4-chloropyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0495] [ka] Starting from 5-bromo-4-chloro-2-fluoropyridine, tert-butyl 3-(5-bromo-4-chloropyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate was obtained by referring to Step 2 of Example 8. MS m / z(ESI):388.0[M+H] + , 390.0[M+H+2] + .

[0496] Step 2: 3-(5-bromo-4-chloropyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane

[0497] [ka] tert-Butyl 3-(5-bromo-4-chloropyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (300 mg, 0.78 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (3 mL) was slowly added dropwise. The reaction solution was stirred at room temperature for 3 hours. The reaction solution was concentrated, dissolved in ethyl acetate (10 mL), and saturated sodium carbonate solution (5 mL) was added to the reaction solution. The reaction solution was washed with saturated sodium chloride solution (5 mL × 2). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 3-(5-bromo-4-chloropyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane (230 mg). MS m / z (ESI): 288.0 [M + H] + , 290.0[M+H+2] + .

[0498] Step 3: 3-(5-bromo-4-chloropyridin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane

[0499] [ka] 3-(5-Bromo-4-chloropyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane (230 mg, 0.78 mmol) and 5-fluoro-6-methoxynicotinaldehyde (120 mg, 0.78 mmol) were dissolved in dichloroethane (5 ml), and sodium borohydride acetate (248 mg, 1.17 mmol) was added with stirring. The reaction solution was then stirred at room temperature for 12 hours. Saturated sodium carbonate solution (5 mL) was added to the reaction solution, extracted with ethyl acetate (10 mL), washed with saturated sodium chloride solution (5 mL × 2), the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, separated by column chromatography (dichloroethane / methanol: 30 / 1) and purified to give 3-(5-bromo-4-chloropyridin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane (200 mg, white solid, 58.1%). MS m / z(ESI):427.0[M+H] + , 429.0[M+H+2] + .

[0500] Step 4: 3-(4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane

[0501] [ka] A 25 mL three-neck flask was charged with 3-(5-bromo-4-chloropyridin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane (200 mg, 0.47 mmol), bis(pinacolato)diboron (142 mg, 0.56 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (19 mg, 0.023 mmol), potassium acetate (91 mg, 0.93 mmol), and dioxane (5 mL), and the reaction solution was purged with nitrogen gas five times. The reaction solution was heated to 85°C under nitrogen gas protection and stirred for 5 hours. After cooling to room temperature, the reaction solution was concentrated and dissolved in ethyl acetate (10 mL). After washing with saturated brine (5 mL x 3), the organic layer was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by prep-HPLC to give 3-(4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane (160 mg, yield: 72.2%). MS m / z (ESI): 475.2 [M + H] + .

[0502] Step 5: 4-(4-chloro-6-(6-((5-fluoro-6-methoxypyridine -3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0503] [ka] Starting from 3-(4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane, the product 4-(4-chloro-6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 3 of Example 7. MS m / z (ESI): 578.2 [M + H] + .

[0504] Example 58 4-(4-chloro-6-(4-(pyridine-2-oxy)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0505] [ka] Step 1: 5-Bromo-4-chloro-2-(4-(pyridin-2-oxy)piperidin-1-yl)pyridine

[0506] [ka]

[0507] Starting from 5-bromo-4-chloro-2-fluoropyridine, 5-bromo-4-chloro-2-(4-(pyridin-2-oxy)piperidin-1-yl)pyridine was obtained by referring to Step 2 of Example 8. MS m / z (ESI): 368.0 [M + H] + , 370.0[M+H+2] + . Step 2: 4-chloro-2-(4-(pyridin-2-oxy)piperidin-1-yl) )-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

[0508] [ka] Starting from 5-bromo-4-chloro-2-(4-(pyridin-2-oxy)piperidin-1-yl)pyridine, the product 4-chloro-2-(4-(pyridin-2-oxy)piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine was obtained by following Step 4 of Example 57. MS m / z(ESI): 416.2 [M+H].

[0509] Step 3: 4-(4-chloro-6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0510] [ka] Using 4-chloro-2-(4-(pyridine-2-oxy)piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine as a starting material, 4-(4-chloro-6-(4-(pyridine-2-oxy)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 3 of Example 7. MS m / z(ESI):519.1[M+H] + .

[0511] Example 59 4-(6-(4-amino-4-((6-methoxypyridin-3-yl)methyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0512] [ka] Step 1: Preparation of 1-(tert-butyl) 4-ethyl 4-((6-methoxypyridin-3-yl)methyl)piperidine-1,4-dicarboxylate

[0513] [ka] 1-(tert-Butyl) 4-ethylpiperidine-1,4-dicarboxylate (10 g, 38.9 mmol) was dissolved in anhydrous tetrahydrofuran (100 mL) and cooled to -76 °C under nitrogen gas protection. LDA (29.2 mL, 58.4 mmol) was slowly added dropwise to the reaction solution, controlling the temperature below -70 °C. After the addition was complete, the reaction solution was slowly warmed to 0 °C, stirred for 30 minutes, and cooled to -76 °C. 5-(Bromomethyl)-2-methoxypyridine (9.4 g, 46.6 mmol) was slowly added to the reaction solution. After the addition was complete, the reaction solution was warmed to room temperature and stirred for 4 hours. The reaction was quenched by the addition of saturated aqueous ammonium chloride solution, and further extraction was performed with ethyl acetate. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give 1-(tert-butyl) 4-ethyl 4-((6-methoxypyridin-3-yl)methyl)piperidine-1,4-dicarboxylate (3.5 g, yield: 24%). MS m / z (ESI): 379.2 [M + H] + .

[0514] Step 2: Preparation of 1-(tert-butoxycarbonyl)-4-((6-methoxypyridin-3-yl)methyl)piperidine-4-carboxylic acid

[0515] [ka] Using 51-(tert-butyl) 4-ethyl 4-((6-methoxypyridin-3-yl)methyl)piperidine-1,4-dicarboxylate as the starting material, 1-(tert-butoxycarbonyl)-4-((6-methoxypyridin-3-yl)methyl)piperidine-4-carboxylic acid (2 g, yield: 80%) was obtained by following Step 2 of Example 40. MS m / z(ESI):351.2[M+H] + .

[0516] Step 3: Preparation of tert-butyl 4-((tert-butoxycarbonyl)amino)-4-((6-methoxypyridin-3-yl)methyl)piperidine-1-carboxylate

[0517] [ka] 1-(tert-Butoxycarbonyl)-4-((6-methoxypyridin-3-yl)methyl)piperidine-4-carboxylic acid (2 g, 5.7 mmol) was dissolved in tert-butanol (50 ml), and DIEA (1.1 g, 8.6 mmol) and diphenyl azidophosphate (1.7 g, 6.3 mol) were added. The reaction solution was stirred at 80°C for 6 hours. The reaction solution was spun dry. The crude product was purified by column chromatography to give tert-butyl 4-((tert-butoxycarbonyl)amino)-4-((6-methoxypyridin-3-yl)methyl)piperidine-1-carboxylate (1.6 g, yield: 67%). MS m / z(ESI):422.2[M+H] + . Step 3: Preparation of 4-((6-methoxypyridin-3-yl)methyl)piperidin-4-amine

[0518] [ka] Using tert-butyl 4-((tert-butoxycarbonyl)amino)-4-((6-methoxypyridin-3-yl)methyl)piperidine-1-carboxylate as the starting material, 4-((6-methoxypyridin-3-yl)methyl)piperidin-4-amine (0.8 g, yield: 70%) was obtained by following Step 4 of Example 43. MS m / z(ESI):222.2[M+H] + .

[0519] Step 4: Preparation of 4-(6-(4-amino-4-((6-methoxypyridin-3-yl)methyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0520] [ka] 4-((6-methoxypyridin-3-yl)methyl)piperidin-4-amine and 4-( Using 6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as the raw material, 4-(6-(4-amino-4-((6-methoxypyridin-3-yl)methyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (55 mg, yield: 46%) was obtained by referring to step 6 of Example 42. MS m / z(ESI):528.2[M+H] + .

[0521] Example 60 4-(6-(4-amino-4-(pyridin-3-ylmethyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0522] [ka] Step 1: Preparation of 1-(tert-butyl) 4-ethyl 4-(pyridin-3-ylmethyl)piperidine-1,4-carboxylate

[0523] [ka] Using 1-(tert-butyl) 4-ethylpiperidine-1,4-dicarboxylate and 3-(bromomethyl)pyridine as raw materials, 1-(tert-butyl) 4-ethyl 4-(pyridin-3-ylmethyl)piperidine-1,4-dicarboxylate (3 g, yield: 68%) was obtained by following Step 1 of Example 59. MS m / z(ESI):349.2[M+H] + .

[0524] Step 2: Preparation of 1-(tert-butoxycarbonyl)-4-(pyridin-3-ylmethyl)piperidine-4-carboxylic acid

[0525] [ka] Starting from 1-(tert-butyl) 4-ethyl 4-(pyridin-3-ylmethyl)piperidine-1,4-dicarboxylate, 1-(tert-butoxycarbonyl)-4-(pyridin-3-ylmethyl)piperidine-4-carboxylic acid (2.2 g, yield: 78%) was obtained by following Step 2 of Example 40. MS m / z(ESI):321.2[M+H] + .

[0526] Step 3: Preparation of tert-butyl 4-((tert-butoxycarbonyl)amino)-4-(pyridin-3-ylmethyl)piperidine-1-carboxylate

[0527] [ka]

[0528] Starting from 1-(tert-butoxycarbonyl)-4-(pyridin-3-ylmethyl)piperidine-4-carboxylic acid, tert-butyl 4-((tert-butoxycarbonyl)amino)-4-(pyridin-3-ylmethyl)piperidine-1-carboxylate (1.2 g, yield: 48%) was obtained by following Step 3 of Example 59. MS m / z (ESI): 392.2 [M + H] + . Step 4: Preparation of 4-(pyridin-3-ylmethyl)piperidin-4-amine

[0529] [ka] Starting from tert-butyl 4-((tert-butoxycarbonyl)amino)-4-(pyridin-3-ylmethyl)piperidine-1-carboxylate, 4-(pyridin-3-ylmethyl)piperidin-4-amine (0.6 g, yield: 73%) was obtained by following Step 4 of Example 43. MS m / z (ESI): 192.2 [M + H] + .

[0530] Step 5: Preparation of 4-(6-(4-amino-4-(pyridin-3-ylmethyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0531] [ka] Using 4-(pyridin-3-ylmethyl)piperidin-4-amine and 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as raw materials, and referring to step 6 of Example 42, 4-(6-(4-amino-4-(pyridin-3-ylmethyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (65 mg, yield: 44%) was obtained. MS m / z (ESI): 498.2 [M + H] + .

[0532] Example 61 4-(4-(4-amino-1-((6-methoxypyridin-3-yl)methyl)piperidin-4-yl)phenyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0533] [ka] Step 1: Preparation of benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-(4-chlorophenyl)piperidine-1-carboxylate

[0534] [ka] Using benzyl 4-((tert-butylsulfinyl<sulfinyl>)imino)piperidine-1-carboxylate and (4-chlorophenyl)magnesium bromide as starting materials, and following Step 1 of Example 42, benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-(4-chlorophenyl)piperidine-1-carboxylate (2 g, yield: 33%) was obtained. MS m / z(ESI):449.2[M+H] + .

[0535] Step 2: Benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazoline) Preparation of (1,5-a)pyridin-4-yl)phenyl)piperidine-1-carboxylate

[0536] [ka] Using benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-(4-chlorophenyl)piperidine-1-carboxylate and 6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile as starting materials, and following Step 3 of Example 37, benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)piperidine-1-carboxylate (1.2 g, yield: 66%) was obtained. MS m / z(ESI):644.2[M+H] + .

[0537] Step 3: Preparation of N-(4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)piperidin-4-yl)-2-methylpropane-2-sulfinamide

[0538] [ka] Using benzyl 4-((tert-butylsulfinyl<sulfinyl>)amino)-4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)piperidine-1-carboxylate as the starting material, N-(4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)piperidin-4-yl)-2-methylpropane-2-sulfinamide (0.8 g, yield: 80%) was obtained by referring to Step 4 of Example 42. MS m / z(ESI):510.2[M+H] + .

[0539] Step 4: Preparation of N-(4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)-1-((6-methoxypyridin-3-yl)methyl)piperidin-4-yl)-2-methylpropane-2-sulfinamide

[0540] [ka] Using N-(4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)piperidin-4-yl)-2-methylpropane-2-sulfinamide and 6-methoxynicotinaldehyde as raw materials, and referring to Step 3 of Example 55, N-(4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)-1-((6-methoxypyridin-3-yl)methyl)piperidin-4-yl)-2-methylpropane-2-sulfinamide (0.3 g, yield: 56%) was obtained. MS m / z(ESI):631.3[M+H] + .

[0541] Step 5: Preparation of 4-(4-(4-amino-1-((6-methoxypyridin-3-yl)methyl)piperidin-4-yl)phenyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0542] [ka] Using N-(4-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)-1-((6-methoxypyridin-3-yl)methyl)piperidin-4-yl)-2-methylpropane-2-sulfinamide as a raw material, 4-(4-(4-amino-1-((6-methoxypyridin-3-yl)methyl)piperidin-4-yl)phenyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (yield: 85%) was obtained by referring to Step 2 of Example 42. MS m / z(ESI):527.3[M+H] + .

[0543] Example 62 4-(6-(4-amino-4-(indoline-1-carbonyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0544] [ka] Step 1: Ethyl 4-((tert-butoxycarbonyl)amino)-1-(5-( 3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)piperidine-4-carboxylate

[0545] [ka] A mixture of 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (3 g, 9.2 mmol), ethyl 4-((tert-butoxycarbonyl)amino)piperidine-4-carboxylate (3.0 g, 11.04 mmol), N,N-diisopropylethylamine (3.6 g, 27.6 mmol), and acetonitrile (30 mL) was stirred at 80° C. for 16 hours. After the reaction was completed, the mixture was mixed with silica gel, concentrated under reduced pressure, dried, and separated by column chromatography (dichloromethane / methanol=10:1) to obtain a colorless oily substance, ethyl 4-((tert-butoxycarbonyl)amino)-1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)piperidine-4-carboxylate (800 mg, yield: 15%). MS m / z (ESI): 579.3 [M + H] + .

[0546] Step 2: 4-((tert-butoxycarbonyl)amino)-1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)piperidine-4-carboxylic acid

[0547] [ka] To a solution of ethyl 4-((tert-butoxycarbonyl)amino)-1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)piperidine-4-carboxylate (800 mg, 1.38 mmol) in methanol (10 mL) and water (10 mL) was added lithium hydroxide monohydrate (116 mg, 2.76 mmol), followed by stirring at room temperature for 16 hours. After stirring, the reaction mixture was adjusted to pH 2 by adding dilute hydrochloric acid, and a white solid precipitated. The mixture was filtered, the cake was washed with water, and the cake was dried to obtain a white solid, 4-((tert-butoxycarbonyl)amino)-1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)piperidine-4-carboxylic acid (800 mg, yield: 79%). MS m / z (ESI): 551.2 [M + H] + .

[0548] Step 3: tert-butyl (1-(5-(3-cyano-6-(2-hydroxy-2- Methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-4-(indoline-1-carbonyl)piperidin-4-yl)carbamate

[0549] [ka] A mixture of 4-((tert-butoxycarbonyl)amino)-1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)piperidine-4-carboxylic acid (100 mg, 0.18 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (82.91 mg, 0.22 mmol), triethylamine (36 mg, 0.36 mmol), dihydroindole (32 mg, 0.27 mmol), and dichloromethane (5 mL) The mixture was stirred at room temperature for 16 hours, and after completion of the reaction, water was added to quench the reaction, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and separated by column chromatography (dichloromethane / methanol=10:1) to obtain a colorless oily substance, tert-butyl (1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-4-(indoline-1-carbonyl)piperidin-4-yl)carbamate (30 mg, yield: 26%). MS m / z(ESI):652.3[M+H] + .

[0550] Step 4: 4-(6-(4-amino-4-(indoline-1-carbonyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0551] [ka] tert-Butyl (1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-4-(indoline)-1-carbonyl)piperidin-4-yl)carbamate (30 mg, 0.046 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure, dried, and separated by preparative chromatography to obtain a pale yellow oily substance, 4-(6-(4-amino-4-(indoline-1-carbonyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (12 mg, yield: 47%).

[0552] 11 H NMR(400MHz,CDCl3)δ8.34(s,1H),8.26-8.18(m,2H),8.16(s,1H),7.70(d,J=6.6Hz,1H), 7.18(m,3H),7.07-7.03(m,1H),6.83(d,J=8.7Hz,1H),4.42-4.39(m,2H),4.11-4.07(m,2H),3. 85-3.81(m,4H),3.13-3.09(t,J=7.7Hz,2H),2.51-2.47(m,2H),1.92-1.89(m,4H),1.40(s,6H). MS m / z(ESI):552.3[M+H] + .

[0553] Example 63 4-Amino-1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-N-(6-methoxypyridin-3-yl)piperidine-4-formamide

[0554] [ka] The synthesis of Example 63 was carried out in accordance with Example 62. MS m / z(ESI):557.2[M+H]+ .

[0555] Example 64 4-Amino-1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-N-methyl-N-phenylpiperidine-4-formamide

[0556] [ka] The synthesis of Example 64 was carried out in accordance with Example 62. MS m / z(ESI):540.2[M+H] + .

[0557] Example 65 4-(6-(4-amino-4-(2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0558] [ka] The synthesis of Example 65 was carried out in accordance with Example 62. MS m / z (ESI): 553.2 [M + H] +

[0559] Example 66 4-(6-(3-((1H-pyrazol-1-yl)methyl)-3-aminoazetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0560] [ka] Step 1: Preparation of 1-(tert-butyl) 3-methyl 3-((tert-butoxycarbonyl)amino)azetidine-1,3-dicarboxylate

[0561] [ka] 1-(tert-butyl) 3-methyl 3-aminoazetidine-1,3-dicarboxylate (10 g, 43.4 mmol) was dissolved in dichloromethane (100 mL), and di-tert-butyl dicarbonate (10 g, 45.6 mmol) and DIEA (8.4 g, 65.1 mmol) were added. The reaction solution was stirred at room temperature overnight. Water was added to the reaction solution, followed by extraction with dichloromethane. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give 1-(tert-butyl) 3-methyl 3-((tert-butoxycarbonyl)amino)azetidine-1,3-dicarboxylate (13 g, yield: 91%). MS m / z(ESI):331.2[M+H] + .

[0562] Step 2: Preparation of tert-butyl 3-((tert-butoxycarbonyl)amino)-3-(hydroxymethyl)azetidine-1-carboxylate

[0563] [ka] 1-(tert-Butyl) 3-methyl 3-((tert-butoxycarbonyl)amino)azetidine-1,3-dicarboxylate (5 g, 15.1 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL) and lithium tetrahydroaluminum (0.86 g, 22.7 mmol) was added. The reaction solution was stirred at 70 °C overnight. Water was added to quench the reaction, and ethyl acetate was added for extraction. The mixture was filtered. The filtrate was dried and then spin-dried. The crude product was purified by column chromatography to give tert-butyl 3-((tert-butoxycarbonyl)amino)-3-(hydroxymethyl)azetidine-1-carboxylate (2.3 g, 50% yield). MS m / z (ESI): 303.2 [M + H] + .

[0564] Step 3: Preparation of tert-butyl 3-((tert-butoxycarbonyl)amino)-3-(((methylsulfonyl)oxo)methyl)azetidine-1-carboxylate

[0565] [ka] tert-Butyl 3-((tert-butoxycarbonyl)amino)-3-(hydroxymethyl)azetidine-1-carboxylate (2.3 g, 7.6 mmol) was dissolved in anhydrous dichloromethane (30 mL) and DIEA (2 g, 15.2 mmol) was added. MsCl (1.1 g, 9.1 mmol) was slowly added dropwise to the reaction solution at 0 °C. After the addition was complete, the reaction solution was warmed to room temperature and stirred for 4 hours. Water was added to the reaction solution, followed by extraction with dichloromethane. The organic layer was spin-dried to give tert-butyl 3-((tert-butoxycarbonyl)amino)-3-(((methylsulfonyl)oxo)methyl)azetidine-1-carboxylate (2.8 g, yield: 97%). MS m / z(ESI):381.2[M+H] + .

[0566] Step 4: Preparation of tert-butyl 3-((1H-pyrazol-1-yl)methyl)-3-((tert-butoxycarbonyl)amino)azetidine-1-carboxylate

[0567] [ka]

[0568] Using tert-butyl 3-((tert-butoxycarbonyl)amino)-3-(((methylsulfonyl)oxo)methyl)azetidine-1-carboxylate and 1H-pyrazole as starting materials, and following Step 5 of Example 37, tert-butyl 3-((1H-pyrazol-1-yl)methyl)-3-((tert-butoxycarbonyl)amino)azetidine-1-carboxylate (1.5 g, yield: 45%) was obtained. MS m / z (ESI): 353.2 [M + H] + . Step 5: Preparation of 3-((1H-pyrazol-1-yl)methyl)azetidin-3-amine

[0569] [ka] Starting from tert-butyl 3-((1H-pyrazol-1-yl)methyl)-3-((tert-butoxycarbonyl)amino)azetidine-1-carboxylate, 3-((1H-pyrazol-1-yl)methyl)azetidin-3-amine (0.7 g, yield: 90%) was obtained by following Step 4 of Example 43. MS m / z (ESI): 153.1 [M + H] + .

[0570] Step 5: Preparation of 4-(6-(3-((1H-pyrazol-1-yl)methyl)-3-aminoazetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0571] [ka] Using 3-((1H-pyrazol-1-yl)methyl)azetidin-3-amine and 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as raw materials, and referring to step 6 of Example 42, 4-(6-(3-((1H-pyrazol-1-yl)methyl)-3-aminoazetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (63 mg, yield: 69%) was obtained. MS m / z(ESI):459.2[M+H] + .

[0572] Example 67 4-(6-(3-amino-3-((6-methoxypyridin-3-yl)methyl)azetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0573] [ka] Step 1: Preparation of 1-(tert-butyl) 3-methyl 3-((6-methoxypyridin-3-yl)methyl)azetidine-1,3-dicarboxylate

[0574] [ka] Using 1-(tert-butyl) 3-methylazetidine-1,3-dicarboxylate and 5-(bromomethyl)-2-methoxypyridine as starting materials, 1-(tert-butyl) 3-methyl 3-((6-methoxypyridin-3-yl)methyl)azetidine-1,3-dicarboxylate (5 g, yield: 63%) was obtained by following Step 1 of Example 59. MS m / z(ESI):337.2[M+H] + . Step 2: Preparation of 1-(tert-butoxycarbonyl)-3-((6-methoxypyridin-3-yl)methyl)azetidine-3-carboxylic acid

[0575] [ka] Using 1-(tert-butyl) 3-methyl 3-((6-methoxypyridin-3-yl)methyl)azetidine-1,3-dicarboxylate as the starting material, 1-(tert-butoxycarbonyl)-3-((6-methoxypyridin-3-yl)methyl)azetidine-3-carboxylic acid (2.5 g, yield: 76%) was obtained by following Step 2 of Example 40. MS m / z(ESI):323.2[M+H] + . Step 3: Preparation of tert-butyl 3-((tert-butoxycarbonyl)amino)-3-((6-methoxypyridin-3-yl)methyl)azetidine-1-carboxylate

[0576] [ka] Starting from 1-(tert-butoxycarbonyl)-3-((6-methoxypyridin-3-yl)methyl)azetidine-3-carboxylic acid, tert-butyl 3-((tert-butoxycarbonyl)amino)-3-((6-methoxypyridin-3-yl)methyl)azetidine-1-carboxylate (1.5 g, yield: 67%) was obtained by following Step 3 of Example 59. MS m / z (ESI): 394.2 [M + H] + . Step 4: Preparation of 3-((6-methoxypyridin-3-yl)methyl)azetidin-3-amine

[0577] [ka] Starting from tert-butyl 3-((tert-butoxycarbonyl)amino)-3-((6-methoxypyridin-3-yl)methyl)azetidine-1-carboxylate, 3-((6-methoxypyridin-3-yl)methyl)azetidin-3-amine (0.7 g, yield: 91%) was obtained by following Step 4 of Example 43. MS m / z (ESI): 194.1 [M + H] + .

[0578] Step 5: Preparation of 4-(6-(3-amino-3-((6-methoxypyridin-3-yl)methyl)azetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0579] [ka] Using 3-((6-methoxypyridin-3-yl)methyl)azetidin-3-amine and 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as raw materials, and referring to step 6 of Example 42, 4-(6-(3-amino-3-((6-methoxypyridin-3-yl)methyl)azetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (53 mg, yield: 59%) was obtained. MS m / z (ESI): 500.2 [M + H] + .

[0580] Example 68 4-(4-(3-amino-1-((6-methoxypyridin-3-yl)methyl)azetidin-3-yl)phenyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0581] [ka] Step 1: Preparation of benzyl 3-((tert-butylsulfinyl<sulfinyl>)amino)-3-(4-chlorophenyl)azetidine-1-carboxylate

[0582] [ka] Using benzyl 3-((tert-butylsulfinyl<sulfinyl>)imino)azetidine-1-carboxylate and (4-chlorophenyl)magnesium bromide as starting materials, and following Step 1 of Example 42, benzyl 3-((tert-butylsulfinyl<sulfinyl>)amino)-3-(4-chlorophenyl)azetidine-1-carboxylate (2.2 g, yield: 35%) was obtained. MS m / z(ESI):421.2[M+H] + .

[0583] Step 2: Preparation of benzyl 3-((tert-butylsulfinyl<sulfinyl>)amino)-3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)azetidine-1-carboxylate

[0584] [ka] Using benzyl 3-((tert-butylsulfinyl<sulfinyl>)amino)-3-(4-chlorophenyl)azetidine-1-carboxylate and 6-(2-hydroxy-2-methylpropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile as starting materials, and following Step 3 of Example 37, benzyl 3-((tert-butylsulfinyl<sulfinyl>)amino)-3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)azetidine-1-carboxylate (1.3 g, yield: 68%) was obtained. MS m / z(ESI):616.2[M+H] + .

[0585] Step 3: Preparation of N-(3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)azetidin-3-yl)-2-methylpropane-2-sulfinamide

[0586] [ka] Using benzyl 3-((tert-butylsulfinyl<sulfinyl>)amino)-3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)azetidine-1-carboxylate as the starting material, N-(3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)azetidin-3-yl)-2-methylpropane-2-sulfinamide (0.9 g, yield: 82%) was obtained by following Step 4 of Example 42. MS m / z (ESI): 482.2 [M + H] + .

[0587] Step 4: Preparation of N-(3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)-1-((6-methoxypyridin-3-yl)methyl)azetidin-3-yl)-2-methylpropane-2-sulfinamide

[0588] [ka] Using N-(3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)azetidin-3-yl)-2-methylpropane-2-sulfinamide and 6-methoxynicotinaldehyde as raw materials, and referring to Step 3 of Example 55, N-(3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)-1-((6-methoxypyridin-3-yl)methyl)azetidin-3-yl)-2-methylpropane-2-sulfinamide (0.4 g, yield: 62%) was obtained. MS m / z(ESI):603.3[M+H] + .

[0589] Step 5: Preparation of 4-(4-(3-amino-1-((6-methoxypyridin-3-yl)methyl)azetidin-3-yl)phenyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0590] [ka] Using N-(3-(4-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)phenyl)-1-((6-methoxypyridin-3-yl)methyl)azetidin-3-yl)-2-methylpropane-2-sulfinamide as a raw material, 4-(4-(3-amino-1-((6-methoxypyridin-3-yl)methyl)azetidin-3-yl)phenyl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (150 mg, yield: 84%) was obtained by referring to Step 2 of Example 42. MS m / z (ESI): 499.2 [M + H] + .

[0591] Example 69 4-(6-(3-(3-amino-1H-pyrazol-1-yl)azetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0592] [ka] Step 1: Preparation of tert-butyl 3-(3-nitro-1H-pyrazol-1-yl)azetidine-1-carboxylate

[0593] [ka]

[0594] 3-Nitro-1H-pyrazole (10 g, 88.4 mmol) was dissolved in anhydrous DMF (120 mL), and tert-butyl 3-iodoazetidine-1-carboxylate (30 g, 106.1 mmol) and potassium carbonate (24.4 g, 176.9 mmol) were added. The reaction solution was stirred at 60 °C overnight. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give tert-butyl 3-(3-nitro-1H-pyrazol-1-yl)azetidine-1-carboxylate (20 g, 84% yield). MS m / z (ESI): 269.1 [M + H] + . Step 2: Preparation of 1-(azetidin-3-yl)-3-nitro-1H-pyrazole

[0595] [ka] Starting from tert-butyl 3-(3-nitro-1H-pyrazol-1-yl)azetidine-1-carboxylate, 1-(azetidin-3-yl)-3-nitro-1H-pyrazole (5 g, yield: 93%) was obtained by following Step 4 of Example 43. MS m / z (ESI): 169.1 [M+H] + .

[0596] Step 3: Preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(3-(3-nitro-1H-pyrazol-1-yl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0597] [ka] Using 1-(azetidin-3-yl)-3-nitro-1H-pyrazole and 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as raw materials, and referring to step 6 of Example 42, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(3-(3-nitro-1H-pyrazol-1-yl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (500 mg, yield: 68%) was obtained. MS m / z (ESI): 475.2 [M + H] + .

[0598] Step 4: Preparation of 4-(6-(3-(3-amino-1H-pyrazol-1-yl)azetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0599] [ka] 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(3-(3-nitro-1H-pyrazol-1-yl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (200 mg, 0.42 mmol) was dissolved in tetrahydrofuran (20 mL), and iron powder (235 mg, 4.22 mmol), ammonium chloride (225 mg, 4.22 mmol), and water (10 mL) were added. The reaction solution was stirred at 80°C for 1 hour. Ethyl acetate was added to the reaction solution, which was then filtered. The filtrate was dried and then spin-dried. The crude product was purified by prep-HPLC to give 4-(6-(3-(3-amino-1H-pyrazol-1-yl)azetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3 -carbonitrile (75 mg, yield: 40%) was obtained. MS m / z(ESI):445.2[M+H] + .

[0600] Example 70 N-(1-(1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)azetidin-3-yl)-1H-pyrazol-3-yl)cyclopropanecarboxamide

[0601] [ka]

[0602] [ka] Using 4-(6-(3-(3-amino-1H-pyrazol-1-yl)azetidin-1-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile and cyclopropylcarboxylic acid as raw materials, and referring to step 3 of Example 40, N-(1-(1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)azetidin-3-yl)-1H-pyrazol-3-yl)cyclopropanecarboxamide (85 mg, yield: 72%) was obtained. MS m / z(ESI):513.2[M+H] + .

[0603] Example 71 1-(1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)azetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide

[0604] [ka] Step 1: Preparation of 1-diphenylmethylazetidin-3-yl methanesulfonate

[0605] [ka] Starting from 1-diphenylmethylazetidin-3-ol, 1-diphenylmethylazetidin-3-yl methanesulfonate (10 g, yield: 95%) was obtained by following Step 3 of Example 66. MS m / z(ESI):318.2[M+H] + .

[0606] Step 2: Preparation of methyl 1-(1-diphenylmethylazetidin-3-yl)-1H-pyrazole-3-carboxylate

[0607] [ka]

[0608] Using 1-diphenylmethylazetidin-3-ylmethanesulfonic acid and methyl 1H-pyrazole-3-carboxylate as starting materials, methyl 1-(1-diphenylmethylazetidin-3-yl)-1H-pyrazole-3-carboxylate (3.5 g, yield: 40%) was obtained by following Step 5 of Example 37. MS m / z (ESI): 348.2 [M + H] + . Step 3: Preparation of 1-(1-diphenylmethylazetidin-3-yl)-1H-pyrazole-3-carboxylic acid

[0609] [ka] Starting from methyl 1-(1-diphenylmethylazetidin-3-yl)-1H-pyrazole-3-carboxylate, 1-(1-diphenylmethylazetidin-3-yl)-1H-pyrazole-3-carboxylic acid (2.0 g, yield: 75%) was obtained by following Step 2 of Example 40. MS m / z (ESI): 334.2 [M + H] + .

[0610] Step 4: Preparation of 1-(1-diphenylmethylazetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide

[0611] [ka] Using 1-(1-diphenylmethylazetidin-3-yl)-1H-pyrazole-3-carboxylic acid and cyclopropylamine as raw materials, 1-(1-diphenylmethylazetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide (500 mg, yield: 71%) was obtained by referring to Step 3 of Example 40. MS m / z (ESI): 373.2 [M + H] + .

[0612] Step 5: Preparation of 1-(azetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide

[0613] [ka] Using 1-(1-diphenylmethylazetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide as the raw material, 1-(azetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide (250 mg, yield: 72%) was obtained by referring to Step 4 of Example 42. MS m / z(ESI):207.2[M+H] + .

[0614] Step 6: Preparation of 1-(1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)azetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide

[0615] [ka] Starting from 1-(azetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide and 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile, 1-(1-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)azetidin-3-yl)-N-cyclopropyl-1H-pyrazole-3-formamide was prepared by referring to Step 6 of Example 42. (80 mg, yield: 66%) was obtained. MS m / z(ESI):513.2[M+H] + .

[0616] Example 72 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-((6-methoxypyridin-3-yl)oxo)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0617] [ka] Step 1: tert-Butyl 5-((6-methoxypyridin-3-yl)oxo)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate

[0618] [ka] Starting from 6-methoxypyridin-3-ol and tert-butyl 5-hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate, tert-butyl 5-((6-methoxypyridin-3-yl)oxo)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate was obtained by following Step 1 of Example 34.

[0619] MS m / z(ESI):335.2[M+H] + . Step 2: 5-((6-methoxypyridin-3-yl)oxo)octahydrocyclopenta[c]pyrrole

[0620] [ka] Starting from tert-butyl 5-((6-methoxypyridin-3-yl)oxo)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate, the product 5-((6-methoxypyridin-3-yl)oxo)octahydrocyclopenta[c]pyrrole was obtained by following Step 2 of Example 57. MS m / z(ESI):235.1[M+H] + .

[0621] Step 3: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-((6-methoxypyridin-3-yl)oxo)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0622] [ka] Starting from 5-((6-methoxypyridin-3-yl)oxo)octahydrocyclopenta[c]pyrrole, the product 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-((6-methoxypyridin-3-yl)oxo)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 2 of Example 8. MS m / z (ESI) 541.2 [M+H] + .

[0623] Example 73 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-(pyridin-3-ylmethoxy)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0624] [ka] Step 1: tert-Butyl 5-(pyridin-3-ylmethoxy)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate

[0625] [ka]

[0626] tert-Butyl 5-hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (660 mg, 2.9 mmol) was dissolved in tetrahydrofuran (10 mL). Sodium hydride (140 mg, 3.5 mmol, 60%) was added with stirring, and the reaction solution was stirred at room temperature for 1 hour. 3-(Bromomethyl)pyridine (500 mg, 2.9 mmol) was then added to the reaction solution, and the reaction solution was stirred for 12 hours. Water (5 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL). The extract was washed with saturated sodium chloride solution (5 mL x 2). The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (dichloroethane / methanol: 30 / 1) to give tert-butyl 5-(pyridin-3-ylmethoxy)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (550 mg, white solid, 59.5%). MS m / z (ESI): 319.2 [M + H] + . Step 2: 5-(pyridin-3-ylmethoxy)octahydrocyclopenta[c]pyrrole

[0627] [ka] Starting from tert-butyl 5-(pyridin-3-ylmethoxy)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate, the product 5-(pyridin-3-ylmethoxy)octahydrocyclopenta[c]pyrrole was obtained by following Step 2 of Example 57. MS m / z (ESI) 219.2 [M+H] + .

[0628] Step 3: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-(pyridin-3-ylmethoxy)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0629] [ka] Starting from 5-(pyridin-3-ylmethoxy)octahydrocyclopenta[c]pyrrole, the product 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-(pyridin-3-ylmethoxy)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 2 of Example 8. MS m / z (ESI) 525.2 [M+H] + .

[0630] Example 74 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-(((6-methoxypyridin-3-yl)methyl)amino)-5-methylhexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0631] [ka] Step 1: 2-(5-bromopyridin-2-yl)hexahydrocyclopenta[c]pyrrol-5(1H)-one

[0632] [ka]

[0633] Starting from 5-bromo-2-fluoropyridine and hexahydrocyclopenta[c]pyrrol-5(1H)-one, the product 2-(5-bromopyridin-2-yl)hexahydrocyclopenta[c]pyrrol-5(1H)-one was obtained by referring to Step 2 of Example 8. MS m / z (ESI) 281.0 [M+H] + . Step 2: 2-(5-bromopyridin-2-yl)-5-methyleneoctahydrocyclopenta[c]pyrrole

[0634] [ka] Methyltriphenylphosphine bromide (870 mg, 2.45 mmol) was dissolved in tetrahydrofuran (10 mL), purged with N, cooled to 0 °C, potassium tert-butoxide (330 mg, 2.93 mmol) was added, and the reaction was stirred at room temperature for 2 hours. After cooling to 0 °C, a solution of 2-(5-bromopyridin-2-yl)hexahydrocyclopenta[c]pyrrol-5(1H)-one (450 mg, 1.60 mmol) in tetrahydrofuran (10 mL) was added. The reaction was stirred at room temperature for 2 hours and then at 50 °C overnight. The reaction was quenched by adding water (10 mL), and the aqueous layer was extracted with ethyl acetate (10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated and purified by column chromatography (petroleum ether / ethyl acetate: 1 / 1) to give 2-(5-bromopyridin-2-yl)-5-methyleneoctahydrocyclopenta[c]pyrrole (300 mg, yield: 67%). MS m / z (ESI) 279.0 [M+H] + .

[0635] Step 3: N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)formamide

[0636] [ka] 2-(5-Bromopyridin-2-yl)-5-methyleneoctahydrocyclopenta[c]pyrrole (300 mg, 1.07 mmol) was dissolved in dichloromethane (30 mL), acetic acid (180 mg, 3.0 mmol) was added, the mixture was cooled to 0°C, trimethylcyanosilane (200 mg, 2.0 mmol) was added dropwise, and the reaction was stirred at 0°C for 30 minutes. A mixture of acetic acid (180 mg, 3.0 mmol) and concentrated sulfuric acid (400 mg, 4.0 mmol) was slowly added dropwise, and the reaction mixture was stirred overnight from 0 °C to room temperature. 3 M aqueous sodium hydroxide solution was added at 0 °C until the pH reached pH > 12. The solution was separated, and the aqueous layer was extracted with ethyl acetate (20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)formamide (230 mg, yield: 66.0%). MS m / z(ESI):324.0[M+H] + .

[0637] Step 4: 2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine

[0638] [ka] N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)formamide (230 mg, 0.7 mmol) was dissolved in ethanol (5 mL), sodium hydroxide (80 mg, 2.1 mmol) and water (2 mL) were added, and the reaction was stirred at 70 °C overnight. The solvent was spun off, water (5 mL) was added, and the aqueous layer was extracted with ethyl acetate (5 mL × 2). The organic layer was washed with 1 M aqueous hydrochloric acid (5 mL). The aqueous layer was adjusted to pH > 12 with 3 M aqueous sodium hydroxide, and the aqueous layer was extracted with ethyl acetate (5 mL × 2). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give 2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine (150 mg, 71% yield). MS m / z (ESI): 296.0 [M + H] + .

[0639] Step 5: 2-(5-bromopyridin-2-yl)-N-((6-methoxypyridin-3-yl)methyl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine

[0640] [ka] Starting from 2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine, the product 2-(5-bromopyridin-2-yl)-N-((6-methoxypyridin-3-yl)methyl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine was obtained by following Step 3 of Example 57. MS m / z(ESI):417.1[M+H] + .

[0641] Step 6: N-((6-methoxypyridin-3-yl)methyl)-5-methyl-2- (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-amine

[0642] [ka] Starting from 2-(5-bromopyridin-2-yl)-N-((6-methoxypyridin-3-yl)methyl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine, the product N-((6-methoxypyridin-3-yl)methyl)-5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-amine was obtained by following Step 4 of Example 57. MS m / z(ESI):465.3[M+H] + .

[0643] Step 7: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-(((6-methoxypyridin-3-yl)methyl)amino)-5-methylhexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0644] [ka] Starting from N-((6-methoxypyridin-3-yl)methyl)-5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-amine, the product 6-(2-hydroxy-2-methylpropoxy)-4-(6-(5-(((6-methoxypyridin-3-yl)methyl)amino)-5-methylhexahydrocyclopenta[c]pyrrol-2(1H)-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 3 of Example 7. MS m / z (ESI): 568.3 [M + H] + .

[0645] Example 75 N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-5-fluoro-2-methylbenzamide

[0646] [ka] Step 1: N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-5-fluoro-2-methylbenzamide

[0647] [ka] A 25 mL three-neck flask was charged with 2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine (300 mg, 1.0 mmol), 5-fluoro-2-methylbenzoic acid (156 mg, 1.0 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (380 mg, 1.0 mmol), diisopropylethylamine (390 mg, 3 mmol), and dimethylformamide (5 mL). The reaction solution was stirred at room temperature for 5 h, then dissolved in ethyl acetate (10 mL). The solution was washed with saturated brine (5 mL x 3). The organic layer was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography to give N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-5-fluoro-2-methylbenzamide (260 mg, yield: 59.3%). MS m / z(ESI):432.1[M+H] + .

[0648] Step 2: 5-fluoro-2-methyl-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)benzamide

[0649] [ka] Starting from N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-5-fluoro-2-methylbenzamide, the product 5-fluoro-2-methyl-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)benzamide was obtained by following Step 4 of Example 57. MS m / z(ESI):480.2[M+H] + .

[0650] Step 3: N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-5-fluoro-2-methylbenzamide

[0651] [ka] Starting from 5-fluoro-2-methyl-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)benzamide, the product N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-5-fluoro-2-methylbenzamide was obtained by referring to Step 3 of Example 7. MS m / z (ESI): 583.2 [M + H] + .

[0652] Example 76 2-chloro-N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)benzamide

[0653] [ka] Step 1: N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-2-chlorobenzamide

[0654] [ka] Starting from 2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine and 2-chlorobenzoic acid, the product N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-2-chlorobenzamide was obtained by referring to Step 1 of Example 75. MS m / z(ESI):434.0[M+H] + .

[0655] Step 2: 2-chloro-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)benzamide

[0656] [ka] Starting from N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-2-chlorobenzamide, the product 2-chloro-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)benzamide was obtained by following Step 4 of Example 57. MS m / z (ESI): 482.2 [M + H] + .

[0657] Step 3: 2-chloro-N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)benzamide

[0658] [ka] Starting from 2-chloro-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)benzamide, the product 2-chloro-N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)benzamide was obtained by referring to Step 3 of Example 7. MS m / z (ESI): 585.2 [M + H] + .

[0659] Example 77 N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-3-fluoro-6-methylpicolinamide

[0660] [ka] Step 1: N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-3-fluoro-6-methylpicolinamide

[0661] [ka] Starting from 2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-amine and 3-fluoro-6-methylpicolinic acid, the product N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-3-fluoro-6-methylpicolinamide was obtained by referring to Step 1 of Example 75. MS m / z(ESI):433.0[M+H] + .

[0662] Step 2: 3-Fluoro-6-methyl-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)picolinamide

[0663] [ka] Starting from N-(2-(5-bromopyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-3-fluoro-6-methylpicolinamide, the product 3-fluoro-6-methyl-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)picolinamide was obtained by following Step 4 of Example 57. MS m / z (ESI): 481.2 [M + H] + .

[0664] Step 3: N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-3-fluoro-6-methylpicolinamide

[0665] [ka] Starting from 3-fluoro-6-methyl-N-(5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-5-yl)picolinamide, the product N-(2-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)-3-fluoro-6-methylpicolinamide was obtained by referring to Step 3 of Example 7. MS m / z (ESI): 584.2 [M + H] + .

[0666] Example 78 6-(2-hydroxy-2-methylpropoxy)-4-(6-((1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octan-8-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0667] [ka] Step 1: tert-Butyl (1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octane-8-carboxylate

[0668] [ka] Using 6-methoxypyridin-3-ol and tert-butyl (1R,5S)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate as starting materials, tert-butyl (1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octane-8-carboxylate was obtained by following Step 1 of Example 34. MS m / z(ESI):335.1[M+H] + .

[0669] Step 2: (1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octane

[0670] [ka] Using tert-butyl (1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octane-8-carboxylate as the starting material, (1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octane was obtained by following Step 2 of Example 57. MS m / z(ESI):235.1[M+H] + .

[0671] Step 3: 6-(2-hydroxy-2-methylpropoxy)-4-(6-((1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octan-8-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0672] [ka] Using (1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octane and 4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as raw materials, and referring to Step 2 of Example 8, the product 6-(2-hydroxy-2-methylpropoxy)-4-(6-((1R,5S)-3-((6-methoxypyridin-3-yl)oxo)-8-azabicyclo[3.2.1]octan-8-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained. MS m / z (ESI): 541.2 [M + H] + .

[0673] Example 79 4-(6-(1-((5-fluoro-6-methoxypyridin-3-yl)methyl)-2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0674] [ka] Step 1: tert-butyl 3-hydroxy-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrrolidine-1-carboxylate

[0675] [ka] 2-Bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (500 mg, 1.7 mmol) was dissolved in 20 mL of THF, and n-BuLi (1 mL, 2.6 mmol) was added at -78°C. The mixture was stirred at -78°C for 30 minutes. tert-Butyl 3-carbonylpyrrolidine-1-carboxylate was added at -78°C and the mixture was stirred from -78°C to room temperature for 2 hours. 10 mL of aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin-drying, the crude product was separated by column chromatography (washing with petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl 3-hydroxy-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrrolidine-1-carboxylate (379 mg, white solid, yield: 57%). MS m / z (ESI): 391.2 [M + H] + .

[0676] Step 2: tert-butyl 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate

[0677] [ka] tert-Butyl 3-hydroxy-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrrolidine-1-carboxylate (300 mg, 0.76 mmol) was dissolved in 20 mL of DCM, added with SOCl (1 mL) at room temperature, stirred at room temperature for 2 hours, added with 10 mL of aqueous ammonium chloride, and extracted with ethyl acetate (20 mL × 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After filtration and spin drying, the crude product was separated by column chromatography (washing with petroleum ether / ethyl acetate = 3 / 1) to give tert-butyl 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (197 mg, white solid, yield: 70%). MS m / z (ESI): 373.2 [M + H] + .

[0678] Step 3: tert-Butyl 3-(5-(3-cyano-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate

[0679] [ka] Starting from 4-bromo-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile and tert-butyl 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate, tert-butyl 3-(5-(3-cyano-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (180 mg, white solid, 72%) was obtained by following Step 8 of Example 1. MS m / z(ESI):448.1[M+H] + .

[0680] Step 4: 4-(6-(2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0681] [ka] Using tert-butyl 3-(5-(3-cyano-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate as the starting material, 4-(6-(2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (120 mg, white solid, 99% yield) was obtained by following Step 5 of Example 1. MS m / z(ESI):348.1[M+H] + .

[0682] Step 5: 4-(6-(1-((5-fluoro-6-methoxypyridin-3-yl)methyl)-2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0683] [ka] 4-(6-(2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)- Starting from 6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile, 4-(6-(1-((5-fluoro-6-methoxypyridin-3-yl)methyl)-2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-6-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (34 mg, white solid, 62%) was obtained by referring to Step 6 of Example 1. MS m / z(ESI):487.1[M+H]+ .

[0684] Example 80 6-(2-hydroxy-2-methylpropoxy)-4-(6-(1-((6-methoxypyridin-3-yl)methyl)-2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0685] [ka] Step 1: tert-butyl 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate

[0686] [ka] Starting from 4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile and tert-butyl 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate, tert-butyl 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (165 mg, white solid, 65%) was obtained by following Step 8 of Example 1.

[0687] MS m / z (ESI): 476.2 [M + H] + . Step 2: 4-(6-(2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0688] [ka] Starting from tert-butyl 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate, 4-(6-(2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (82 mg, white solid, 67%) was obtained by following Step 5 of Example 1.

[0689] MS m / z(ESI):376.1[M+H] + . Step 3: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(1-((6-methoxypyridin-3-yl)methyl)-2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0690] [ka] Using 4-(6-(2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(1-((6-methoxypyridin-3-yl)methyl)-2,5-dihydro-1H-pyrrol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (23 mg, white solid, 42%) was obtained by referring to Step 6 of Example 1. MS m / z (ESI): 497.2 [M + H] + .

[0691] Example 81 6-(3-hydroxy-3-methylbutyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-7-carbonyl-6,7-dihydropyrazolo[1,5-c]pyrimidine-3-carbonitrile

[0692] [ka] MS m / z (ESI): 541.2 [M + H] + .

[0693] Example 82 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfonyl)ethyl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0694] [ka] Step 1: 3-Bromo-5-(2-(methylsulfonyl)ethyl)pyridine

[0695] [ka] DMSO (780 mg, 10 mmol) was dissolved in 10 mL of THF, and n-BuLi (4 mL, 10 mmol) was added at -78 °C. The mixture was stirred at -78 °C for 0.5 h. 3-Bromo-5-(bromomethyl)pyridine (500 mg, 2 mmol) was added at -78 °C. The mixture was slowly warmed to room temperature and stirred for 2 h. 10 mL of aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered and spin-dried. The crude product was separated by column chromatography (dichloromethane / methanol = 10 / 1) to give 3-bromo-5-(2-(methylsulfonyl)ethyl)pyridine (252 mg, yield: 48%). MS m / z(ESI):263.9[M+H] + .

[0696] Step 2: 4-Bromo-6-(2-(methylsulfonyl)ethyl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0697] [ka] Using 3-bromo-5-(2-(methylsulfonyl)ethyl)pyridine as a starting material, 4-bromo-6-(2-(methylsulfonyl)ethyl)pyrazolo[1,5-a]pyridine-3-carbonitrile (350 mg, white solid) was obtained by referring to Example 11. MS m / z(ESI):327.9[M+H] + .

[0698] Step 3: 6-(2-(methylsulfonyl)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0699] [ka] Starting from 4-bromo-6-(2-(methylsulfonyl)ethyl)pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-(2-(methylsulfonyl)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (230 mg, white solid, 68%) was obtained by following Step 7 of Example 1. MS m / z(ESI):376.1[M+H] + .

[0700] Step 4: 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfonyl)ethyl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0701] [ka] Using 6-(2-(methylsulfonyl)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material, 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(methylsulfonyl)ethyl)pyrazolo[1,5-a]pyridine-3-carbonitrile (30 mg, white solid, 48%) was obtained by following Step 8 of Example 1. MS m / z(ESI):544.2[M+H] + .

[0702] Example 83 6-(3-hydroxy-3-methylbutyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0703] [ka] Referring to Example 82, 6-(3-hydroxy-3-methylbutyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (33 mg, white solid) was obtained. MS m / z(ESI):524.2[M+H] + .

[0704] Example 84 6-(3-hydroxy-3-methylbutyl)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0705] [ka] Referring to Example 82, 6-(3-hydroxy-3-methylbutyl)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (38 mg, white solid) was obtained. MS m / z (ESI): 483.2 [M + H] + .

[0706] Example 85 6-((1-Imino-1-hydroxy-1l6-thietan-3-yl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0707] [ka] Step 1: Thietan-3-ylmethanol

[0708] [ka] Thietane-3-carboxylic acid (500 mg, 4.2 mmol) was dissolved in 10 mL of THF, and LiAlH4 (8.4 mL, 8.4 mmol) was added at -78 °C. The mixture was stirred at -78 °C for 2 hours, slowly warmed to room temperature, and stirred for 2 hours. 10 mL of aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The crude product, thietane-3-carboxylic acid, was obtained by filtration and spin-drying. As a result, benzo-3-ylmethanol (314 mg, yield: 72%) was obtained.

[0709] Step 2: 4-Bromo-6-(thietan-3-ylmethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0710] [ka] Using 4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile and thietan-3-ylmethanol as starting materials, 4-bromo-6-(thietan-3-ylmethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (210 mg, white solid, 67%) was obtained by following Step 2 of Example 1.

[0711] MS m / z(ESI):323.9[M+H] + . Step 3: 4-Bromo-6-((1-hydroxythietan-3-yl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0712] [ka] Starting from 4-bromo-6-(thietan-3-ylmethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile, 4-bromo-6-((1-hydroxythietan-3-yl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (180 mg, white solid, 85%) was obtained by following Step 3 of Example 1. MS m / z(ESI):339.9[M+H] + .

[0713] Step 4: 4-Bromo-6-((1-imino-1-hydroxy-1l6-thietan-3-yl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0714] [ka] Using 4-bromo-6-((1-hydroxythietan-3-yl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as a starting material, 4-bromo-6-((1-imino-1-hydroxy-116-thietan-3-yl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (150 mg, white solid, 79%) was obtained by referring to Example 3. MS m / z(ESI):354.9[M+H] + .

[0715] Step 5: 6-((1-Imino-1-hydroxy-1,16-thietan-3-yl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0716] [ka] Starting from 4-bromo-6-((1-imino-1-hydroxy-116-thietan-3-yl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-((1-imino-1-hydroxy-116-thietan-3-yl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by following Step 7 of Example 1. (96 mg, white solid, 64%) MS m / z(ESI):403.1[M+H] + .

[0717] Step 6: 6-((1-Imino-1-hydroxy-116-thietan-3-yl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0718] [ka] Using 6-((1-imino-1-hydroxy-116-thietan-3-yl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material, and following Step 8 of Example 1, 6-((1-imino-1-hydroxy-116-thietan-3-yl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (30 mg, white solid, 34%) was obtained.

[0719] MS m / z (ESI): 571.2 [M + H] + . 1 H NMR(400MHz,MeOD)δ8.53(s,1H),8.38(s,1H),8.36(s,1H),8.19(s,1H),7. 87(d,J=8.8Hz,1H),7.77(d,J=8.7Hz,1H),7.32(s,1H),6.90(d,J=8.7Hz,1H ),6.83(d,J=8.7Hz,1H),4.43-4.22(m,4H),4.21-4.05(m,4H),4.06-3.94(m ,5H),3.91(s,3H),3.67-3.59(m,1H),3.22-3.11(m,1H),2.25-1.88(m,2H).

[0720] Example 86 6-((1-Imino-1-hydroxy-116-thietan-3-yl)methoxy)-4-(6-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0721] [ka] Using 6-((1-imino-1-hydroxy-116-thietan-3-yl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile as the starting material, and following Step 8 of Example 1, 6-((1-imino-1-hydroxy-116-thietan-3-yl)methoxy)-4-(6-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (34 mg, white solid, 36%) was obtained. MS m / z(ESI):560.2[M+H] + .

[0722] Example 87 6-(2-(1-Imino-1-hydroxy-116-thietan-3-yl)ethoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0723] [ka] Using 2-(thietan-3-yl)ethan-1-ol as a starting material, 6-(2-(1-imino-1-hydroxy-116-thietan-3-yl)ethoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (35 mg, white solid) was obtained by referring to Example 85. MS m / z (ESI): 585.2 [M + H] + .

[0724] Example 88 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(1-hydroxytetrahydro-2H-thiopyran-4-yl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0725] [ka] Using 2-(tetrahydro-2H-thiopyran-4-yl)ethan-1-ol as a starting material, 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(1-hydroxytetrahydro-2H-thiopyran-4-yl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (29 mg, white solid) was obtained by referring to Example 85. MS m / z (ESI): 598.2 [M + H] + .

[0726] Example 89 6-(2-(1-Imino-1-hydroxyhexahydro-1l6-thiopyran-4-yl)ethoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0727] [ka] Using 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(1-hydroxytetrahydro-2H-thiopyran-4-yl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile as a raw material, 6-(2-(1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)ethoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (18 mg, white solid) was obtained by referring to Example 3. MS m / z(ESI):613.2[M+H] + .

[0728] Example 90 6-((1-Imino-1-hydroxyhexahydro-1l6-thiopyran-4-yl)oxo)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0729] [ka] Step 1: Preparation of 4-bromo-6-((tetrahydro-2H-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0730] [ka] 4-Bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (10 g, 42.0 mmol) was dissolved in tetrahydrofuran (100 ml), and tetrahydro-2H-thiopyran-4-ol (6 g, 50.4 mmol) and triphenylphosphine (22 g, 84.0 mmol) were added. DEAD (14.6 g, 84.0 mmol) was slowly added dropwise to the reaction solution. The reaction was stirred overnight at room temperature. Water was added to quench the reaction, and ethyl acetate was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography to give 4-bromo-6-((tetrahydro-2H-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-carbonitrile (7 g, 49% yield). MS m / z(ESI):337.9[M+H] + .

[0731] Step 2: Preparation of 4-bromo-6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0732] [ka] 4-Bromo-6-((tetrahydro-2H-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-carbonitrile (3 g, 8.9 mmol) was dissolved in methanol (40 mL) and ammonium carbonate (1.6 g, 16.9 mmol) and (diacetoxyiodo)benzene (5.7 g, 17.8 mmol) were added. The reaction was stirred overnight at room temperature. The reaction solution was spun to dryness. The crude product was purified by column chromatography to give 4-bromo-6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-carbonitrile (350 mg, 11% yield). MS m / z(ESI):368.9[M+H] + .

[0733] Step 3: 6-((1-Imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)-4-(6-(6-((6-methoxypyridin-3-yl)methyl) Preparation of )-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0734] [ka] 4-Bromo-6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-carbonitrile and 6-((6-methoxypyridin-3-yl)methyl)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane Using this as the starting material, 6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (35 mg, yield: 36%) was obtained by referring to Step 3 of Example 37.

[0735] MS m / z (ESI): 585.2 [M + H] + . 1H NMR(400MHz,DMSO-d6)δ8.89(dd,J=7.6,2.0Hz,1H),8.62(s,1H),8.42(t,J=2.4Hz,1H),8.07(s,1 H),7.85(d,J=8.6Hz,1H),7.72-7.60(m,1H),7.51-7.40(m,1H),6.78(t,J=9.4Hz,2H),4.90-4.78 (m,1H),3.82(s,3H),3.79-3.61(m,4H),3.60-3.45(m,4H),3.27-3.13(m,2H),3.13-2.98(m,2H), 2.65-2.53(m,1H),2.31-2.14(m,3H),2.13-1.92(m,1H),1.59(d,J=8.4Hz,1H),0.84-0.69(m,1H).

[0736] Example 91 6-((1-Imino-1-hydroxyhexahydro-1l6-thiopyran-4-yl)oxo)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0737] [ka] Step 1: 6-((1-Imino-1-hydroxyhexahydro-1l6-thiopyran-4-yl)oxo)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0738] [ka] 4-Bromo-6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-carbonitrile and 2-(4-(pyridin-2-oxy)piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine were used as raw materials, and 6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)-4-(6-(4-(pyridin-2-oxy)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (45 mg, yield: 38%) was obtained by referring to step 3 of Example 37. MS m / z(ESI):544.2[M+H] + .

[0739] Example 92 6-(3-amino-3-methylbut-1-yn-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0740] [ka] Using 2-methylbut-3-yn-2-amine as a starting material, 6-(3-amino-3-methylbut-1-yn-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Example 31.

[0741] MS m / z (ESI): 519.2 [M + H] + . 1H NMR(400MHz,Methanol-d4)δ8.82(d,J=1.3Hz,1H),8.46(s,1H),8.34(d,J=2.4Hz,1H) ,8.09(d,J=2.3Hz,1H),7.84(dd,J=8.9,2.5Hz,1H),7.72(dd,J=8.5,2.5Hz,1H),7.41( d,J=1.4Hz,1H),6.88(d,J=8.9Hz,1H),6.78(d,J=8.5Hz,1H),4.01-3.83(m,5H),3.84- 3.73(m,2H),3.72-3.56(m,4H),2.78-2.65(m,1H),1.71(d,J=9.0Hz,1H),1.52(s,6H).

[0742] Example 93 6-(3-amino-3-methylbut-1-yn-1-yl)-4-(6-(4-((6 -Methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0743] [ka]

[0744] [ka] Using 6-(3-amino-3-methylbut-1-yn-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and 5-bromo-2-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridine as raw materials, 6-(3-amino-3-methylbut-1-yn-1-yl)-4-(6-(4-((6-methoxypyridin-3-yl)oxo)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile was obtained by referring to Step 8 of Example 1. MS m / z (ESI): 508.2 [M + H] + .

[0745] Example 94 4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0746] [ka] Step 1: 6-Bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate

[0747] [ka] 6-Bromo...

Claims

1. A compound represented by general formula (IX), its stereoisomer, or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (where: M 1 and M 2 are each independently selected from CR aa or N; G 1 and G 2 are each independently selected from CR aa or N; L is selected from a bond, -(CH2)n1CRaaRbb-, -(CH2)n1NRaaC(O)(CH2)n2-, -(CH2)n1C(O)(CH2)n2(CRaaRbb)m-, -(CH2)n1C(O)(CRaaRbb)m(CH2)n2-, -(CH2)n1C(O)NRcc(CRaaRbb)n2-, -(CH2)n1(O)(CH2)n2- or -(CH2)n1NRaa(CH2)n2-; X 3 is selected from N or CR 5 ; R 5 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH 2 ) n1 R aa , -(CH 2 ) n1 OR aa , -(CH 2 ) n1 S(CH 2 ) n2 R aa , -(CH 2 ) n1 C(O)R aa , -(CH 2 ) n1 C(O)OR aa , -(CH 2 ) n1 S(O) m R aa , -(CH 2 ) n1 S(O)(═NR aa )(CH 2 ) n2 R bb , -(CH 2 ) n1 NR aa R bb , -(CH 2 ) n1 P(O)R aa R bb , -(CH 2 ) n1 C(O)NR aa R bb , -(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR dd S(O) m R bb ; R 7 is alkenyl, alkynyl, a heterocyclic group, -(C≡C) n1 (CR aa R bb ) m R cc , -(C═C) n1 (CR aa R bb ) m R cc , -(CH 2 ) n1 O(CH 2 ) n2 (CR aa R bb ) m R cc , -(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa (CH 2 ) n2 R bb . wherein the alkenyl, alkynyl, and heterocyclic groups are further selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxy, cyano, oxo, thiol, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic groups, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH 2 ) n1 R dd , -(CH 2 ) n1 OR dd , -(CH 2 ) n1 S(CH 2 ) n2 R dd , -(CH 2 ) n1 C(O)R optionally substituted with one or more substituents selected from among -NR dd, -(CH 2 ) n1 C(O)OR dd, -(CH 2 ) n1 S(O) m R dd, -(CH 2 ) n1 S(O)(═NR dd )(CH 2 ) n2 R ee, -(CH 2 ) n1 NR dd R ee, -(CH 2 ) n1 P(O)R dd R ee, -(CH 2 ) n1 C(O)NR dd R ee, -(CH 2 ) n1 NR dd C(O)R ee and -(CH 2 ) n1 NR dd S(O) m R ee; R 8 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; R 9 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH 2 ) n1 R aa , -(CH 2 ) n1 OR aa , -(CH 2 ) n1 S(CH 2 ) n2 R aa , -(CH 2 ) n1 C(O)R aa , -(CH 2 ) n1 C(O)OR aa , -(CH 2 ) n1 S(O) m R aa , -(CH 2 ) n1 S(O)(═NR aa )(CH 2 ) n2 R bb , -(CH 2 ) n1 NR aa R bb , -(CH 2 ) n1 P(O)R aa R bb , -(CH 2 ) n1 C(O)NR aa R bb , -(CH 2 ) n1 NR aa C(O)R bb or -(CH 2 ) n1 NR aa S(O) m R bb ; R 10 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; or any two adjacent or non-adjacent R 10 are linked together to form a cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl and heteroaryl are further optionally substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; R aa , R bb , R dd and R ee are each independently selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, cyano, nitro, hydroxy, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl are optionally substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxy, amino, oxo, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; Each R cc is independently selected from cyano or alkynyl; or any two of R aa , R bb , R dd and R ee are linked together to form a cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl and heteroaryl are further optionally substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxy, amino, oxo, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl and substituted and unsubstituted heteroaryl; t is 0, 1, 2, 3, or 4; p is 0, 1, 2, or 3; q is 0, 1, 2, 3, or 4; s is 0, 1, 2, 3, 4, or 5; m is 0, 1, or 2; n1 is 0, 1, 2, or 3; and n2 is 0, 1, 2, or 3; The general formula (IX) is not the following compound: 【Chemistry 2】

2. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the general formula (IX) is further represented by general formula (X). 【Chemistry 3】 (where: G 2 is CR aa or N; M 2 is CR aa or N; L is a bond, -(CH 2 ) n1 CR aa R bb -, -(CH 2 ) n1 N.R. aa C(O)(CH 2 ) n2 -, -(CH 2 ) n1 C(O)(CH 2 ) n2 (CR aa R bb ) m -, -(CH 2 ) n1 C(O)(CR aa R bb ) m (CH 2 ) n2 -, -(CH 2 ) n1 C(O)NR cc (CR aa R bb ) n2 -, -(CH 2 ) n1 (O) (CH 2 ) n2 Or (CH 2 ) n1 N.R. aa (CH 2 ) n2 - selected from; R 7 is an alkenyl, alkynyl, heterocyclic group, -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH 2 ) n1 O (CH 2 ) n2 (CR aa R bb ) m R cc , -(CH 2 ) n1 N.R. aa C(O)R bb , or -(CH 2 ) n1 N.R. aa (CH 2 ) n2 Rbb, wherein the alkenyl, alkynyl, and heterocyclic groups are further selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxy, cyano, oxo, thiol, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic groups, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH 2 ) n1 R dd , -(CH 2 ) n1 OR dd , -(CH 2 ) n1 S (CH 2 ) n2 R dd , -(CH 2 ) n1 C(O)R dd , -(CH 2 ) n1 C(O)OR dd , -(CH 2 ) n1 S (O) m R dd , -(CH 2 ) n1 S(O)(=NR dd ) (CH 2 ) n2 R ee , -(CH 2 ) n1 N.R. dd R ee , -(CH 2 ) n1 P(O)R dd R ee , -(CH 2 ) n1 C(O)NR dd R ee , -(CH 2 ) n1 N.R. dd C(O)R ee and -(CH 2 ) n1 N.R. dd S (O) m R ee and optionally substituted with one or more substituents selected from among R 9 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH 2 ) n1 R aa , -(CH 2 ) n1 OR aa , -(CH 2 ) n1 S (CH 2 ) n2 R aa , -(CH 2 ) n1 C(O)R aa , -(CH 2 ) n1 C(O)OR aa , -(CH 2 ) n1 S (O) m R aa , -(CH 2 ) n1 S(O)(=NR aa ) (CH 2 ) n2 R bb , -(CH 2 ) n1 N.R. aa R bb , -(CH 2 ) n1 P(O)R aa R bb , -(CH 2 ) n1 C(O)NR aa R bb , -(CH 2 ) n1 N.R. aa C(O)R bb or -(CH 2 ) n1 N.R. aa S (O) m R bb Selected from: R 10 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; Or any two adjacent or non-adjacent R 10 are linked to form a cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl and heteroaryl are further optionally substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; R 11 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH 2 ) n1 R aa , -(CH 2 ) n1 OR aa , -(CH 2 ) n1 S.R. aa , -(CH 2 ) n1 C(O)R aa , -(CH 2 ) n1 C(O)OR aa , -(CH 2 ) n1 S (O) m R aa , -(CH 2 ) n1 N.R. aa R bb , -(CH 2 ) n1 P(O)R aa R bb , -(CH 2 ) n1 C(O)NR aa R bb , -(CH 2 ) n1 N.R. aa C(O)R bb or -(CH 2 ) n1 N.R. aa S (O) m R bb Selected from: R aa , R bb , R dd and R ee are each independently selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, cyano, nitro, hydroxy, amino, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl are further optionally substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxy, amino, oxo, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; Each R cc is independently selected from cyano or alkynyl; Or, R aa , R bb , R dd and R ee any two of the above may be linked together to form a cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl and heteroaryl may be further optionally substituted with one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxy, amino, oxo, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; s is 0, 1, 2, 3, 4, or 5; t is 0, 1, 2, 3, or 4; and p is 0, 1, 2, or 4.

3. The compound according to claim 2, its stereoisomer or its pharma- ceutically acceptable salt, wherein the general formula (IX) is further represented by general formula (XI) or general formula (XI-A). 【Chemistry 4】 (where: R 12 is hydrogen; R 13 is an alkenyl, alkynyl, heterocyclic group, -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH 2 ) n1 O (CH 2 ) n2 (CR aa R bb ) m R cc , -(CH 2 ) n1 N.R. aa C(O)R bb , or -(CH 2 ) n1 N.R. aa (CH 2 ) n2 Rbb, wherein the alkenyl, alkynyl, and heterocyclic groups are further selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxy, cyano, oxo, thiol, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic groups, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -(CH 2 ) n1 R dd , -(CH 2 ) n1 OR dd , -(CH 2 ) n1 S (CH 2 ) n2 R dd , -(CH 2 ) n1 C(O)R dd , -(CH 2 ) n1 C(O)OR dd , -(CH 2 ) n1 S (O) m R dd , -(CH 2 ) n1 S(O)(=NR dd ) (CH 2 ) n2 R ee , -(CH 2 ) n1 N.R. dd R ee , -(CH 2 ) n1 P(O)R dd R ee , -(CH 2 ) n1 C(O)NR dd R ee , -(CH 2 ) n1 N.R. dd C(O)R ee and -(CH 2 ) n1 N.R. dd S (O) m R ee and optionally substituted with one or more substituents selected from among R14 is hydrogen; R 15 and R 16 each independently represents hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, or -(CH 2 ) n1 OR aa Selected from: L, R 11 , R aa ~R ee , n1, n2 and m are as defined in claim 2.

4. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the general formula (IX) is further represented by general formula (XII). 【Chemistry 5】 (where: L is a bond, -(CH 2 ) n1 CR aa R bb -, -(CH 2 ) n1 N.R. aa C(O)(CH 2 ) n2 -, -(CH 2 ) n1 C(O)(CH 2 ) n2 (CR aa R bb ) m -, -(CH 2 ) n1 C(O)(CR aa R bb ) m (CH 2 ) n2 -, -(CH 2 ) n1 C(O)NR cc (CR aa R bb ) n2 -, -(CH 2 ) n1 (O) (CH 2 ) n2 Or (CH 2 ) n1 N.R. aa (CH 2 ) n2 - selected from; M 1 and M. 2 are each independently CR aa or N; X1 is N; X 2 is C; R 3 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; R 9 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH 2 ) n1 R aa , -(CH 2 ) n1 OR aa , -(CH 2 ) n1 S (CH 2 ) n2 R aa , -(CH 2 ) n1 C(O)R aa , -(CH 2 ) n1 C(O)OR aa , -(CH 2 ) n1 S (O) m R aa , -(CH 2 ) n1 S(O)(=NR aa ) (CH 2 ) n2 R bb , -(CH 2 ) n1 N.R. aa R bb , -(CH 2 ) n1 P(O)R aa R bb , -(CH 2 ) n1 C(O)NR aa R bb , -(CH 2 ) n1 N.R. aa C(O)R bb or -(CH 2 ) n1 N.R. aa S (O) m R bb Selected from: R 11 is hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -(CH 2 ) n1 R aa , -(CH 2 ) n1 OR aa , -(CH 2 ) n1 S.R. aa , -(CH 2 ) n1 C(O)R aa , -(CH 2 ) n1 C(O)OR aa , -(CH 2 ) n1 S (O) m R aa , -(CH 2 ) n1 N.R. aa R bb , -(CH 2 ) n1 P(O)R aa R bb , -(CH 2 ) n1 C(O)NR aa R bb , -(CH 2 ) n1 N.R. aa C(O)R bb or -(CH 2 ) n1 N.R. aa S (O) m R bb Selected from: z is 0, 1, 2, 3, or 4; s is 0, 1, 2, 3, 4, or 5; R 12 ~R 14 , R aa ~R ee , n1, n2 and m are as defined in claim 3.

5. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the general formula (IX) is further represented by general formula (IX-B): 【Chemistry 6】 (where: L is selected from a bond, -(CH2)n1CRaaRbb-, -(CH2)n1NRaaC(O)(CH2)n2-, -(CH2)n1C(O)(CH2)n2(CRaaRbb)m-, -(CH2)n1C(O)(CRaaRbb)m(CH2)n2-, -(CH2)n1C(O)NRcc(CRaaRbb)n2-, -(CH2)n1(O)(CH2)n2- or -(CH2)n1NRaa(CH2)n2-; G2 is selected from N or CR aa ; M 1 is selected from N or CR aa ; M2 is selected from N or CR aa ; M 3 is a bond, —O—, —NH— or —NCH 3 - selected from; R 9 is selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, a 3- to 12-membered heterocyclic group, C 6-10 aryl, a 5- to 12-membered heteroaryl or -(CH 2 ) n1 OR aa ; R 18 and R 19 are each independently hydrogen, deuterium, or C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 aryl or 5-12 membered heteroaryl; Or, R 18 and R 19 C together with the carbon atom connected thereto 3-8 cycloalkyl or 3- to 12-membered heterocyclic group, 3-8 The cycloalkyl or 3- to 12-membered heterocyclic group may further include hydrogen, C 1-6 Alkyl, hydroxy, cyano and C 1-6 Optionally substituted with one or more substituents selected from among hydroxyalkyl; R 20 is cyano or C 2-6 alkynyl; R 24 and R 25 are each independently hydrogen, deuterium, or C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 aryl or 5-12 membered heteroaryl; Or, R 24 and R 25 is a carbon atom and G 2 Together with C 3-8 forming a cycloalkyl or 3- to 12-membered heterocyclic group; r is 0, 1, or 2; s is 0, 1, 2, or 3.

6. R 9 is selected from hydrogen, deuterium, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, C 6-10 aryl, a 5- to 10-membered heteroaryl, or -(CH 2 ) n1 OR aa ; In the general formula (IX-B), R 18 and R 19 each independently represents hydrogen, deuterium, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 8-membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; Or, R 18 and R 19 C together with the carbon atom connected thereto 3-6 forming a cycloalkyl or 3-7 membered heterocyclic group containing 1-2 oxygen, nitrogen or sulfur atoms; R 20 is selected from cyano or C2-4 alkynyl; R 24 and R 25 are each independently selected from hydrogen, deuterium, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, C 6-10 aryl, or a 5- to 10-membered heteroaryl; Or, R 24 and R 25 together with the carbon atom to which they are linked and G 2 form a C 3-6 cycloalkyl or 3- to 8-membered heterocyclic group, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof according to claim 5.

7. L is selected from -CH 2 -, -CD 2 -, -O-, or -NHC(O)-; G2 is selected from N, CH or CCH3; M 1 is selected from N, CH or CCH 3 ; M2 is selected from N or CH; R 9 is selected from hydrogen, fluorine, chlorine, methyl, methoxy, deuterated methoxy or cyclopropoxy; R 18 and R 19 are each independently selected from hydrogen, methyl, ethynyl, amino, cyano, or hydroxy; or R 18 and R 19 together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, tetrahydropyran, bicyclo[1,1,1]pentane, or 1-imino-1-oxothiopyran; R 20 is selected from ethynyl or cyano; R 24 and R 25 are each independently selected from hydrogen or methyl; Or, R 24 and R 25 together with the carbon atom to which they are attached and G 2 form an azetidinyl, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof, according to claim 5.

8. The compound according to claim 2, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the general formula (IX) is further represented by general formula (XIII). 【Chemistry 7】 (where: R 11 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; R 13 is C 2-6 Alkenyl, C 2-6 Alkynyl, -O(CH 2 ) n1 (CR aa R bb ) m R cc or 【Chemistry 8】 Selected from: R aa and Rbb are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; R cc is selected from cyano or C 2-6 alkynyl; R c and R d are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; Or, R c and R d C together with the adjacent carbon atom 3-8 Cycloalkyl is formed by deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 Optionally substituted with one or more substituents selected from among alkynyl; M 1 and M. 2 are each independently selected from -N- or -CH-; R 16 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; R a and R b are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; k is an integer of 0, 1, or 2; n1 is an integer of 1, 2, or 3; m is an integer of 1, 2, or 3.

9. R 11 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, or C 1-3 alkyl; R 13 is C 2-4 Alkenyl, C 2-4 Alkynyl, -OCH 2 CR aa R bb R cc or 【Chemistry 9】 Selected from: R aa and Rbb are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl or C 2-6 alkynyl; R cc is selected from cyano or C 2-4 alkynyl; R c and R d are each independently hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy or C 1-3 haloalkoxy; Or, R c and R d C together with the adjacent carbon atom 3-6 Cycloalkyl is formed by deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 deuterated alkoxy or C 1-3 optionally substituted with one or more substituents selected from among haloalkoxy; M 1 is -N-, and M 2 is —CH—, or M 1 is -CH-, M 2 is -N-; R 16 is hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy or C 1-3 haloalkoxy; R a and R b The compound according to claim 8, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein each is independently selected from hydrogen, deuterium or halogen.

10. The compound according to claim 5, wherein the general formula (IX) is further represented by general formula (X), or a stereoisomer or a pharma- ceutically acceptable salt thereof. 【Chemistry 10】

11. R 18 and R 19 are each independently hydrogen, deuterium, or C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C1-3 alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3- to 6-membered heterocyclic group, C 6-10 aryl or 5-6 membered heteroaryl; R 9 are hydrogen, deuterium, and C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 Alkenyl or C 2-4 alkynyl; 11. The compound according to claim 10, wherein s is 0, 1, 2 or 3, or a stereoisomer or a pharma- ceutically acceptable salt thereof.

12. 【Fig. 11】 teeth, 【Chemistry 12】 6. The compound according to claim 5, wherein:

13. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the general formula (IX) is further represented by general formula (IX-C): 【Chemistry 13】 (where: L is selected from a bond, -(CH2)n1CRaaRbb-, -(CH2)n1NRaaC(O)(CH2)n2-, -(CH2)n1C(O)(CH2)n2(CRaaRbb)m-, -(CH2)n1C(O)(CRaaRbb)m(CH2)n2-, -(CH2)n1C(O)NRcc(CRaaRbb)n2-, -(CH2)n1(O)(CH2)n2- or -(CH2)n1NRaa(CH2)n2-; G2 is selected from N or CR aa ; M 1 is selected from N or CR aa ; M2 is selected from N or CR aa ; R 9 is selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, a 3- to 12-membered heterocyclic group, C 6-10 aryl, a 5- to 12-membered heteroaryl or -(CH 2 ) n1 OR aa ; R 21 and R 22 are each independently hydrogen, deuterium, or C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5- to 12-membered heteroaryl, -C(O)R aa or -(CH 2 ) n1 R aa Selected from: Or, R 21 and R 22 together with the carbon atom to which they are attached form a 3- to 12-membered heterocyclic group, wherein the 3- to 12-membered heterocyclic group can further include hydrogen, amino, halogen, cyano, hydroxy, oxo, C 1-6 Alkyl and C 1-6 Optionally substituted with one or more substituents selected from among hydroxyalkyl; R 24 and R 25 are each independently hydrogen, deuterium, or C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-10 Aryl, 5- to 12-membered heteroaryl or -(CH 2 ) n1 OR aa Selected from: Or, R 24 and R 25 is a carbon atom and G 2 Together with C 3-8 forming a cycloalkyl or 3- to 12-membered heterocyclic group; R aa and R bb are each independently selected from hydrogen, deuterium, cyano, amino, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, hydroxy, C 3-8 cycloalkyl, a 3- to 12-membered heterocyclic group, or C 6-14 aryl, wherein the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, hydroxy, C 3-8 cycloalkyl, a 3- to 12-membered heterocyclic group, and C 6-14 aryl are optionally further substituted with one or more substituents selected from hydrogen, halogen, cyano, hydroxyl, oxo, imino, C 1-6 alkyl, or C 1-6 hydroxyalkyl; R cc is selected from cyano; or any two of R aa and R bb are optionally linked to form a C 3-8 cycloalkyl or 3-12 membered heterocyclic group, wherein the C 3-8 cycloalkyl and 3-12 membered heterocyclic groups are further optionally substituted with one or more substituents selected from among hydrogen, amino, halogen, cyano, hydroxy, oxo, imino, C 1-6 alkyl or C 1-6 hydroxyalkyl; s is 0, 1, 2 or 3.

14. L is a bond, -(CH2)n1CRaaRbb-, -(CH2)n1NRaaC(O)(CH2)n2-, -(CH2)n1C(O)(CH2)n2(CRaaRbb)m-, -(CH2)n1C(O)(CRaaRbb)m(CH2)n2-, -(CH2)n1C(O)NRcc(CRaaRbb)n2-, -(CH2)n1(O)(CH2)n2-, or -(CH2)n1NRaa(CH2)n2 - selected from; G2 is selected from N or CR aa ; M 1 is selected from N or CR aa ; M2 is selected from N or CR aa ; R 9 is selected from hydrogen, deuterium, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, a 3-8 membered heterocyclic group, C 6-10 aryl, a 5-10 membered heteroaryl or -(CH 2 ) n1 OR aa ; R 21 and R 22 each independently represents hydrogen, deuterium, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 8-membered heterocyclic group, C 6-10 Aryl, 5- to 10-membered heteroaryl, -C(O)R aa or -(CH 2 ) n1 R aa Selected from: Or, R 21 and R 22 together with the carbon atom to which they are attached form a 3- to 8-membered heterocyclic group, wherein said 3- to 8-membered heterocyclic group is optionally further substituted with one or more substituents selected from among hydrogen, amino, halogen, cyano, hydroxy, oxo, C1-3 alkyl, and C1-3 hydroxyalkyl; R 24 and R 25 are each independently selected from hydrogen, deuterium, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, C 6-10 aryl, a 5- to 10-membered heteroaryl, or -(CH 2 ) n1 OR aa ; or R 24 and R 25 together with the carbon atom to which they are attached and G 2 form a C 3-6 cycloalkyl or 3- to 8-membered heterocyclic group; R aa and R bb are each independently selected from hydrogen, deuterium, cyano, amino, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, hydroxy, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, or C 6-10 aryl, wherein the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, hydroxy, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, and C 6-10 aryl are optionally further substituted with one or more substituents selected from hydrogen, halogen, cyano, hydroxyl, oxo, imino, C 1-3 alkyl, or C 1-3 hydroxyalkyl; R cc is selected from cyano; or any two of R aa and R bb are optionally linked to form a C 3-6 cycloalkyl or 3- to 8-membered heterocyclic group, wherein the C 3-6 cycloalkyl and 3- to 8-membered heterocyclic group are further optionally substituted with one or more substituents selected from hydrogen, amino, halogen, cyano, hydroxy, oxo, imino, C 1-3 alkyl or C 1-3 hydroxyalkyl, the compound according to claim 13, its stereoisomer or a pharma- ceutically acceptable salt thereof.

15. L is selected from -CH 2 -, -CD 2 -, -O-, or -NHC(O)-; G2 is selected from N, CH or CCH3; M 1 is selected from N, CH or CCH 3 ; M2 is selected from N or CH; R 9 is selected from hydrogen, fluorine, chlorine, methyl, methoxy, deuterated methoxy or cyclopropoxy; R 21 and R 22 are each independently selected from hydrogen, deuterium, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, halogen, amino, hydroxy, cyano, -C(O)R aa or -(CH 2 ) n1 R aa ; or R 21 and R 22 together with the carbon atom to which they are attached form an azetidinyl, pyrrolidinyl, 2-azaspiro[3.3]heptane, or piperidinyl, wherein the azetidinyl, pyrrolidinyl, 2-azaspiro[3.3]heptane, or piperidinyl is optionally further substituted with one or more substituents selected from hydrogen, C 1-3 alkyl, cyano, hydroxyl, or C 1-3 hydroxyalkyl; R 24 and R 25 are each independently selected from hydrogen or methyl; or R 24 and R 25 together with the carbon atom to which they are attached and G 2 form an azetidinyl; R aa and R bb are each independently selected from hydrogen, deuterium, cyano, amino, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, hydroxy, C 3-6 cycloalkyl, or a 3- to 8-membered heterocyclic group, wherein said C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, hydroxy, C 3-6 cycloalkyl, or a 3- to 8-membered heterocyclic group is optionally further substituted with one or more substituents selected from hydrogen, halogen, cyano, hydroxy, oxo, imino, C 1-3 alkyl, or C 1-3 hydroxyalkyl; 14. The compound of claim 13, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, wherein Rcc is selected from cyano.

16. 【Fig. 14】 15. The compound of claim 14, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, selected from: (where: R 26 and R 27 are each independently selected from hydrogen, halogen, amino, hydroxy, cyano, C1-3 alkyl, and C1-3 hydroxyalkyl.

17. The compound, stereoisomer or pharma- ceutically acceptable salt thereof according to claim 16, wherein R26 and R27 are each independently selected from hydrogen, hydroxy, cyano, methyl or hydroxyisopropyl.

18. The compound according to claim 1, its stereoisomer or its pharma- ceutically acceptable salt, wherein the general formula (IX) is further represented by general formula (IX-A). 【Chemistry 15】 (where: L is selected from a bond, -(CH2)n1CRaaRbb-, -(CH2)n1NRaaC(O)(CH2)n2-, -(CH2)n1C(O)(CH2)n2(CRaaRbb)m-, -(CH2)n1C(O)(CRaaRbb)m(CH2)n2-, -(CH2)n1C(O)NRcc(CRaaRbb)n2-, -(CH2)n1(O)(CH2)n2- or -(CH2)n1NRaa(CH2)n2-; G2 is selected from N or CR aa ; M 1 is selected from N or CR aa ; M2 is selected from N or CR aa ; R 9 is selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, a 3- to 12-membered heterocyclic group, C 6-10 aryl, a 5- to 12-membered heteroaryl or -(CH 2 ) n1 OR aa ; R 17 is selected from C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 2-6 alkynyl, a 3- to 12-membered heterocyclic group, a 5- to 12-membered heteroaryl, or -(CR aa R bb )R cc , wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 2-6 alkynyl, a 3- to 12-membered heterocyclic group, and a 5- to 12-membered heteroaryl are optionally further substituted by one or more substituents selected from hydrogen, C 1-6 haloalkyl, hydroxy, cyano, oxo, thiol, amino, imino, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 cyanoalkyl, C 3-8 cycloalkyl, or a 3- to 12-membered heterocyclic group; R 24 and R 25 are each independently selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, a 3- to 12-membered heterocyclic group, C 6-10 aryl, a 5- to 12-membered heteroaryl, or -(CH 2 ) n1 OR aa ; or R 24 and R 25 together with the carbon atom to which they are attached and G 2 form a C 3-8 cycloalkyl or 3- to 12-membered heterocyclic group; R aa and R bb are each independently selected from hydrogen, deuterium, cyano, amino, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, hydroxy, C 3-8 cycloalkyl, a 3- to 12-membered heterocyclic group, or C 6-14 aryl, wherein the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, hydroxy, C 3-8 cycloalkyl, a 3- to 12-membered heterocyclic group, and C 6-14 aryl are optionally further substituted with one or more substituents selected from hydrogen, halogen, cyano, hydroxy, oxo, imino, C 1-6 alkyl, or C 1-6 hydroxyalkyl; R cc is selected from cyano; or any two of R aa and R bb are optionally linked to form a C 3-8 cycloalkyl or 3-12 membered heterocyclic group, wherein said C 3-8 cycloalkyl and 3-12 membered heterocyclic group are optionally further substituted with one or more substituents selected from hydrogen, amino, halogen, cyano, hydroxy, oxo, imino, C 1-6 alkyl or C 1-6 hydroxyalkyl; n1 is 0, 1 or 2; n2 is 0, 1 or 2; m is 0, 1 or 2; s is 0, 1, 2 or 3.

19. L is a bond, -(CH2)n1CRaaRbb-, -(CH2)n1NRaaC(O)(CH2)n2-, -(CH2)n1C(O)(CH2)n2(CRaaRbb)m-, -(CH2)n1C(O)(CRaaRbb)m(CH2)n2-, -(CH2)n1C(O)NRcc(CRaaRbb)n2-, -(CH2)n1(O)(CH2)n2-, or -(CH2)n1NRaa(CH2)n2 - selected from; G2 is selected from N or CR aa ; M 1 is selected from N or CR aa ; M2 is selected from N or CR aa ; R 9 is selected from hydrogen, deuterium, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, a 3-8 membered heterocyclic group, C 6-10 aryl, a 5-10 membered heteroaryl or -(CH 2 ) n1 OR aa ; R 17 is selected from C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 2-4 alkynyl, a 3- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl, or -(CR aa R bb )R cc , wherein said C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 2-4 alkynyl, a 3- to 8-membered heterocyclic group, and a 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, C 1-3 haloalkyl, hydroxy, cyano, oxo, thiol, amino, imino, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-3 cyanoalkyl, C 3-6 cycloalkyl, or a 3- to 8-membered heterocyclic group; R 24 and R 25 are each independently selected from hydrogen, deuterium, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, halogen, amino, nitro, hydroxy, cyano, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, C 6-10 aryl, a 5- to 10-membered heteroaryl, or -(CH 2 ) n1 OR aa ; or R 24 and R 25 together with the carbon atom to which they are attached and G 2 form a C 3-6 cycloalkyl or 3- to 8-membered heterocyclic group; R aa and R bb are each independently selected from hydrogen, deuterium, cyano, amino, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, hydroxy, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, or C 6-10 aryl, wherein the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, hydroxy, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, and C 6-10 aryl are optionally further substituted with one or more substituents selected from hydrogen, halogen, cyano, hydroxy, oxo, imino, C 1-3 alkyl, or C 1-3 hydroxyalkyl; R cc is selected from cyano; or any two of R aa and R bb are optionally linked to form a C 3-6 cycloalkyl or 3-8 membered heterocyclic group, wherein the C 3-6 cycloalkyl and 3-8 membered heterocyclic group are further optionally substituted with one or more substituents selected from hydrogen, amino, halogen, cyano, hydroxy, oxo, imino, C 1-3 alkyl or C 1-3 hydroxyalkyl, the compound according to claim 18, its stereoisomer or a pharma- ceutically acceptable salt thereof.

20. L is selected from -CH 2 -, -CD 2 -, -O-, or -NHC(O)-; G2 is selected from N, CH or CCH3; M 1 is selected from N, CH or CCH 3 ; M2 is selected from N or CH; R 9 is selected from hydrogen, fluorine, chlorine, methyl, methoxy, deuterated methoxy or cyclopropoxy; R 17 is selected from C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 2-4 alkynyl, a 3- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl, or -(CR aa R bb )R cc , wherein said C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 2-4 alkynyl, a 3- to 8-membered heterocyclic group, and a 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents selected from hydrogen, C 1-3 haloalkyl, hydroxy, cyano, oxo, thiol, amino, imino, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-3 cyanoalkyl, C 3-6 cycloalkyl, or a 3- to 8-membered heterocyclic group; R 24 and R 25 are each independently selected from hydrogen or methyl; or R 24 and R 25 together with the carbon atom to which they are attached and G 2 form an azetidinyl; R aa and R bb are each independently selected from hydrogen, deuterium, cyano, amino, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, hydroxy, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, or C 6-10 aryl, wherein said C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, hydroxy, C 3-6 cycloalkyl, a 3- to 8-membered heterocyclic group, and C 6-10 aryl are optionally further substituted with one or more substituents selected from hydrogen, halogen, cyano, hydroxy, oxo, imino, C 1-3 alkyl, or C 1-3 hydroxyalkyl; R cc is selected from cyano; or any two of R aa and R bb are optionally linked to form a C 3-6 cycloalkyl or 3-8 membered heterocyclic group, wherein said C 3-6 cycloalkyl and 3-8 membered heterocyclic group are optionally further substituted with one or more substituents selected from hydrogen, amino, halogen, cyano, hydroxy, oxo, imino, C 1-3 alkyl or C 1-3 hydroxyalkyl, the compound according to claim 18, its stereoisomer or a pharma- ceutically acceptable salt thereof.

21. L is a bond, -(CH 2 ) n1 CR aa R bb -, -(CH 2 ) n1 N.R. aa C(O)(CH 2 ) n2 -, -(CH 2 ) n1 C(O)(CR aa R bb ) m (CH 2 ) n2 -, -(CH 2 ) n1 C(O)(CH 2 ) m (CR aa R bb ) n2 -, -(CH 2 ) n1 C(O)NR cc (CR aa R bb ) n2 -, -(CH 2 ) n1 (O) (CH 2 ) n2 - or - (CH 2 ) n1 N.R. aa (CH 2 ) n2 - selected from; R 5 is cyano, -C(O)NR aa R bb or -(CH 2 ) n1 P(O)R aa R bb Selected from: R 7 is C 2-6 Alkynyl, 3- to 12-membered heterocyclic group, -(C≡C) n1 (CR aa R bb ) m R cc , -(C=C) n1 (CR aa R bb ) m R cc , -(CH 2 ) n1 O (CH 2 ) n2 (CR aa R bb ) m Rcc - (CH 2 ) n1 N.R. aa (CH 2 ) n2 CR bb or -(CH 2 ) n1 N.R. aa C(O)Rbb, 2-6 Alkynyl, 3- to 12-membered heterocyclic groups can further include hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Cyanoalkyl, C 1-6 Alkoxy, halogen, hydroxy, amino, cyano, oxo, thiol, imino, C 3-8 optionally substituted with one or more substituents selected from cycloalkyl or a 3- to 12-membered heterocyclic group; R 8 is selected from hydrogen or halogen; R 9 is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogen or -OR aa Selected from: R 10 is hydrogen, C 1-6 selected from alkyl or amino; Or any two adjacent or non-adjacent R 10 are connected to form one C 3-8 forming a cycloalkyl or 3- to 12-membered heterocyclic group; R aa and Rbb are each independently hydrogen, deuterium, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, hydroxy, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic group or C 6-14 aryl, wherein C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, hydroxy, C 3-8 Cycloalkyl, 3- to 12-membered heterocyclic groups and C 6-14 Aryl can further include hydrogen, halogen, cyano, hydroxy, oxo, imino, C 1-6 Alkyl and C 1-6 Optionally substituted with one or more substituents selected from among hydroxyalkyl; Each R cc is independently selected from cyano; Or, R aa Any two of R and R are linked to form one C 3-8 A cycloalkyl or 3- to 12-membered heterocyclic group can be formed, wherein 3-8 Cycloalkyl and 3- to 12-membered heterocyclic groups are further defined as hydrogen, amino, halogen, cyano, hydroxy, oxo, imino, C 1-6 Alkyl and C 1-6 2. The compound of claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, optionally substituted with one or more substituents selected from among hydroxyalkyl.

22. The specific structure of the compound is as follows: the compound, its stereoisomer or a pharma- ceutically acceptable salt thereof. 【Chemistry 16】 【change】 【change】 【change】 【change】 【change】 【change】 【change】

23. A method for producing a compound represented by general formula (IX-A) or a stereoisomer thereof or a pharma- ceutically acceptable salt thereof according to claim 18, comprising a step of subjecting general formula (IX-A1) and general formula (IX-A2) to a coupling reaction to obtain a compound represented by general formula (IX-A) or a stereoisomer thereof or a pharma- ceutically acceptable salt thereof. 【Chemistry 17】 (where: X 1 is selected from halogens.

24. A method for producing the compound represented by general formula (IX-B) or its stereoisomer and its pharma- ceutically acceptable salt according to claim 5, comprising the step of reacting general formula (IX-B1) with general formula (IX-B2) to obtain a compound represented by general formula (IX-B) or its stereoisomer and its pharma- ceutically acceptable salt. 【Chemistry 18】 (where: R 28 is selected from halogen, boronic acid or boronic ester; R 29 is selected from halogen, boronic acid or boronic ester; R 28 When is selected from halogen, R 29 is selected from a boronic acid or a boronic ester; R 28 When is selected from boronic acids or boronic esters, R 29 is a halogen.)

25. R 28 is fluorine, chlorine, bromine, iodine, -B(OH) 2 , or 【Chemistry 19】 Selected from: R 29 is fluorine, chlorine, bromine, iodine, -B(OH) 2 , or 【Chemistry 20】 Selected from: When R 28 is selected from halogen, R 29 is selected from boronic acid or boronic ester; 25. The method of claim 24, wherein when R28 is selected from a boronic acid or a boronic ester, R29 is a halogen.

26. A method for producing the compound represented by general formula (IX-B) or its stereoisomer and its pharma- ceutically acceptable salt according to claim 5, comprising the step of reacting general formula (IX-B3) with general formula (IX-B4) to obtain a compound represented by general formula (IX-B) or its stereoisomer and its pharma- ceutically acceptable salt. 【Chemistry 21】 (where: R 30 is selected from halogen, hydroxy; Pg is selected from hydrogen, halogen, or a hydroxy protecting group; When Pg is a hydroxy protecting group, it is selected from methyl, tert-butyl, triphenyl, methylthiomethyl ether, 2-methoxyethoxymethyl ether, methoxymethyl ether, p-methoxybenzyl ether, pivaloyl, benzyl ether, methoxymethyl, trimethylsilyl, tetrahydrofuranyl, tert-butyldimethylsilyl, acetyl, benzoyl or p-toluenesulfonyl; M 3 When is -O-, Pg is selected from hydrogen or a hydroxy protecting group.

27. A method for producing a compound represented by general formula (IX-C) or a stereoisomer thereof or a pharma- ceutically acceptable salt thereof according to claim 13, comprising a step of reacting general formula (IX-C1) with general formula (IX-C2) to obtain a compound represented by general formula (IX-C) or a stereoisomer thereof or a pharma- ceutically acceptable salt thereof. 【Chemical 22】 (where: X 2 is selected from halogens.

28. A pharmaceutical composition comprising a therapeutically effective amount of a compound represented by any one of the general formulas according to any one of claims 1 to 22, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers.

29. Use of a compound represented by any one of the general formulas according to any one of claims 1 to 22 and its stereoisomer or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 28, in the manufacture of a RET inhibitor-related medicine.

30. Use of a compound represented by any one of the general formulas according to claims 1 to 22 and a stereoisomer or a pharma- ceutical acceptable salt thereof, or a pharmaceutical composition according to claim 28, in the manufacture of a medicament for treating and / or preventing a disease associated with non-small cell lung cancer, fibrosarcoma, pancreatic tumor, medullary thyroid cancer, papillary thyroid tumor, soft tissue sarcoma, high-grade solid tumor, breast tumor, or colon tumor.

Citation Information

Patent Citations

  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

    WO2017011776A1

  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

    WO2018071447A1

  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

    WO2018071454A1

  • Crystalline forms

    WO2019075108A1

  • Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as RET kinase inhibitors

    WO2020063751A1